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ABSTRACT
T.his t~~sis examines the use of hydro~yprol?ylmethylcellulose (HPM~) of di.tJer~nt
VIScosities and ethylcellulose aqueous dispersion (Surelease), alone or m combination
with each other, to control the release of metoclopramide hydrochloride or diclofenac
sodium from coated pellets or matrices.
The glass transitions of the polymeric films were determined by thermomechanical
analysis and used as a guideline to select the inlet air temperature m coating operation.
The coating procedure was performed using Accela-Cota. Matrices were prepared either
by direct compression or wet granulation. Compendial dissolution methodology was used
to determine drug release from coated pellets as well as matrices. Release exponents
indicating release mechanisms were calculated from the dissolution data.
The release of both drugs from coated pellets decreased as the coating load of HPMC
increased. However HPMC did not control drug release rate and the majority of both
drugs released in less than 1 h. The release exponents for metoclopramide hydrochloride
release from HPMC E5 and HPMC E 15 coated pellets were "0.45 and ..0.40
respectively. The corresponding value for diclofenac sodium was ..0.50. These values
of 11 indicate that diffusion is the predominant mechanism for drug release from HPMC
Cl lilted pellets.
The release of both drugs controlled with application of Surelease on drug-layered
pellets. Increasing coating load of Surelease extensively decreased the release rates of
both drugs and increased the lag times before controlled release was achieved. The
release exponent for rnetoclopramide hydrochloride was independent of coa.ting load and
the mean value was ..0.00 indicating predominantly diffusion controlled release.
However the value of n for diclofenac sodium was higher at low coating loads
suggestmg erosion controlled mechanism and decreased as the coating load increased,
indicating more diffusion controlled mechanism. The mean value was ..0.70. Inclusion
of ~PMC increased the release rates of both drugs. The Surelease:HPMC ratio had a
major role m the release rates of drugs. Addition of HPMC into Surelease did not change
the release exponent for metoclopramide hydrochloride (-0.57) from that of Surelea se
alone and diffusion remained the main mechanism controlling drug release. However the
release .exponent ("1.2X) increased for diclofenac sodium release upon addition of
HPM~ Indicating erosion controlled mechanism. Application of 2% seal-coat of HPMC
E5 pnor to Surelease resulted in decrease in the release rates of both drugs. However the
exponent n and consequently release mechanism remained unchanged for either
metoclopramide hydrochloride (,,0.00) or diclofenac sodium ( ..0.09). Generally release
of diclofenac sodium from Surelease or SureleaselHPMC coated pellets was faster than
metoclopramide hydrochloride. This was attributed mainly to the interaction of the latter
drug with the anionic surfactant ammonium oleate present in the Surelease coat. The
interaction of metoclopramide hydrochloride with ammonium oleate was confirmed by
dialysis studies.
Drug release from HPMC matrices was controlled by the polymer content and viscosity.
The drug release was also dependent on the solubility of the drugs. Metoclopramide
hydrochloride released faster than diclofenac sodium. The release exponent for
metoclupramide hydrochloride was in the ra_nge of 0.53:0.6.4. The ~~)rre.sponding v~ue
tor diclofenuc sodium was O.59-0.XO. Therefore a combination of diffusion and erosrnn
controlled the release of either drug. The higher value of n for diclofenac sodium may
indicate the greater role for erosion than was the case for metoclopramide hydrochloride.
The incorporation of Surelease into HPMC K4M matrices considerably decreased the
release rate of metoclopramide hydrochloride while that of diclofenac sodium was less
affected. The conversion of metoclopramide hydrochloride to its base form was proposed
as an explanation. The release exponents for Surelease granulated matrices was "0.50
for both drugs indicating diffusion mainly controlled the mechanism of release.
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CHAPTER 1. INTRODUCTION
1.1 THE CONCEPT OF CONTROLLED DRUG RELEASE
For many years, the major focus of drug research activities has been the synthesis
or discovery of potent drugs with new kinds of biological activity. While this
remains an interesting area of research, much attention has also been paid to the
delivery of the active substance (Langer and Peppas, 1981).
In solid dosage forms, the drug must dissolve before it can be absorbed by the body,
as depicted in Figure 1.1. Here KT and K, are constants indicating the rate of release
of drug from the dosage form and the rate of absorption of the drug from the
gastrointestinal tract, respectively.
The rate of appearance of the drug in the blood depends on which step is the rate
limiting step. The rate of drug release from a conventional dosage form is rapid and
absorption through the gastrointestinal wall is usually the rate-limiting step (Schwartz
and Ando, 1983). The drug is rapidly liberated from a conventional dosage form,
depending on the rate of its disintegration and the dissolution of the drug. A high
concentration is quickly reached in the blood, and then drug concentration falls until
the next dose. As a result, fluctuating concentration profiles of the drug are observed
either in the blood or in tissue, where high concentrations alternate with low
concentrations producing an alternation of overdosing and underdosing of the drug.







Step 1 Step 2
I-----Release--~ "_--Absorption--~
Figure 1.1 Schematic diagram representing the steps before a drug appears in the
blood (after Schwartz and Ando, 1983).
forms may lead to an excessive use of the drug and to an insufficient influence on
the disease (Langer and Peppas, 1981). Moreover, initial overdosing is responsible
for a high frequency of side effects which may lead to other illness or damage
(Langer and Peppas, 1981).
However in controlled and sustained release products, the release of drug from the
dosage form rather than the absorption of the drug into the blood is the rate-limiting
step. The curves of plasma drug level as a function of time for conventional,
sustained release and controlled release dosage forms are shown in Figure 1.2.
The development of an ideal, orally-administered drug delivery system which aims
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at providing a sustained, relatively constant release of drug during passage through
the gastrointestinal tract (OIT) irrespective of variation in pH, surface tension and
viscosity within OIT, has been the focus of recent research (Kallstrand and Ekman,





Figure 1.2. Plasma drug concentration-profiles for a conventional tablet or capsule
formulation, a sustained release formulation and a zero-order controlled release
formulation (after Grass and Robinson, 1990).
The reasons for increasing attention In the field of controlled release delivery
systems arise as a result of the general problems associated with the administration
of conventional dosage forms, as explained above, and also:
a) As a result of undesirable drug properties, such as short biological half-life or
local irritation.
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b) Through the nature of the disease state.
c) For reasons of patient compliance since the decrease in frequency of daily doses
is more convenient.
d) Most importantly, to improve the efficacy and safety of a drug through proper
temporal and/or spatial control of drug release (Li et al, 1987).
1.2 TERMINOLOGY OF CONTROLLED RELEASE DOSAGE FORM
The concept of controlled release dosage forms is quite old, consequently a
confusing range of names and terms have been used to describe these systems
synonymously. Some terms refer to the duration of release or drug action such as
continuous action or long lasting; other terms indicate the rate of drug action such
as slow release or slow acting while others refer to the frequency of drug release,
such as repeat action. As controlled release dosage forms are one of subgroups of
modified release dosage forms therefore, to explain controlled release drug delivery
systems it is necessary to define the modified release dosage forms.
1.2.1 MODIFIED RELEASE DOSAGE FORMS
Modified release dosage forms are defined as preparations that modify the rate and/
or time and/ or site of release of active ingredient, in order to accomplish therapeutic
objectives which can not be achieved by conventional dosage forms (Caramella et
aI, 1995).
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1.2.1.1 Classification of modified release systems
Modified release dosage forms may be classified according to (Caramella et aI,
1995):
- The route of administration (e.g. oral, parenteral),
- The type of release (e.g. delayed, slow, prolonged),
- The release mechanism (e.g. diffusion, dissolution), and
- The type of technical system (e.g. matrix, reservoir).
Generally the terms which can be used for classification of modified release dosage
forms based on "the type of release" are:
1.2.1.1.1 Delayed release: This term defines systems which do not release their
active component immediately after administration, but do so at a later time.
Examples include enteric-coated products (Madan, 1985a).
1.2.1.1.2 Sustained release: These systems are designed to release rapidly a
predetermined fraction of total dose as a loading dose and to maintain the therapeutic
level of the drug for an extended period of time by slowing the rate of drug release
(Maden, 1985a).
1.2.1.1.3 Repeat action: A repeat action dosage form initially releases the equivalent
of a conventional single dose of the drug and then another single dose of the drug
at some later time. Thus, repeat action dosage forms are not sustained release since
they neither reduce the size of the dose nor extended the duration of action (Grass
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and Robinson, 1990).
1.2.1.1.4 Controlled release: Controlled release indicates that the release of drug from
the dosage form occurs in some planned, predictable and slower than normal,
manner. In other words, controlled release dosage forms deliver the drug at a specific
planned and controlled rate (Schwartz and Ando, 1983).
1.3 THE THERAPEUTIC OBJECTIVES OF CONTROLLED RELEASE
DOSAGE FORMS
Controlled drug delivery systems generally aim to (Li et al, 1987):
1- Sustain drug action at a predetermined rate by maintaining a relatively constant,
effective drug level in the body. The undesirable side effects resulting from
fluctuations in the concentrations of drug in the blood are concomitantly minimized.
2- Localize drug action by spatial placement of a controlled release system adjacent
to or in the diseased tissue or organ. Implant devices are obvious examples.
3- Target drug action by using carriers (such as microspheres or nanoparticles for
pulmonary delivery) or by preparation of chemical derivatives of the drug which are
activated at the target site and deliver the drug to a particular "target" cell type.
1.4 ADVANTAGES OF CONTROLLED RELEASE DOSAGE FORMS
There are many advantages to formulating drugs into controlled release products. The
main ones include:
a) An increase in the time interval between doses which in tum leads to a reduction
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in dosing frequency (Welling, 1983).
b) Reduced fluctuation in circulating drug concentrations by maintaining drug
concentrations in a therapeutically desirable range for a longer period (Langer, 1980;
Chow, 1987).
c) Increased patient compliance by decreasing the frequency of dosing (Welling,
1983; Madan, 1985a).
d) Avoidance of night-time dosing (Baker, 1987; Chow, 1987).
e) Reduction in gastrointestinal irritation and other dose-related side effects (Langer
and Peppas, 1981).
However these advantages must be weighed against the potential disadvantages.
1.S DISADVANTAGES OF CONTROLLED RELEASE DOSAGE FORMS
Controlled release dosage forms have several potential disadvantages which include:
a) A high cost per unit dose (Langer, 1980).
b) Unpredictable and often poor in vitro to in vivo correlations (Welling and
Dobrinska, 1987).
c) Dose dumping. As these systems usually contain larger quantities of drug than
conventional dosage forms, any failure in the performance of these systems could
therefore lead to a sudden release of a high quantity of the drug (Li et al, 1987).
d) A reduced potential for dosage adjustment. The loss of controlled release
properties due to fracture of the dosage form limits the dosing adjustment with some
controlled release formulations when a fraction of a tablet is needed to be
administered (Welling and Dobrinska, 1987).
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e) An increased potential for first-pass clearance and, as a result, poor systemic
availability. As first-pass metabolism is a saturable process, a significant reduction
in bioavailability would be anticipated if the drug was released slowly. This is
because as the release rate of a drug is slowed, the possibility of saturating the
hepatic metabolizing enzymes becomes smaller (Welling, 1983).
g) Toxicity or lack of biocompatibility of the polymeric materials (vehicles) used.
These may cause acute or chronic local inflammatory responses (Langer and Peppas,
1981)
h) Production of harmful by-products from the polymer if it is biodegradable (Langer
and Peppas, 1981).
1.6 FACTORS INFLUENCING THE DESIGN AND PERFORMANCE OF
CONTROLLED RELEASE DOSAGE FORMS
A number of factors affect the design of controlled release products. These include:
1- Drug properties: The physicochemical properties of a drug such as stability,
solubility, partitioning characteristics, charge and its extent of protein binding affect
the design and performance of controlled release doasge forms (Li et al, 1987).
2- Route of drug delivery: The performance of a controlled release system may be
affected by the route of administration. For example, first-pass effects or
gastrointestinal motility affect the bioavailability of a drug administrated by the oral
route (Li et aI, 1987).
3- Target site: To reduce side effects, it is preferable to localize the optimum drug
concentration in the target organ or tissue. This may be achieved by local
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administration of the drug or by the use of carriers. However, most macromolecules
or carriers are not able to pass through the absorptive surfaces of most routes. In this
case intravascular or intra-arterial administration is inevitable (Li et al, 1987).
4- Acute or chronic therapy: The design of a controlled delivery system is different
depending on whether cure or control of a condition is expected. For example, the
design of a contraceptive implant, active over a one year, would be completely
different from that of an antibiotic for acute therapy (Li et al, 1987).
5- The patient: Whether the patient is ambulatory or bedridden, young or old etc, can
influence the design of a controlled release product. For example, an intramuscular
injection may cause different effects in a bedridden patient with little muscle
movement compared with the movement of a ambulatory patient (Li et al, 1987).
1.7 APPLICATIONS OF CONTROLLED RELEASE TECHNOLOGIES
Numerous studies into controlled drug delivery are indicative of recent developments
in the design of novel systems. They are not limited to oral dosage forms. These
systems have been used in parenteral dosage forms (Tice and Cowsar, 1984)
buccal/sublingual (Abrams, 1984), rectal (Nishihata et al, 1983), nasal (Hussain et
aI, 1984), vaginal (Yotsuyanagi et al, 1975), transdermal (Good, 1983) and ocular
(Stratford et al, 1983) systems.
1.8 GENERAL DESIGN OF ORAL CONTROLLED RELEASE DRUG
DELIVERY SYSTEMS
Most controlled release dosage forms consist of two parts: the first part immediately
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releases its content in order to provide the therapeutic drug concentration as rapidly
as possible. The second part is the sustained release portion which has been designed
to provide prolonged blood levels. Obviously, the heart of the system is the sustained
release component (Madan, 1985b). A variety of techniques have been used to
prepare controlled release drug delivery systems. In some cases, the combination of
more than one technique has been used in order to maximize their advantages and
minimize their drawbacks (Hui et al, 1987). Most oral controlled release systems use
dissolution, diffusion, or a combination of both mechanisms, to retard drug release.
These systems are discussed below.
1.8.1 CLASSIFICATION OF ORAL SUSTAINED RELEASE DRUG DELIVERY
SYSTEMS
1.8.1.1 Dissolution controlled release
In sustained release formulations employing dissolution as the rate limiting step, drug
release is controlled by dissolution of a polymer. Most of the products based on
dissolution controlled release provide either an encapsulated or a matrix dissolution
control.
a) Encapsulated dissolution control: In these types of controlled delivery systems
individual drug particles or granules are coated with a slowly dissolving material
such as beeswax or glycerol palmitostearate. The coated particles can be either
compressed directly into tablets or placed into capsules.
b) Matrix dissolution control: This involves compressing the drug with a slowly
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dissolving carrier into a tablet.
1.8.1.2 Diffusion controlled release
Diffusion is the movement or transport of drug molecules due to random thermal
energy from a more concentrated reservoir to a less concentrated site (Schwartz and
Ando, 1983). There are basically two types of diffusion controlled systems:
a) Reservoir devices: In these systems, a core of drug is surrounded by a water-
insoluble polymeric material. The drug will partition into the membrane and
exchange with the fluid surrounding the particle or tablet (figure 1.3A).
b) Matrix devices: In these systems, a solid drug is dispersed in an insoluble matrix.




Figure 1.3. Schematic representation of diffusion-controlled drug release. A.
Diffusion control of drug release via a reservoir device. B. Diffusion control of drug
release via a matrix (after Hui et aI, 1987).
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1.8.1.3 Diffusion and dissolution controlled systems
This system is based on a combination of diffusion and dissolution types of control.
Their main feature is that the drug core is enclosed with a partially soluble
membrane. Dissolution of part of the membrane allows for diffusion of the contained
drug through pores in the polymer coat (figure 1.4).
MembranelQ~ Reservoir
/"-,.0 .
V k: 00.: : .:...~
o : :"::>".: . [J
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()6V\
Pores produced by soluble portion
of polymer membrane
Figure 1.4. Schematic representation of a diffusion and dissolution controlled system
(after Park et al, 1984).
1.8.1.4 Ion-exchange resins
Resins are water-insoluble materials containing salt-forming groups in repeating
positions on the resin chain. Ion-exchange resins have been used as drug carriers for
preparing sustained delivery by releasing the drug from the complex over
approximately 8 to 12 h into the gastrointestinal tract (Park et aI, 1984). The drug
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is released from this system as a result of an ion exchange and depends mainly on
the pH and ionic concentration of the dissolution medium (Caramella et al, 1995).
1.8.1.5 pH-independent formulations
When a drug formulation is administered orally, it encounters several pH
environments ranging from 7 in the mouth, 1 to 4 in the stomach and 5 to 7 in the
small intestine (Hui et al, 1987). Since most drugs are either weak acids or weak
bases, their release from sustained release formulations is pH dependent.
To achieve a pH-independent drug release, buffers can be added to the formulation
to help maintain a constant pH. Salts of phosphoric acid, phthalic acid, citric acid,
tartaric acid or amino acids are preferred, because of their physiological acceptability
(Park et al, 1984).
1.8.1.6 Osmotically controlled release
In this type of drug delivery system, osmotic pressure is the driving force that
generates constant drug release. This system is fabricated by applying a
semipermeable membrane around a core of an osmotically active drug or a core of
an osmotically inactive drug in combination with an osmotically active salt. A
delivery orifice is drilled in each system by laser or by a high-speed mechanical drill.
The semipermeable membrane lets water, but not the drug, diffuse through the
membrane freely. Drug is released through the orifice. The unique feature of this
system is that the drug release is independent of pH (Caramella et al, 1995). A
13





Figure 1.5. Schematic representation of an osmotically controlled system (after Hui
et al, 1987).
1.8.1.7 Altered density formulations
The gastrointestinal transit time varies from one individual to another (Hui et al,
1987). Among the factors that influence the gastrointestinal transit time are the
physical properties of the delivery system and the presence of food (Welling and
Dobrinska, 1987). Several methods have been developed to prolong the residence
time of a drug delivery system in the gastrointestinal tract. One method is the use
of bioadhesion, which is based on the adherence of bioadhesive polymers to the
mucin/epithelial surface of the gastrointestinal tract (Li et al, 1993). Another method
is by changing the density of a formulation by using either high or low density
pellets (Park et al, 1984).
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a) High density pellets: In these systems, the density of the pellets must exceed that
of normal stomach content. In preparing such formulations, the drug can be coated
onto a heavy core or mixed with heavy inert materials such as barium sulphate,
titanium dioxide, iron powder or zinc oxide (Hui et al, 1987). The rate at which
pellets are distributed through the small intestine depends on their density. Devereux
et al (1990) claimed that increasing the density of pellets from 1.5 g.cm" to 2.8
g.cm" prolonged their gastrointestinal residence time.
b) Low density pellets: In these systems, the density of the pellets is lower than that
of the gastric juice. Empty globular shells are used as the carrier. Conventional
capsules, polystyrol, or even popcorn are all candidates as carriers (Park et al, 1984).
The surfaces of empty shells are coated with a polymeric material and then further
coated by a drug-polymer matrix using a polymeric material which shows dissolution
controlled of the drug release. The final product floats on the gastric juice for an
extended period while the drug is slowly released (Hui et al, 1987).
As this thesis examines drug release from coated multiparticulate systems and
hydrophilic matrices therefore the description of these systems along with factors
influencing the release of drug from them will be presented below.
1.9 MODIFIED RELEASE COATINGS
The film-coating process involves spray-depositing a formulation onto the surface of
a tablet, granule or pellet. The coating formulation consists mainly of polymer,
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plasticiser, colorant and other possible additives, dissolved or dispersed in either an
aqueous or organic solvent.
Tablets and other solid dosage forms may be coated for a variety of reasons such as
to mask unpleasant tastes and odours, to hide mottled or discoloured tablet surfaces
and to protect from gastric fluids those drugs which are acid-labile. Another
application of film coating is to provide a semipermeable membrane which limits the
release of a drug from its respective dosage form (Rowe, 1985a). The process of
coating should be capable of producing a dosage form which is evenly coated with
the film layer (Mehta and Jones, 1985). In an ideal coating process each layer of
coating is applied uniformly and is dried completely before tablets or beadlets are
recycled for further coating. The surface of coated tablets or beadlets should appear
smooth and continuous. If the coating process or coating formulation is not
optimized, the deposition of the film onto the substrate would fail to spread
uniformly leaving an imperfect film (Li et aI, 1991).
The United States Pharmacopeia / National Formulary (1995) described three types
of coating:
1- Plain coatings which are applied to improve the taste and appearance of the
dosage form or to protect it from light or moisture.
2- Delayed release coatings which are better known as enteric coatings and are
applied to protect acid sensitive drugs from the low pH of the stomach contents.
3- Sustained release coatings which are used to modify the release rate of the active
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substance from the dosage fonn.
1.9.1 CONTROLLED RELEASE COATED DOSAGE FORMS
Controlled release products based on sustained release coatings may be formulated
as single-unit dosage forms such as tablets or multiple-unit dosage forms
(multiparticulate systems) such as pellets. Single-unit preparations consist of one
non-disintegrating unit while multiple-unit formulations consist of a unit which
disintegrates in the stomach into a large number of sub-units.
1.9.2 MULTIPARTICULATE SYSTEMS
There are various types of substrates which can be used in the production of
multiparticulate systems. These substrates include (Porter and Bruno, 1990):
a) Drug crystals and powders,
b) Extruded and spheronised drug granules,
c) Sugar seeds or non-pariels which are layered with the drug,
d) Ion-exchange resin particles containing the drug, and
f) Small compressed tablets containing the drug.
Generally multi particulate systems can be categorized as minigranules or
microgranules (Follonier and Doelker, 1992). The first class correspond to the
pellets, while the second class include microcapsules and microspheres. Pelletization
is an agglomeration process that converts fine powders or granules of bulk drugs and
excipients into free-flowing, spherical or semi-spherical units, referred to as pellets
17
(Ghebre-Sellassie, 1989). Based on their structure, pellets can be classified into the
following groups (Knoch, 1994):
a) Pellets with homogeneous distribution of drug in a carrier. These pellets may
already show sustained release or may need to be coated with a suitable polymer to
achieve sustained release.
b) Pellets in which the drug is applied to an inert core such as sugar spheres.
A schematic diagram of the different types of controlled release multiparticulate
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Figure 1.6. Schematic representation of controlled release multiparticulate systems
(after Follonier and Doelker, 1992).
1.9.2.1 Advantages of multi particulate systems
It has been asserted that products based on a multiunit system comprising many
small pellets, offer potential advantages over single unit preparations. Pellet mixtures
are attractive in appearance, easily mixed when combinations of different active
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agents are required. They also flow freely and pack uniformly thereby alleviating
problems in handling and packaging (Connie and Hadley, 1970; Ghebre-Sellassie et
al, 1985; Story, 1989). Pelletization enables the incorporation of incompatible active
substances into the same product, or even into the same pellet, by situating the active
substances in different layers and/or by separating the layers from each other with
coatings (Lehmann and Dreher, 1979). Furthermore cores, because of their spherical
shape, have the lowest surface area to volume ratio and are easy to coat (Rowe,
1985b). They also offer a practicable method to control the site and rate of drug
distribution in the gastrointestinal tract (Niskanen et al, 1990).
However, the main advantage of pellets is their in vivo behaviour. This benefit is
obtained by administering the controlled release in the form of tablets or capsules
that disintegrate in the gastrointestinal tract. When the pellets have a diameter of
<1.0-1.5 mm, they pass the pylorus even when the sphincter is closed and spread out
over a large surface area in the stomach and small intestine (Bechgaard and Nielsen,
1978). This yields a more predictable drug release profile by reducing local
differences in the gastrointestinal environment. In addition, this is reported to
minimise the risk of local mucosal damage (Bechgaard and Nielsen, 1978;
Bechgaard, 1982; Flament et aI, 1994). Moreover, since each dose consists of many
subunits, there is a better statistical assurance of drug release (Lordi, 1986) and the
risk of dose dumping is reduced (Davis et al. 1984; Ganderton, 1985)
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1.9.2.2 Manufacture of multiparticulate systems
The techniques which are used in the production of either un-coated or coated
multiparticulate systems include the use of rotating pans, extruder/spheronisers,
fluidized bed and microencapsulation.
1- Rotating pans
The use of a conventional coating pan in the production of pellets is a slow process,
lasting several days or weeks to process a single batch of material. Products with a
high drug content >50% can be produced by the addition of the drug in powder
form, although the addition of drug as a solution or suspension is common (Ghebre-
Sellassie, 1989). Coating pans are used for one or more of the following (Chambliss,
1989):
a) The formation of pellets from dry powder, granules or crystals.
b) The addition of drug as a dry powder onto an inert substrate.
c) The addition of drug in the form of a solution or suspension onto an inert
substrate.
d) The addition of an outer controlled-release layer to drug-layered pellets.
2- ExtruderlSpheroniser
The extrusion of a moist material followed by rounding on a rapidly rotating,
roughened plate is known as spheronisation (Gamlen, 1985). This technique may be
the only practical way of producing pellets with high drug content. In this process,
the drug and other excipients are mixed in the dry state and then the binder solution,
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is added to form a wet mass. The mass is then extruded and the extrudate IS
transferred to the spheroniser. Various types of extrusion devices are available.
3- Fluidized bed
The fluidized bed is ideal for the production of active-coated cores by layering, as
well as for applying any type of controlled release coat (Story, 1989). The types of
equipment include the top spray fluidized bed, the bottom spray fluidized bed and
the tangential spray fluidized bed. The high evaporative efficiency and the ability to
reproducibly control a wide range of process variables have resulted in the increased
use of fluidized beds to produce pellets (Jones, 1989).
4- Microencapsulation
Microencapsulation is a process in which tiny particles or droplets are surrounded
by a uniform coating (microcapsule) or held in a matrix of polymer (microsphere).
A number of microencapsulation techniques, including aqueous phase separation,
three-phase dispersion, organic phase separation and interfacial polymerization have
been used to encapsulate pharmaceuticals (Chang and Robinson, 1990).
1.10 HYDROPHILIC MATRICES
Matrices are widely used as the simplest and the cheapest way of producing oral
sustained drug delivery systems. They are defined as a homogeneous dispersion of
-
an active substance in a polymeric carrier (Alderman, 1984). Many polymers, waxes
and gums have been used in the formulation of the matrix tablets using direct
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compression, wet granulation or dry granulation. Drug diffusion through the polymer
matrix is generally the rate-limiting step. The ease of fabrication of these systems
and their lower cost are their advantages compared to reservoir devices (Langer and
Peppas, 1981).
Hydrophilic polymer-based sustained release matrix tablets are well used in oral
sustained release dosage forms (Timmins et ai, 1991). The most widely used
polymers in hydrophilic matrices are cellulose ethers due to their safety, acceptable
cost, wide availability (Colombo, 1993), good compression properties and their
ability to accommodate high drug loadings (Ranga Rao and Padmalatha Devi, 1988;
Kawashima et al, 1993; Iannuccelli et al, 1995).
Among cellulose ethers, hydroxypropylmethylcellulose (HPMC) has been extensively
used in hydrophilic matrices. The performance of HPMC in sustained release
hydrophilic matrices is based on the rapid formation of a gel layer at the tablet
surface which postpones hydration of the matrix core and prevents disintegration of
the tablet (Alderman, 1984; Colombo, 1993). A schematic diagram of the
performance of hydrophilic matrices is shown in Figure 1.7.
Generally two factors control the rate of drug release from hydrophilic matrices: one
is the rate of aqueous infiltration into the matrix followed by a relaxation process
(hydration, gelation or swelling) and the other is the rate of erosion of the matrix
(Tahara et al, 1995). Initially, dissolution of the drug present at the surface of the
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Figure 1.7. Schematic diagram of the performance of hydrophilic matrices (after
Alderman, 1984).
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matrix occurs which leaves some pores in the matrix. These pores facilitate the
ingress of water into the matrix. As a result of polymer-solvent interactions the gel
layer forms on the matrix periphery. The release of drug occurs by diffusion through
the gel layer and/or by erosion of the swollen matrix depending on the solubility of
the drug (Ford et al, 1987).
1.11 CELLULOSE DERIVATIVES
Cellulose derivatives are very popular in the production of controlled release dosage
forms. As this thesis examines the application of cellulose ethers in oral controlled
drug delivery systems, it is necessary to introduce some of the properties of these
materials and their applications in pharmacy before discussing the factors controlling
the drug release from coated pellets and hydrophilic matrices.
Cellulose, the starting source for all cellulose derivatives, is the most abundant
natural polymeric raw material. Structurally, cellulose consists of repeating units of
anhydro-jf-Dsglucopyranose units, linked together by ~-1,4-glycoside bonds. The
various chemically-modified cellulose products used in food, cosmetic,
pharmaceutical, medical and related applications can be grouped into four classes,
based on their method of preparation. These are: hydrocellulose, cellulose ethers,
cellulose esters, and oxycelluloses (Kumar and Banker, 1993).
Cellulose ethers are the cellulose derivatives used most widely in the pharmaceutical
industry. Some of the major applications of cellulose ethers include their use as:
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i) Tableting aids (binders, fillers, disintegrants).
ii) Viscosity enhancing agents in the preparation of semi-solids, solutions and
suspensions, shampoos, hair conditioners and food products.
iii) Taste and odour masking agents.
iv) Coating materials for tablets and other dosage forms.
v) Carriers for cosmetic and topical formulations.
vi) Controlled and/or sustained release carriers for veterinary, agricultural and
pharmaceutical preparations.
Cellulose is obtained from cotton linters or wood pulp. Cellulose is first converted
into an alkali cellulose by reaction with sodium hydroxide and then treated with
ethyl halide to produce ethy!cellulose (EC) or with mixtures of methylchloride and
propylene oxide to give hydroxypropylmethy!cellulose (HPMC). For each
anhydroglucose unit, three hydroxyl groups are available for nucleophilic
substitution. The term "degree of substitution" (DS) is used to identify the average
number of hydroxyl groups reacted per ring. The maximum DS is 3. The properties
of cellulose ethers depend on the type, distribution and amount of the substitution
groups (Greminger and Krumel, 1980). Some of the cellulose ethers are
meth ylcell ulose, ethy!cellulose, hydrox yeth y!cellulose, hydrox ypropy leell ulose,
hydroxypropylmethy!cellulose, sodium carboxymethy!cellulose. Their structures are














R=- H, -CH2CH20H, -CH2CH20CH2CH20H
R= -H, -CH2CH(OH)CH3
R= -H, -CH3, -CH2CH(OH)CH3
R= -H, -CH2COONa
Figure 1.8. Structure of cellulose ethers (after Doelker, 1987).
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1.11.1 HYDROXYPROPYLMETHYLCELLULOSE
Hydroxypropylmethylcellulose is a water soluble polymer and is available in various
grades of molecular weights and viscosities. Various grades of HPMC are
differentiated by the viscosities of their 2% w/w aqueous solutions at 20°C. The
United States Pharmacopeia / National Formulary (1995) specifies the HPMCs of
different substitution by four digits as HPMC 2208, HPMC 2906 and HPMC 2910.
The first two digits refer to the approximate percentage content of the methoxyl
group and the second two digits refer to the approximate percentage content of the
hydroxypropoxyl group.
The low viscosity grades of HPMC are useful in low concentrations as tablet binders,
whereas the high viscosity grades are used in preparing liquid formulations (e.g.
creams, lotions, gels, ointments, and suspensions) and also in sustained release
matrix tablets (Kumar and Banker, 1993).
The commercially-available brands of HPMC which are used widely for film coating
are Pharmacoat 615, Pharmacoat 606 or Pharmacoat 603 (Shin-Etsu Chemical Co.,
Japan) and Methocel EI5, Methocel E5 or Methocel E3 (Dow Chemical Co., USA).
HPMCs of lower viscosities (~15 mPa.s) are commonly used in film coating and are
produced by depolymerization of higher viscosity HPMCs. Although it is reported
that HPMC of a higher viscosity grade may be used in film coating, this involves the
use of organic solvents (Maffione et al, 1993). The viscosities required for aqueous
film coating are commonly less than 100 mPa.s (Nagai et al, 1989).
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As a film-coating material, HPMC has the characteristics of producing a transparent,
tough, flexible, and non-tacky film when cast from an organic or aqueous solution.
The film is stable to a wide range of biochemical or enzyme systems. The HPMC
coat dissolves completely in the gastrointestinal tract at any biological pH and
provides a good bioavailability of the active ingredients (Nagai et al, 1989).
Plasticizers are usually added to a film coating solution in order to decrease the
minimum film formation temperature. Johnson et al (1991) showed that both
polyethylene glycol 400 (water soluble) and triacetin (slightly soluble in water) were
effective plasticizers for HPMC with PEG 400 being slightly more efficient.
However, the presence of 15% or 20% w/w PEG 400 significantly increased the
water vapour permeability while 20% w/w of the less hydrophilic triacetin lowered
the ability of the film to absorb water (Johnson et al, 1991). In general, plasticizers
with low water solubility are recommended for controlled drug release formulations
(Chang and Robinson, 1990).
1.11.2 ETHYLCELLULOSE
Ethylcellulose (EC) is the most stable of the cellulose derivatives (Rekhi and
Jambhekar, 1995) which is available as an aqueous dispersion as well as a dry
,
powder. It is an inert film forming, hydrophobic polymer and has been used
extensively in controlled drug delivery systems. It is used in the fabrication of
sustained release dosage forms by addition to direct compression formulations
(Upadrashta et aI, 1993; Katikaneni et al, 1995; Dabbagh et aI, 1996),
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microencapsulation (Hasan et al, 1992; Tirkkonen et al, 1993), coating of tablets and
multiparticulates (Miller and Vadas, 1984; Bianchini and Vecchio, 1987; Lippold et
al, 1989; Dressman et al, 1995), or solid dispersions (Najib and Soleiman, 1985;
Hernandez et al, 1994). Aqueous dispersions of ethylcellulose have also been used
in matrix formulations using wet granulation to retard drug release (Klinger et al,
1990).
Ethylcellulose is insoluble in water but dissolves in a wide variety of organic
solvents (e.g. esters, aromatic hydrocarbons, alcohol, chlorinated solvents). The
solution viscosity increases with an increase in molecular weight and concentration.
Ethylcellulose is available in three types of ethoxyl substitution from Hercules Inc.
(USA) (Grade K: 46.1-47.2%; Grade N: 48.0-49.5%; Grade T: 49.6%) and Dow
Chemical Co. (USA) (Trade name: Ethocel Grade M: 45.0-47.0%; Grade S: 48.0-
49.5%; Grade HE: 49.5-52.0%). Because of its solubility characteristics,
ethylcellulose has been applied mainly from organic solutions to generate film
coating of various permeabilities. Due to the disadvantages of using organic solvents
(e.g. high cost of solvent and solvent recovery, environmental pollution, explosion
hazards and toxicity) the pharmaceutical industry has shifted towards aqueous film
coating. As a result, extensive effort has been devoted to the development of water-
based coatings and various aqueous polymeric dispersions (latexes and
pseudolatexes) that have potential applications in enteric-coated and modified-release
preparations are now available.
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1.11.2.1 Latexes and pseudolatexes
A true latex is prepared by the polymerisation of a monomer or monomer blend,
normally emulsified in an aqueous medium with the aid of anionic or nonionic
surfactants. The polymerisation process requires addition of an initiator. In general,
the particle size of the polymer produced in this way tends to be very small and
there can be problems of toxicity associated with the presence of residual monomer.
A pseudolatex, on the other hand, can be prepared from any existing thermoplastic,
water-insoluble polymer. It is usually prepared by an emulsification-evaporation
technique in which a polymer solution in a water-immiscible organic solvent is finely
emulsified in an aqueous phase containing surfactants; the emulsion is subsequently
heated to eliminate the solvent (de Labouret et al, 1995).
Recently, pseudolatex preparations or aqueous dispersions of EC have been
manufactured under the trade names of Surelease (Colorcon Inc. USA) and Aquacoat
(FMC Corp. USA) and are increasingly used in controlled release formulations.
These are aqueous colloidal dispersions of solid and spherical particles with mean
diameter of about 0.1-1 urn, They are characterized by low viscosity and a high (20-
30% w/w) polymer concentration (de Labouret et al, 1995). Because ethylcellulose
has a high glass-transition temperature (Onions, 1986b) it does not form flexible
films under normal coating conditions and must be plasticised before application.
Effective plasticizers that can be used with the Aquacoat aqueous dispersion are
dibutylsebacate, diethyl phthalate and triethyl citrate (Harris and Ghebre-Sellassie,
1989). For Surelease, the plasticiser (dibutylsebacate) is incorporated into the
30
dispersion during the manufacture. A hot melt of the polymer, dibutylsebacate and
a stabilizer (oleic acid) is created to form a homogenous mixture. The mixture is
then diluted with ammoniated water to obtain a dispersion of the polymer (lyer et
aI, 1990). The fumed silica acts as an anti-adherent, facilitating the application of
Surelease during coating.
1.11.2.2 Advantages of latex or pseudolatex dispersions
Pseudolatex dispersions exhibit many advantages over polymer solutions. The low
viscosities of pseudolatex dispersions and the high concentration of polymers they
may contain in comparison to polymer solutions, gives them considerable advantages
in use (Onions, 1986a). Thus,
a) Less water needs to be removed during drying and film formation,
b) Less water may be available to penetrate the tablet surface so that sealing of water
sensitive tablets may not be necessary,
c) Less energy, particularly heat, is required to remove water during coating, and
d) Less time is required for coating.
1.11.2.3 The mechanism of the film formation from coating solutions and
dispersions
The formation of a coat from polymer solutions involves the conversion of a viscous
liquid into a visco-elastic solid (Porter, 1989a). In general, films from polymer
solutions can be formed in three stages. Initially, the rapid evaporation of the solvent
leads to an increase in polymer concentration. Secondly, further loss of solvent
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immobilizes the polymer molecules. Lastly, additional loss of solvent, resulting from
slow diffusion of residual solvent through the dry coating occurs. This latter stage
is very time-dependent.
Film formation from latexes or psuedolatexes involves deposition of discrete polymer
particles from water onto a tablet or pellet. In the first stage of film formation, the
aqueous phase evaporates leaving the polymer particles in close proximity. Upon
further evaporation of water, coalescence of the polymer particles into a continuous
film commences. However, the complete coalescence to uniform film is only
possible when the polymer chains are mobile enough to facilitate deformation and
total fusion of the particles (Arwidsson et al, 1991).
Many theories purport to describe the mechanism of film formation from latexes.
Dillon et al (1951) proposed that the main driving force for the coalescence of the
polymeric spheres was the polymer-water interfacial tension. Later, Brown (1956)
suggested that capillary forces generated by the water-air interfacial tension during
the evaporation of water were responsible for the coalescence of the polymer
particles. Voyutskii (1958) proposed an interdiffusion of the polymer chains through
the particle/particle interface, without which the film would be inhomogeneous and
not cohesive. Vanderhoff et al (1966) proposed that, in addition to surface tension
and capillary forces, a phenomenon known as Further Gradual Coalescence (FGe)
had a significant role in the formation of films which became more homogeneous
upon aging.
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Vanderhoff et al (1973) stated that film formation from latexes took place in three
stages: an initial stage where the polymer particles are free to move and drying
occurs at a constant rate; an intermediate stage in which the particles come into an
irreversible contact with one another and start coalescing into a continuous film and
a final stage in which the residual water evaporates at a very slow rate by diffusion
either through capillary channels between the deformed polymer particles or through
the polymer itself. It has been shown that a plasticised ethylcellulose latex film
applied to non-pareils at 43°C requires approximately four weeks to complete the
process (Onions, 1986b). If the same film is applied at a higher temperature, (lOoe,
or if it is dried for 1 h at 60°C after initial film formation, the FOC is essentially
complete (Onions, 1986b).
1.12 FACTORS AFFECTING DRUG RELEASE FROM COATED PELLETS
Although ethy1cellulose has been mainly used as a coating membrane, factors which
affect other polymers are equally applicable and are discussed in this section.
The manufacturing of coated pellets products is a highly complex process influenced
by at least the following parameters (Eskilson, 1985):
a) The active substance,
b) The core characteristics,
c) The coating technique and equipment, and
d) The membrane material and formulation.
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1.12.1 THE ACTIVE SUBSTANCE
The physicochemical properties of an active substance playa crucial role in its
release from coated pellets. The water solubility of a drug is important to the
formulation. Ghebre-Sellassie et al (1988) investigated the release of
diphenhydramine and theophylline as model drugs with high and low water solubility
respectively, from pellets coated with Surelease (aqueous dispersion of
ethylcellulose). It was shown that at a given level of coating, the rate of drug release
from pellets was mainly a function of the drug solubilities. Similar results were
reported by Iyer et al (1990) for the release of acetaminophen, guaifenesin and
diphenhydramine hydrochloride from ethylcellulose coated pellets.
Ragnarsson et al (1992) investigated the impact of drug solubility on the in vitro
release characteristics of ethylcellulose coated pellets for the sorbate, benzoate,
succinate and fumarate salts of metoprolol. As the solubility of the salt increased, the
rates of release became greater.
The faster release of drugs of higher water solubility than drugs of lower solubility
was partly attributed to the different rates of migration of drug into the coat during
film application (Ghebre-Sellassie et al, 1987). The migration process of a drug
during film application is shown in Figure 1.9. When the first layer of film is applied
(step 1) highly water soluble drugs are dissolved in the coating formulation to a
greater extent and remain in the coat after evaporation of water. As more layers of




Figure 1.9. Schematic representation of drug migration into the coat during film
application (after Porter and Ghebre-SeUassie, 1994).
layer free from drug is deposited (step 5). During dissolution, the drug present in the
inner layer of a film dissolves and leaves some pores in the coat. These pores
facilitate the ingress of dissolution medium into the core and consequently lead to
a faster drug release. Therefore highly water soluble drugs require a thicker coat in
order to show the same release profiles as a poorly water soluble drug.
1.12.2 CORE PROPERTIES
In order to obtain the desired drug release profiles from sustained release coated
pellets, the core should have the following characteristics:
I. Sufficient mechanical strength and density to withstand the mechanical attrition
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during coating (Eskilson, 1985).
2. A compact and smooth surface in order to minimize the defects in the coating due
to the entrance of coating fluid into the pores (Bey, 1991).
3. Suitable shape and size to optimize the specific surface area for the applied coat
(Hey, 1991).
4. Good flow properties to ensure uniform movement and also to alleviate packaging
problems (Eskilson, 1985).
Ragnarsson and Johanson (1988) studied the influence of the size of barrier-coated
beads on their release properties. They showed that the release rate was directly
proportional to the surface area of the cores. Similar results were reported by Li et
al (1989a) and EI-Mahrouk et al (1993) for the release of indomethacin from non-
pareil seeds having different particle size and coated with Eudragit polymers.
Porter (1989a) indicated that the release of chlorpheniramine maleate from Surelease
coated pellets was faster for smaller sized beads than larger sized beads. Porter
(1989a) postulated that geometry plays an important part in controlling drug release
from coated dosage forms. The surface area to be covered by a coating would be
.
affected by the particle size, resulting in a variation in coating thickness, when a
fixed weight of coating fluid is used. Therefore, this would influence the rate at
which the drug is released. Porter (1989a) also demonstrated that when rough or
smooth surface beads were coated, drug release rate was affected. In other words,
beads with rough surfaces demonstrated faster release of drug than beads with
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smooth surfaces. This effect was attributed to the higher surface area of the beads
with a rough surface (Porter. 1989a).
1.12.3 COATING TECHNIQUE AND EQUIPMENT
The morphological differences in the coating surface appeared to determine the rates
at which a drug was released (Metha, 1986). It has been reported that the type of
coating equipment (Mehta and Jones, 1985; Mehta, 1985; Porter and D'Andrea,
1985; Mehta, 1986; Jackson et al, 1989; Yang et al, 1992; Bertelsen et al, 1994) has
a significant influence on the release of a drug by affecting the structure of the
ultimate film coating. It is also well known that processing parameters of the coating
process (Yang and Ghebre-Sellasie, 1990; Bodmeier and Paeratakul, 1991; Laicher
et al, 1993) affect the quality of the film deposited onto the substrate and
consequently the release of the drug. The effect of inlet air temperature, the amount
of air introduced in the equipment and spray rate are important variables to be
considered during the coating process (Chang et aI, 1989).
The nozzle size, together with the atomizing air pressure determine the size of the
coating droplet and as a general rule, the finer the droplet size the better the
characteristics of the film (Mehta, 1986). As the atomizing air pressure increases it
prov.des more energy to overcome the viscous and surface tension forces resisting
droplet formation and facilitates movement of the coating fluid. Increasing the
atomizing air pressure also improves the droplet spreading on the substrate. This in
tum makes the drying process more efficient by enhancing the surface area exposed
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to the drying air and also reduces the tendency of the substrate to stick (Twitchell
et al, 1995). However the higher spreading of coating droplet reduces the extent of
penetration of coating fluid into the substrate and therefore reduces the strength of
the coat (Twitchell et al, 1995).
The effect of different spray rates on the in vitro release of granules coated with an
aqueous polymeric dispersion has been investigated by Russo (1984). It was
observed that granules coated under slower spraying conditions released drug more
slowly than granules coated under faster spray rates. It was suggested that the slower
spray rates allowed a warmer bed temperature, which in turn allowed more extensive
coat curing and less coat permeability.
1.12.4 MEMBRANE MATERIAL AND FORMULATION
1.12.4.1 Polymer effect
The type of polymer used in coating multiparticulate systems can substantially alter
the release of drug from the system (Dyer et al, 1995). Bianchini et al (1993) found
that acrylic resin coatings were more suitable to reduce the release rate of d-
Indobufen than Aquacoat. Several studies have also demonstrated differences in the
release rates of drugs coated with different types of Eudragit polymers (Munday and
Fassihi, 1989; Lehman and Petereit, 1994).
Significant differences can also be identified in the performance between various
formulations of the same polymer type. In a comparative study on three forms of
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ethylcellulose suitable for coating; Aquacoat, Surelease and ethylcellulose from an
organic solvent solution, differences between the dissolution characteristics of their
coated pellets have been reported (lyer et al, 1990; Mathieu et al, 1995). Using a
mixture of water and ethanol as the solvent for a ethylcellulose coating formulation,
Narisawa et al (1994) reported that the porosity of the coating and consequently the
drug release rates could be controlled by altering the ethanolic concentration.
In the case of aqueous dispersions of polymers, the solid concentration of the coating
formulation also affects the release rate of the drug. Wagner and Keitel (1995) found
that as the concentration of Eudragit NE 30D dispersion in a coating formulation was
decreased, the amount of drug released also decreased. As water plays an important
role in the process of film formation from aqueous dispersions, increasing the water
fraction in a dispersion facilitated the coalescence of the particles to form a
continuous film. Similar results were reported by Porter and Ghebre-Sellassie (1994).
Water acts as a plasticizer during deposition of the film, so that the film coating
process should be more complete when the water content is higher than when the
water content is lower (Laicher et al, 1993).
Rowe (1986) showed that the molecular weight of the polymer used in coating could
also affect the release process of the drug. When using low molecular weight
ethylcellulose, the release was faster than when using high molecular weights of
ethylcellulose. This was attributed to the formation of more flaws as a result of
internal stresses that developed on drying in the coating containing low molecular
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weight ethy1cellulose. As the molecular weight of the polymer increased, the coating
became more resistant to the effects of this stress, and above a certain molecular
weight, any additional increase in molecular weight had no further effect (Rowe,
1986).
1.12.4.2 Coating thickness
As drug transport through a polymeric membrane is determined by Pick's first law
of diffusion (1ambhekar et al, 1987), the quantity of drug released after a given time
will be dependent on the thickness of the controlling membrane. Shah and Sheth
(1972) showed that the passage of a dye solution through a membrane composed of
ethylcellulose and hydroxypropylcellulose was dependent on the membrane thickness.
The release rate increased as the membrane thickness decreased. This dependency
of release on coating thickness has been subsequently reported by many authors
(Ghebre-Sellassie et al, 1987; Jambhekar et al, 1987; Ghebre-Sellassie et al, 1988;
Chang et al, 1989; Munday and Fassihi, 1989; Li et al, 1991).
Coating thickness is also an important factor in determining the mechanism of
release of drug from coated pellets. Zhang et al (1991a) demonstrated that the release
mechanism of acetaminophen changed from diffusion through pores to diffusion
through intact polymer when the coating thickness of ethylcellulose increased.
Similarly Dyer et al (1995) demonstrated the existence of a critical coating level for
ibuprofen pellets coated with different polymers, above which the drug release
kinetics changed from first-order to zero-order.
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1.12.4.3 Additives
Several additives may be added to coating formulations in order to change the
mechanical properties of the film, to change the permeability of the film, as anti-tack
agents or to change the colour of the film. These additives include plasticizer, water
soluble additives or water insoluble additives.
,..
Plasticizer: Plasticizers playa crucial role in the formation of a film coat and its
ultimate structure. They modify the mechanical properties of the polymers and
improve their film forming ability. Plasticization in general refers to a change in the
thermal and mechanical properties of a polymer (Guo, 1994). The ideal plasticizer
used in film coating should not only be compatible with the polymer but also must:
a) be safe for use in pharmaceuticals.
b) be compatible with the drug and other components.
c) remain permanently in the resultant film.
To be effective, the plasticizer molecule must interpose between the polymer chains
and interact with forces holding the chains together, thereby extending and softening
the polymer matrix (Rowe, 1982). One of the theories that is used to explain changes
in the mechanical properties of the films upon adding the plasticizer is the "gel
theory" (Aulton et al, 1981). In this theory, there are some active centres along the
polymer chain which bind the polymer molecules in solution. In solution, these
bonds are in dynamic equilibrium, ie constantly forming and breaking. As they
break, solvent (i.e., water) molecules compete for the active sites. Plasticizers
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compete for the active sites and consequently decrease the number of polymer-
polymer contacts, resulting in a decrease in the cohesive forces between the polymer
chains. In summary, plasticizers act by preventing the aggregation of polymer
molecules during gel formation as the solvent is evaporated (Aulton et al, 1981).
It is well known that not only the type of plasticizer but also its concentration are
parameters which modify the release characteristics of an active substance. Goodhart
et al (1984) reported that since the film forming process of the latex involves the
fusion of individual polymer particles into a homogeneous film, particle coalescence
is dependent upon the presence of enough plasticizer to soften the latex particles so
that deformation can occur. Chang et al (1989) showed that the release rate of
theophylline from pellets coated with 9% Eudragit RS was inversely proportional to
plasticizer (dibutyl sebacate or triacetin) concentration. Schmidt and Niemann (1993)
found that the release of theophylline from pellets coated with Eudragit RS30D was
affected by the type and concentration of plasticizers. At a coating level of 4%,
sustained release profiles were obtained from dispersions plasticized with 20%
triethyl citrate or dibutyl phthalate but not for pellets plasticized with polyethylene
glycol.
In general, by increasing the amount of plasticizer, the rate of drug release is
reduced. However certain studies have revealed that release rates increased with
higher plasticizer levels. Li et al (1991), examining the effect of plasticizer type and
concentration on the release of pseudoephedrine from Eudragit RL coated pellets
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pointed out that beads coated with lower levels of diethylphtalate showed slower
release profiles than when higher levels of plasticizer were used. This was attributed
to a higher degree of bead agglomeration, sticking and other problems related to the
softer films which resulted from higher plasticizer levels. Hutchings and Sakr (1994)
found that when the amount of dibutyl sebacate was increased from 30 to 35%, the
release rate of propranolol hydrochloride increased for pellets coated with Aquacoat.
These authors postulated that increasing the amount of plasticizer beyond a certain
saturation point is associated with no further enhancement of film formation, but may
result in detrimental effects on the film coating during processing.
Water soluble additives: Water soluble materials of high molecular weight or low
molecular weight are added into the rate retarding films to enhance the permeability
of that film towards the active agent. Muhammad et al (1991) investigated the
influence of various additives, namely polyethylene glycol (PEG), mannitol, and
HPMCP 50 (Hydroxypropylmethylcellulose phtalate 50) incorporated with Eudragit
L30D on the release of a drug. It was shown that drug release from coated pellets
was dependent on the type and the level of the additive. For example, at pH 1.5,
PEG, regardless of its molecular weight, had no significant effect on drug release.
At pH 5.5, however, the inclusion of PEG significantly decreased the drug release
from coated pellets. This was attributed to the formation of a film which was not
soluble at pH conditions where Eudragit L30D normally dissolves.
Porter (1989a) reported an increase in the release rate of chlorpheniramine maleate
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from beads coated with Surelease when methylcellulose 15 mPa.s was added. The
increase in release rate was attributed to the formation of pores upon dissolution of
the water soluble methylcellulose (Porter, 1989a). Lindholm et al (1982) reported that
the release rate of sodium salicylate from tablets coated with ethylcellulose was
dependent on the water solubility of the solids which were added to the film (e.g.
sodium chloride, sucrose, tetrabutylammonium chloride).
Water insoluble additives: Water insoluble materials are used in sustained release
film coatings either to reduce the tackiness of the formulation or to change its colour
(Porter, 1989a). Li et al (1989b) reported a decrease in the release rate of
theophylline from pellets coated with Eudragit E30D on increasing the amount of
talc in the formulation. This was attributed to an increase in thickness of the coating.
However Chang and Hiaso (1989) found that the addition of talc and silica to the
coating dispersion of Eudragit RL or Eudragit RS pseudolatices increased the release
of theophylline. Similar results were reported by Ghebre-Sellassie et al (1986; 1987),
upon addition of talc, kaolin or magnesium trisilicate into Eudragit E30D
formulations on the release of diphenhydramine hydrochloride from coated beads.
Wan and Lai (1993) demonstrated the effect of various anti-tack additives such as
magnesium stearate, stearic acid, talc and silicon dioxide, on the release of
diphenhydramine hydrochloride from pellets coated with methylcellulose. These
authors found that all the additives caused an increase in the release rate of drug
from the coated granules with the effect being more in the case of magnesium
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stearate. This was attributed to the uneven swelling of methylcellulose coated beads
and also to the production of more interfacial voids in the film due to the uneven
distribution of the hydrophobic magnesium stearate in the hydrophilic
methylcellulose film.
1.12.5 RELEASE KINETICS OF COATED MULTIPARTICULATE DOSAGE
FORMS
It is necessary to refer to the model of the reservoir device in which the active agent
forms a core surrounded by a polymeric diffusion barrier in order to predict drug
release from a coated solid dosage form. According to this model, the drug release
rate will be either constant if the thermodynamic activity of the drug is maintained
constant within the device with perfect sink conditions in the receptor medium
(Jambhekar, 1987) or it will follow a first-order relationship if the core is not
saturated with the drug or if sink conditions are not maintained (Friedman et al,
1979).
Many theoretical models have been used to describe drug release from controlled
release devices. Theoretically, optimal release kinetics from a sustained release
product should be zero-order (Kruger- Thiemer and Eriksen, 1966; Robinson and
Eriksen, 1966; Robinson and Eriksen, 1970). Such a release follows equation 1.1:
W=W-Kt•
Equation 1.1
where W is the amount remaining to be released at time t, Wo is the initial amount
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of drug in the dosage form and K is the zero-order release rate constant.
In studies on microcapsules and coated granules, in addition to zero-order kinetics,
Higuchian kinetics (Donbrow and Friedman, 1975; Alpar and Walters, 1981), first-
order kinetics (Benita and Donbrow, 1982; Donbrow and Benita, 1982) and Hixon-
Crowell equation kinetics (Benita and Donbrow, 1982) have been reported.
Higuchi (1963) developed kinetic equations for the release of active substances from
inert matrices. The cumulative release per unit area, Q, versus time t, from a planar
surface is determined by equation 1.2.
EqUlltion 1.2
Here, E is the porosity of the matrix and 't is a tortuosity factor which denotes the
extra path to be taken by the diffusing drug molecules around the matrix particles.
D and C, are the diffusion coefficient and solubility in the dissolution medium
respectively and A is the concentration of drug in the tablet.




where k is a first-order release rate constant (Kruger-Thiemer and Eriksen, 1966). W
and Wo are the same as in equation 1.1.
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Hixon and Crowell (1931) derived equation 1.4 to explain the dissolution rate of a
single crystal under sink conditions.
wl/3 = W 1/3 - Kt
o
Equation 1.4
W is the amount of drug remaining to be dissolved at time t, Wo is the initial amount
and K is a constant. This equation has been applied to microcapsules by Benita and
Donbrow (1982).
1.13 FACTORS AFFECTING DRUG RELEASE FROM
HYDROXYPROPYLMETHYLCELLULOSE MATRICES
As the factors influencing drug release from hydrophilic matrices have been the
focus of a vast number of studies, this section describes those which affect drug
release from HPMC matrices.
1.13.1 POLYMER EFFECT
1.13.1.1 Polymer viscosity
The effect of viscosity grade of HPMC on the release of drugs has been the focus
of many research articles. There are conflicting reports. Lapidus and Lordi (1968)
stated that a lower molecular weight of HPMC with lower viscosity (the viscosity
of its 2% solution at 20°C was 25 mPa.s) was more susceptible to erosion than the
higher molecular weight with higher viscosity (15000 mPa.s). Alderman (1984)
stated that the release of a drug would be slower if a higher viscosity grade of
HPMC was used in the matrix. This was attributed to an increase in gel layer viscosity.
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Ford et al (1985a) reported that HPMC K4M, HPMC K15M, HPMC KIOOM gave
similar release profiles of promethazine hydrochloride while a lower viscosity grade
(HPMC K1(0) behaved differently and gave the fastest release rates. Ford et al
(1985a) claimed that the viscosities of the matrices containing hydrated higher
molecular HPMC may be similar, in spite of differences in their viscosities. Ford et
a1 (1985b) showed that both the lag time and release rate were not affected by the
viscosity grade of HPMC for propranolol hydrochloride and aminophylline. However
Ford et al (1985c) claimed that for poorly water soluble drugs, such as indomethacin,
the viscosity grade plays a major role in controlling drug release.
Baveja et al (1988) reported that the release rate of a series of bronchodilators did
not vary for matrices containing HPMC K4M, HPMC K15M, and HPMC KIOOM
which was in agreement with the earlier studies of Ford et a1 (1985b). Similar results
were reported by Mitchell et al (l993b) for the release of propranolol hydrochloride
from matrices containing HPMC K4M or HPMC K15M.
Liu (1995) stated that the resistance of a gel layer is controlled by the viscosity
grade of HPMC. Wan et a1 (1995a) claimed that the thickness of the swollen layer
formed around the core was greater in compacts composed of HPMC of higher
viscosity grade. Tahara et a1 (1995) demonstrated that the viscosity of HPMC had
a great effect on the erosion rate of matrix tablets and consequently on the release
rate of the drug.
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1.13.1.2 Polymer substitution type
Alderman (1984) claimed that different levels of methoxyl and hydroxypropoxyl
substitution in the HPMC affect the release of a drug from the matrices by
influencing the hydration rates of the HPMC. Dahl et al (1990) examined different
lots of HPMC 2208 from two suppliers and reported that the release of naproxen was
dependent on the hydroxypropoxyl content in the polymer. Dahl et al (1990) claimed
that suitable dissolution profiles were obtained only when the hydroxypropoxyl
content was >7.5% in the HPMC. However Mitchell et al (1993a) and Rajabi-
Siahboomi et al (1994b) showed that there was no differences in the hydration rates
of HPMC E4M, HPMC F4M and HPMC K4M.
1.13.1.3 Polymer particle size
The polymer particle size affects its hydration rate and consequently the rate of drug
release (Alderman, 1984). Alderman (1984) showed that the release of riboflavin was
fast from matrices prepared of a coarse particle size of HPMC (>210 urn) while
dissolution rates for tablets made from smaller particles «150 urn) were sustained.
Mitchell et al (1993d) reported that the role of particle size was dependent on the
polymer concentration. At high polymer concentrations, coarse and fine fractions
I
behaved similarly. However at low HPMC contents, drug release was faster from
matrices prepared with coarser particles (>355 urn).
1.13.1.4 Polymer particle shape
Bonferoni et al (1995) stated that when HPMC E4M was sieved to give two different
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shape fractions, matrices prepared from the fraction rich in fibrous particles showed
drug release similar to the unsieved HPMC E4M. However, matrices prepared from
the sieved fraction containing as low as 22.8% fibrous particles showed a lack of
control of drug release. This was attributed to the better particle interlocking of
fibrous particles which helped to strengthen the matrix structure.
1.13.2 EFFECT OF DRUG:POLYMER RATIO
Ford et al (1985a, b) demonstrated that the drug/HPMC ratio was the most important
factor controlling the release of drug from HPMC matrices. Ford et al (1985a) found
that a straight-line relationship existed between the Higuchian release rate (%min-
I12
)
of promethazine hydrochloride and the reciprocal of the polymer content in the
matrix.
1.13.3 EFFECT OF DRUG
1.13.3.1 Effect of drug solubility and molecular size
The molecular size and water solubility of a drug are important factors which
determine its release from swelling and erosion controlled polymeric matrices (Ranga
Rao et al, 1990). Baveja et al (1988) examined the release of a series of structurally
related water-soluble bronchodilators having almost identical solubilities from HPMC
matrices. It was reported that the drugs showed different release rates from matrix
tablets due to differences in the shape and size of the drug molecules (Ranga Rao
et al, 1990).
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Ford et aI (1987) by studying 7 soluble and insoluble drugs, reported that the
solubility of the drug plays an important role in its release from HPMC matrices.
Skoug et al (1993) developed a method to measure polymer concentration in the
dissolution medium and showed that the release of flurbiprofen (low solubility) from
HPMC matrices was primarily by erosion whereas adinazelam mesylate (freely
soluble) matrices exhibited diffusion controlled mechanisms. On the other hand, both
diffusion and erosion contribute to the drug release from alprazolam (moderate
solubility) matrices (Skoug et al, 1993).
1.13.3.2 Effect of drug particle size
Ford et al (l985a, 1985b) evaluated the effect of drug particle size on the release
from HPMC matrices. The release of promethazine hydrochloride, propranolol
hydrochloride and aminophylline was not dependent on their particle size except
when the polymer/drug ratio was low and the particle size of the drugs was large.
However, Ford et al (l985c) indicated that for insoluble drugs, the particle size plays
an important role in controlling of release rate.
1.13.4 EFFECT OF EXCIPIENTS
Excipients are added to matrix tablets to provide enough volume for tableting, to
modify the release rate of drug, to lubricate the formulation or to change the colour.
As these materials may affect the release characteristics of a drug it is therefore
necessary to study the effects which these excipients may have on release.
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Lapidus and Lordi (19.66) stated that the replacement of HPMC by insoluble or
soluble excipients increased the rate of drug release. Lapidus and Lordi (1968)
showed at only high excipient concentrations (>50%) that the release of
chlorphenirarnine maleate was faster when lactose was used than when an equivalent
amount of dicalcium phosphate was used. Similar results were reported by Ford et
al (1987) who found that differences between dicalcium phosphate and lactose were
observed when tablets contained low amounts of HPMC (10 mg) and high amounts
of excipients (30 mg). Ford et al (1985a) found that the presence or absence of
lubricant did not have any effect on the release of promethazine hydrochloride from
HPMC K15M matrices.
Daly et al (1984) observed that the release rates of chlorpheniramine maleate
decreased in HPMC matrices.containing the surfactant, sodium dodecyl sulphate.
This was attributed to an increase in viscosity of the polymer due to its interaction
with the surfactant. Feely and Davis (1988a) found that the release of
chlorpheniramine maleate from HPMC matrices was decreased by the addition of
anionic sodium alkyl sulphates and that was due to the formation of an insoluble
complex. Ford et al (199Ib) reported that the release of propranolol hydrochloride
from HPMC matrices decreased in the presence of sodium dodecyl sulphate as a
result of formation of propranolol dodecyl sulphate.
1.13.5 EFFECT OF COMPACTION FORCE
The effect of compaction force has been studied by many workers (Lapidus and
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Lordi, 1968; Salomon et al, 1979; Conte et al, 1993). Generally, differences in
compaction force have little effect on either tablet density or porosity of hydrophilic
polymers such as HPMC and sodium carboxymethylcellulose (Huber and
Christenson, 1968; Ford et al, 1985a; Dahl et al, 1990; Bettini et al, 1994; Sheskey
et al, 1994).
However Korsmeyer et al (1983b) found that the release rate of potassium chloride
from HPMC matrices compressed at forces ranging from 28 MPa to 280 MPa varied
inversely with tablet porosity and mean pore diameter. They claimed that air trapped
within the tablets acted as a transport barrier. Therefore as the porosity of the tablet
increased, the initial air trapped in the tablet increased and this caused drug release
to be reduced.
1.13.6 RELEASE KINETICS FOR MATRICES
Many mathematical models have been proposed to interpret drug release from
matrices. Higuchi (1963) derived equation 1.2 to describe the release of dispersed
drug from matrices. This equation predicts that the release of drug from a matrix is
. proportional to square root of time. The simple form of this equation is shown as
equation 1.5 (Ford et al, 1991a).
Q = Ato.s+ C EqlUltion 1.5
Q is the fraction of drug released, A is root time dissolution rate constant and C is
a constant. The Higuchi equation can be applied if the mechanism of drug release
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from HPMC matrices. Erosion of the polymer also contributes to the process.
is diffusion. However diffusion is not always the only mechanism for release of drug








Korsmeyer et al (1983a) used equation 1.6 to describe the release mechanism of
hydrophilic matrices.
In equation 1.6, Q is the percentage of drug released at time t, K is a constant
relating to the structural and geometric characteristics of the controlled release
device, t is the release time and n is the release exponent, indicating the mechanism
of drug release. Peppas (1985) stated that equation 1.6 can be used to analyse the
first 60% of a release curve. Peppas and Ritger (1987) gave the dependence of n on
the diffusional mechanism as depicted in Table 1.1. Fickian diffusion involves the
molecular diffusion of the drug due to a chemical potential gradient (Peppas and
Sahlin, 1989) and is linearly related to the square root of time. In Case II transport
(or relaxational release mechanism) the release rate is independent of time and zero
order release can be observed. Non-Fickian or anomalous release is the coupling of
diffusion and relaxation mechanisms. Super case II transport mechanism is a non-
Fickian diffusion which is observed for systems exhibiting increased swelling at the
relaxing front usually at long period of time (Langer and Peppas, 1981).
The effect of lag time was ignored in the equation 1.6. Later Ford et at (1987) stated
that equation 1.6 was valid if the release occured as soon as the matrix was exposed
to the dissolution fluid. Usually, however, a lag time prior to the release of a drug
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Table 1.1. Analysis of diffusional release mechanism (after Peppas and Ritger 1987).
Cylindrical sample Spherical sampleThin film
0.5 0.45 0.43 Fickian diffusion
0.5 < n < 1.0 0.45 < n < 0.89 0.43 < n < 0.85 Non-Fickian diffusion
1.0 0.89 0.85 Case- II transport
> 1.0 >0.89 >0.85 Super case II
was observed. Therefore equation 1.7 was proposed by Ford et al (1991 a) to account
for a lag time.
Q == K (t-l)" Equation 1.7
In this equation I is lag time and the other terms are the same as in equation 1.6. As
both diffusion and erosion take part in release of drug from hydrophilic matrices,
Catelani et al (1988) and Harland et al (1988) used equation 1.8 to analyse the
release data. In this equation diffusion and polymer relaxation mechanisms are
simultaneously considered.
Equation 1.B
In equation 1.8, KJ and K2 are relative contribution of Fickian and relaxational
mechanism respectively.
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The fact that most systems have a value of n which is intermediate between the
Fickian diffusion value and the zero-order release profile has led Peppas and Sahlin
(1989) to describe an equation by which it was possible to calculate the contribution
due to relaxation and that due to diffusion (equation 1.9). K and K' in equation 1.9
are Fickian and relaxation release constants, respectively. They claimed that the
exponent n for case II transport mechanism is twice that of the Fickian diffusional
mechanism regardless of the geometric device used. Peppas and Sahlin (1989)
considered that Fickian diffusion and relaxational mechanism were additive.
Q = Kt" + K1l11 EqlUltio1l 1.9
Ford et al (1991a) derived equation 1.10 by adding a lag time correction to equation
1.9. In equation 1.10 K and K' are the same as equation 1.9 and 1 is the lag time.
Q = K (t-l)" + K' (t-li" EqlUltio1l 1.10
1.14 AIMS AND OBJECTIVES
The aims and objectives of the work presented in this thesis were mainly to
investigate the performance of cellulose ethers, namely hydroxypropylmethylcellulose
and ethylcellulose in "coated pellets" and "matrices". Their performance was assessed
by using two structurally different drugs with different solubilities (metoclopramide
hydrochloride and diclofenac sodium). The study was performed:
(1) To examine the effect ofhydroxypropylmethylcellulose (HPMC) of low viscosity
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factors controlling drug release rate from pellets coated with the water soluble
grades in the production of sustained release coated pellets. Chapter 4 deals with
HPMC. The effect of coating load of polymer on drug release and the kinetics of
drug release from coated pellets was assessed.
(2) To evaluate the effect of coating load of ethylcellulose aqueous dispersion
(Surelease) on the release of drug. Chapter 5 investigates the factors controlling drug
release from pellets coated with water insoluble ethylcellulose. The release kinetics
were also characterized.
(3) To study the effect of inclusion of water soluble HPMC to water insoluble
ethylcellulose on drug release profiles. Chapter 6 examines the effect of different
ratios of HPMC:EC on drug release from coated pellets.
(4) To examine the release characteristics of drugs from HPMC matrices prepared
•by direct compression. Chapter 9 investigates the release kinetics and mechanism of
drug release from HPMC matrices. The effect of polymer viscosity and polymer/drug
ratio were studied.
(5) To explore the effect of incorporation of EC in HPMC matrices using wet
granulation method on drug release and compare with matrices prepared by direct
compression (chapter 10).
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CHAPTER 2. MATERIALS AND GENERAL METHODOLOGY
2.1 MATERIALS
The following materials were used throughout this study:
2.1.1 HYDROXYPROPYLMETHYLCELLULOSE
Batches of hydroxypropylmethylcellulose USP types 2910 and 2208 manufactured
by Dow Chemicals (Midland, Michigan, USA) and obtained from Colorcon Ltd
(Orpington, Kent, UK) were used. The molecular structure and formula of HPMC
were shown in Figure 1.8. The two HPMC grades which were used in this study
were Methocel E (corresponds to USP type 2910) and Methocel K (corresponds to
USP type 2208).
Methocel E has a methoxyl content of 28-30% and a hydroxypropoxyl content of 7-
12%. Methocel E5 Premium (HPMC E5), Methocel E15-LV Premium (HPMC E15)
and Methocel E4M Premium (HPMC E4M) were used in this study. The batch
numbers and the nominal viscosities of their 2% solutions in water at 20°C are
shown in Table 2.1.
Methocel K has a methoxyl content of 19-24% and a hydroxypropoxyl content of 7-
12%. Methocel KI00 LV Premium (HPMC K100) and Methocel K4M Premium
(HPMC K4M) were used in this study. The batch numbers and the nominal
viscosities of their 2% solutions in water at 20°C are shown in Table 2.1.
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Table 2.1. The batch numbers and nominal viscosities of 2% w/w solutions
of hydroxyproylmethylcellulose polymers used in this thesis.
Polymer Batch number Viscosity· (mPa.s)
HPMC ES MM930S1871E S
HPMC E15 MM93042522E 15
HPMCE4M MM91061011E 4000
HPMC Kl00 MM94051022K 100
HPMC K4M MM92031903K 4000
*: Raw material specification supplied by Colorcon Ltd.
2.1.2 ETHYLCELLULOSE AQUEOUS DISPERSION (SURELEASE)
Throughout the study, pellets were coated mainly with a commercially available
ethylcellulose aqueous dispersion (Surelease E-7-70S0) obtained from Colorcon Ltd
(Orpington, Kent, UK). The molecular structure and formula of ethylcellulose were
shown in Figure 1.8. Surelease E-7 -7050 has been described as an off white liquid
(Raw material specification supplied by Colorcon Ltd.). It contains ethylcellulose 20
mPa.s (17.36% w/w), dibutyl sebacate (3.76% w/w), oleic acid (2.03% w/w), fumed
silicon (1.85% w/w) and ammoniated water (7SJ)0% w/w). The pH of dispersion is
9.5-11.S (Moore, 1989). The solid content of the dispersion is 2S% w/w and the
average ammonia content in the liquid dispersion is 0.8-1.0% w/w (calculated as
ammonia, not ammonium hydroxide). Its boiling point is about 95°C. Surelease was
also used as a granulating agent (chapter 10) in the preparation of matrix tablets.
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Metoclopramide hydrochloride (Figure 2.1) is a white odourless, crystalline powder,
soluble 1 in 0.7 of water, 1 in 3 of ethanol, 1 in 55 of chloroform and practically
insoluble in ether (Pitre and Stardi, 1987). It melts at about 182-183°C with
maxima at 273 nm and 309 nm (Moffat et al, 1986). Metoc!opramide hydrochloride
was obtained from Wilfrid Smith Limited (Edgware, Middlesex, UK).
Cl
-HCI-~O
Figure 2.1. The molecular structure of metoc!opramide hydrochloride.
2.1.4 DICLOFENAC SODIUM
Diclofenac sodium (Figure 2.2) is a white to slightly yellowish crystalline powder,
sparingly soluble in water, freely soluble in methanol, soluble in ethanol (96%);
slightly soluble in acetone, practically insoluble in chloroform and in ether (Adeyeye
and Li, 1990). Its solubility is pH dependent (Navarro and Ballesteros, 1994).
Dic!ofenac sodium melts at about 282-285°C with decomposition and has a pKa of
4.0. Its ultraviolet spectrum in aqueous acid has a maximum at 273 nm and in
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aqueous alkali has a maximum at 275 nm (Moffat et al, 1986). Diclofenac sodium :
was obtained from Industria Chimica Profarmaco (Milan, Italy).
C~COONa Cl
Figure 2.2. The molecular structure of diclofenac sodium.
2.1.5 NON-PAREILS
Non-pareil seeds (commercially available sugar spheres) were used as inert core in
the formulations of pellets. Sugar spheres are prepared from crystalline sucrose
which is coated using sugar syrup and a starch dusting powder. The United States
Pharmacopeia / National Formulary (1995) describes sugar spheres as approximately
spherical granules with a uniform diameter and containing not less than 62.5% and
not more than 91.5% of sucrose, calculated on the dried basis. The rest of the
formulation is mainly starch. Non-pareil seeds with size of 16/20 mesh (0.850-1.18
mm) and 20-25 mesh (0.710-0.850 mm) obtained from Edward Mendel Co. (Redhill,










Triacetin (Figure 2.3) was obtained from Colorcon (Orpington, Kent, UK). It is a
colourless and odourless liquid with specific gravity of about 1.15-1.16 g.cm", It
boils at 266°C and its solubility in water is about 6.1% at 25°C (raw material
specification data supplied by Colorcon).
Figure 2.3. The molecular structure of triacetin.
2.1.7 TALC
Talc Fine Powder (Laboratory Reagent) was obtained from British Drug Houses
(Poole, Dorset, UK) and used as an anti-adhering agent in coating formulations.
2.1.8 MAGNESIUM STEARATE
Magnesium stearate (General Purpose Reagent) was obtained from British Drug
Houses (Poole, Dorset, UK) and used as lubricant in the preparation of tablets.
2.2 METHODS
2.2.1 UV CALIBRATION OF DRUGS
2.2.1.1 Metoclopramide hydrochloride
Solutions of metoclopramide hydrochloride in distilled water were prepared by
62
dissolving 4, 8, 12, 16 or 20 mg of metoclopramide hydrochloride, accurately
weighed on an Oertling analytical balance (West Midlands, UK), in 1000 ml water.
The UV absorbances of these solutions at 309 nm were determined using a
spectrophotometer (Philips PU 8625, Cambridge, UK) and are shown in Figure 2.4.
The best fit equation for the Beers's law plot of the UV absorbance versus drug
concentration, is given by equation 2.1.
A = -0.0013 + 34.3 C (r = 0.9998) Equation 2.1
Where A is the absorbance of the solution and C is the concentration of
metoclopramide hydrochloride (mg/ml). This equation was used to assay the drug
content of pellets.
As the drug content of the pellets used in dissolution studies was 15 mg, solutions
of metoclopramide hydrochloride in distilled water were prepared by dissolving 15
mg of metoclopramide hydrochloride, accurately weighed using an Oertling
analytical balance (West Midland, UK), in 900 ml water. The W absorbances of
these solutions were determined at 309 nm using the Diode Array spectrophotometer
(Hewlett Packard HP8452A, Waldbronn, Germany, coupled to the dissolution tester)
and were 0.583 ± 0.008 (n=3). Its E 1%, 1 cm value, determined experimentally and
used in dissolution studies, was 342.9.
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2.2.1.2 Diclofenac sodium
Solutions of diclofenac sodium in distilled water were prepared by dissolving 4, 8,
12, 16 or 20 mg of diclofenac sodium, accurately weighed on an Oertling analytical
balance (West Midlands, UK), in 1000 ml water. The UV absorbances of these
solutions at 275 nm were determined using a spectrophotometer (Philips PU 8625,
Cambridge, UK) and are shown in Figure 2.5. The best fit equation for the Beers's
law plot of the UV absorbance versus drug concentration, is given by equation 2.2,
A = 0.0050 + 31.3 C (r = 0.9997) Equation 2.2
Where A is the absorbance of the solution and C is the concentration of diclofenac
sodium (mg/ml). This equation was used to assay the drug content of pellets.
As the drug content of the pellets used for dissolution studies was 15 mg, solutions
of diclofenac sodium in distilled water were prepared by dissolving 15 mg of
diclofenac sodium, accurately weighed using an Oertling analytical balance (West
Midland, UK), in 900 ml water. The UV absorbances of these solutions were
determined at 275 nm using the Diode Array spectrophotometer (Hewlett Packard
HP8452A, Waldbronn, Germany coupled to the dissolution tester) and were 0.535
± 0.010 (n=3). Its E 1%, 1 cm value, determined experimentally and used in
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Figure 2.4. Calibration CUIVeof metoc1opramide hydrochloride in distilled water at
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,
Figure 2.5. Calibration CUIVeof diclofenac sodium in distilled water at 275 nm. (each
point is the mean ± SD of three determinations).
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2.2.2 DETERMINATION OF DRUG SOLUBILITY
2.2.2.1 Determination of solubility of metoclopramide hydrochloride
Because metoclopramide hydrochloride is a highly water soluble drug, in order to
determine its solubility in water at 37°C, 2.5 g samples of metoclopramide
hydrochloride were added into 5 ml test tubes containing 1 ml of distilled water. The
test tubes were placed in a shaking water bath (Companstat 882942, UK), at 37°C.
After complete dissolution of the drug, accurately weighed, additional amounts of
drug in increments of 20 mg, were added and the test tubes were examined after 1
h for the occurrence of any crystals. The solubility of metoclopramide hydrochloride
was reported at the point where the crystals of drug appeared in the tubes and
remained for 48 h.
2.2.2.2 Determination of solubility of diclofenac sodium
Samples (500 mg) of diclofenac sodium powder were added into 10 ml test tubes
containing 5 ml of distilled water. The test tubes were placed in a shaking water bath
(Companstat 882942, UK), at 37°C for 48 h. Then the suspended solids were
allowed to settle and the supernatants were filtered through a Whatman No. 1 filter
paper (Whatman International Ltd., Maidstone, UK). The drug' concentration was
determined spectrophotometrically (Philips PU 8625 Cambridge, UK) at 275 nm after
appropriate dilution. The mean of three determinations was used to calculate the
solubility of diclofenac sodium in distilled water.
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2.2.3 PREPARATION OF COATING FLUIDS
2.2.3.1 Preparation of coating fluids containing HPMC ES or HPMC EIS
Batches (8 kg) of coating fluids containing HPMC E5 or HPMC E15 were prepared
at each time of coating. The composition of the coating suspensions for HPMC E5
and HPMC E15 are shown in Tables 2.2 and 2.3 respectively. The concentrations of
HPMC E5 and HPMC E15 in the coating fluids were around the values (6% and 4%
w/w respectively) needed to achieve uniform coating (Nagai et al, 1989). The
amount of plasticizer (triacetin) added was 25% of the polymer weight on the basis
of a study performed by Johnson et al (1991).
Solutions of HPMC E5 or HPMC E15 were prepared by initially heating one third
of the total amount of water to 80-90°C. The desired amount of HPMC powder was
added while stirring with a paddle stirrer. The mixtures were stirred until all
agglomerates had disappeared and the particles were thoroughly wetted. Whilst
stirring, the remaining water was added as cold water. The talc and plasticizer
(triacetin) were added at this stage. The coating fluids were prepared 24 h before use
to ensure uniform solvation of the polymer.













2.2.3.2 Preparation of coating suspension of Surelease
The commercial ethylcellulose aqueous dispersion (Surelease E-7-7050 which
contains 25% w/w solids) was diluted to a solid content of 15% w/w with distilled
water. This was based on the recommendation of Colorcon Ltd. The suspension was
stirred for approximately 30 min. The composition of the diluted coating suspension
of Surelease is shown in Table 2.4. The coating dispersion was prepared 30 min
before use.




2.2.4 EVALUATION OF PELLETS
2.2.4.1 Coating efficiency
The solid contents of each polymeric suspension (HPMC E5, HPMC EI5 or
Surelease) were determined by drying aliquots (20 g) of the suspensions in an oven
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at 60°C until constant weights were obtained. The amounts of dry substance were
calculated after weighing the solid contents which rernained following drying.
The arnount of dry substance applied in each coating process was calculated based
on the arnount of the coating suspension that had been consurned for coating, as a
theoretical weight gain (%A) for each coating process. The increase in pellet weight
after each coating process, which was determined by weighing the pellets before and
after the coating process was used as the experirnental weight gain (%8). Then, the
coating efficiencies were calculated using equation 2.3.
BCoating e/ficiBncy = - x 100
A
EqUlltion 2.3
This procedure was used in the optirnization of the coating conditions (chapter 3)
that were used to apply the polymeric filrns.
i
2.2.4.2 Degree of aggregation of the pellets
The degree of aggregation of placebo pellets (see section 3.4) was evaluated by
rnechanical sieving using a series of 20 cm diameter sieves (Endcotts Ltd., London,
UK) with aperture sizes 1.4 mrn, 1 mm, 0.850 rnrn, and 0.710 rnm. A sample load
of 100 g of coated pellets was sieved using the nest of sieves which were shaken on
a rnechanical shaker (Pascal Engineering, Sussex, UK) continuously for 10 min. A
visual analysis showed that the pellet fraction retained on the 1.4 rnm sieve consisted
of aggregated pellets. Therefore, the percentages of the final product that was
retained on the 1.4 rnm sieve were used as an indicator of the degree of aggregation.
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Duplicate samples were used to calculate the degree of aggregation. This procedure
was used in optimization of coating conditions that were used to apply the polymeric
film.
2.2.4.3 Scanning Electron Microscopy (SEM)
Coated pellets were examined under a scanning electron microscope (SEM) (Jeol
model JSM-T200, Tokyo, Japan) to study the surface morphology of the pellets. This
study was used in evaluating the coating conditions and also to investigate the
surface of the drug-loaded pellets coated with polymers before and after dissolution.
Dry samples were mounted onto stubs using double sided adhesive tape and vacuum
coated with gold in an argon atmosphere in the coating chamber of a Polaron E500
diode sputter coating unit (Holywell Industrial Estate, Watford, UK). The coated
samples were individually placed on the specimen holder of the scanning electron
microscope in a vacuum chamber. The chamber was evacuated and a voltage of 25
kV was selected for accelerating the electrons from electron gun onto the specimen.
The image formed was viewed directly via a screen or recorded photographically.
2.2.4.4 Assay of drug content of the drug layered pellets
From each batch, 400 mg of pellets was weighed accurately, ground to fine powder
with the use of a glass pestle and mortar and transferred into a 1000 ml volumetric
flask using water. The flask was shaken for a period of 1 hour and then brought to
volume with water. An aliquot of this solution was filtered 'and assayed
spectrophotometrically at 309 nm and 275 nm for metoclopramide hydrochloride and
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diclofenac sodium respectively using a spectrophotometer (model Phillips PU 8625,
Cambridge, UK). All the assays were carried out in triplicate and the mean value
reported. The concentration of metocIopramide hydrochloride or diclofenac sodium
in the each batch of pellets was calculated from the calibration curves (Figures 2.4
and 2.5).
2.2.5 PREPARATION OF MATRICES
Matrices prepared' by direct compression of blends containing metoclopramide
hydrochloride <90!lm or diclofenac sodium <90 urn, polymers (HPMC EI5, HPMC
E4M, HPMC KIOOor HPMC K4M) in drug:polymer ratios of 1/3, 1/4, 1/5 and 1/10
and 0.5% magnesium stearate as lubricant. The blends were mixed for 15 minutes
using a tumbler mixer. Flat-faced tablets, 7.14 mm diameter, were directly
compressed on a Manesty F3 single punch tabletting machine (Manesty Machines
Ltd., Liverpool, UK) at 20 kN compression force.
2.2.6 DISSOLUTION TESTING
Dissolution was measured by a Pharmatest (GMbH, Hainburg, Germany) dissolution
tester coupled with a Diode Array spectrophotometer (Hewlett Packard HP8452A,
Waldbronn, Germany). The USP XXII (apparatus I) was used, rotating at 50 rpm in
900 ml distilled water at 37 ± 0.5°C and maintained at this temperature. The media
were automatically sampled using an Ismatec peristaltic pump (lSP 81B, Carshalton,
UK) at 50 ml.min' flow rate. Metoc1opramide hydrochloride and dicIofenac sodium
were monitored at 309 and 275 nm respectively. The mean of six determinations was
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used to calculate the drug release for each formulation.
2.2.7 RELEASE KINETICS
In order to determine drug release rates, data were fitted to various kinetic models
discussed in chapter 1 (equations 1.1-1.4) using statistical software (Mini tab,
Standard Release 9.1). Regression analyses were used to obtain the release constants
(K) and correlation coefficients (r) for each model. The correlation coefficients for
the best statistical fit were used as the principal criteria to evaluate the models. The
equation with the highest correlation coefficient was judged to be the most
appropriate model for each system. Lag times were also defined as the X intercept
when the fitted curve of each model was extrapolated to 0% drug release.
The release data were also analyzed using equations 1.6 and 1.7 in order to evaluate
the mechanism of drug release. The data were fitted to equations 1.6 and 1.7 using
a privately produced "Curfit" (Philip Rowe: Liverpool John Moores University)
computer program. This program calculates the optimum values for n, K, and I using
a non-linear, least-squares fitting method (Ford et al, 1991). The understanding of
the release mechanism is possible by fitting the release data to these equations and
comparing the value of n to the semi-empirical values for various geometries (Table
1.1) reported by Ritger and Peppas (1987). The sums of squares of errors and
Schwartz information criterion (Schwartz, 1978) were used as the basis for the best
fit.
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Sums of squares of errors indicate the discrepancies between the observed data and
the values which were predicted by a particular model. Information criteria are used
to asses the best model for a set of data and they are calculated using sums of
squares of errors and the number of parameters used by a particular model. As a
general rule the higher the sums of squares the poorer the model (Ford et al, 1991).
The lower the Schwartz information criterion the better the model.
For comparative purposes, release data between 15-60% were used for modelling
drug release. This range also corresponded to the limits of applicability of equations
1.6 and 1.7.
2.2.8 THERMAL ANALYSIS
Thermal analysis is a method which can be used to characterize the alterations of
physical or chemical properties of substances induced by temperature changes. The
most common types of thermal analysis are differential scanning calorimetry,
differential thermal analysis, thermogravimetric analysis and thermomechanical
analysis (Ford and Timmins, 1989).
2.2.8.1 Thermomechanical analysis
Thermomechanical analysis (TMA) may be used to measure the dimensional changes
in a solid sample (such as expansion or contraction) as a function of temperature
(Ford and Timmins, 1989). It may also be used to measure deformation of a sample
under a constant load. Properties such as the glass transition temperature (Tg),
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softening temperature (Ts)' tensile modulus. compression modulus, expansion
coefficient and shrinkage temperature can be determined by TMA (Masilungan and
Lordi, 1984). A Perkin Elmer Model TMA7 (Beaconsfield, UK) was used to measure
the glass transition temperature of the polymeric films.
In the penetration mode, the polymeric film initially exhibits resistance to penetration
due to the limited movement of the individual molecules. As the temperature
increases, the amount of thermal energy in the polymer chains increases and this
makes the immobilized chains more flexible (Ford and Timmins, 1989). Near the
glass transition temperature, there is a corresponding increase in void volume in the
polymers, allowing the polymer to become penetrable (Masilungan and Lordi. 1984).
As the polymer softens the position of the probe will change and this position is
accurately monitored as a function of temperature.
2.2.8.1.1 Calibration of TMA
The thermal analyzer was calibrated before use. Four different calibrations were
performed. These were furnace calibration, two standard temperature calibration,
height calibration and force calibration. Furnace calibration linearizes the furnace
response by matching the program temperature to the thermocouple temperature over
the temperature range which had been selected. In practice this was from 30°C to
200°C. This calibration was performed automatically by the analyzer. A two standard
calibration was performed after the furnace calibration using indium (melting
temperature 156.60°C) and zinc (melting temperature 419.47°C) as calibrants to
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correct for differences in temperature between the sample and the thermocouple. The
samples were scanned at a heating rate of 10°C/min and the onset temperatures
which were obtained by the instrument were programmed into the TMA. Height
calibration was used to calibrate the ordinate axis of the TMA7 using a displacement
standard supplied by Perkin Elmer with a defined height accurately measured with
a micrometer (Mitutoyo, Japan). Force calibration was performed to calibrate the
force which the analyzer applied on the sample using a force calibration standard
with weight of 50 g, supplied by Perkin Elmer.
2.2.8.1.2 Thermomechanical analysis measurement
A flat faced quartz probe with 3.66 mm radius was applied with 15 mN force on free
films while they were heated at 10°C/min from 30°C to 160°C for Surelease films
and from 30°C to 200°C for HPMC films. The experiments were performed in
duplicate to obtain the Tg or T, of the polymer films.
2.2.8.2 Differential scanning calorimetry (DSC)
Differential scanning calorimetry measures the heat gain resulting from physical or
chemical changes within a sample as a function of temperature (Fiese and Hagen,
1986). DSC measurements were carried out using a Perkin Elmer (Beaconsfield, UK)
Differential Scanning Calorimeter (Model DSC7) controlled by a Perkin Elmer
TAC7.
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2.2.8.2.1 Calibration of DSC
Calibration of DSC was performed at ambient conditions. Indium (onset of melting
temperature: 156.60°C, enthalpy of fusion (~Hf) = 28.45 J/g) and Zinc (onset of
melting temperature: 4I9.47°C) were used as calibrants. Samples (2-3 mg) were
heated at l()OC/min in crimped aluminium pans under a nitrogen atmosphere. A
similar empty pan was used as the reference. Melting points and enthalpies of fusion
of samples were automatically calculated by the instrument. The calculated peak area
of indium and the melting temperatures of indium and zinc were programmed into
the calorimeter as calibrant data.
2.2.8.2.2 DSC measurements
DSC measurements were performed in order to characterize the drug substances and
to investigate the interaction between metoclopramide hydrochloride and Surelease.
Samples of 2-3 mg of drug was sealed in aluminium pans and scanned at 10°C/min
over the range of 50-220°C for metoclopramide hydrochloride and 80-320°C for
diclofenac sodium.
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CHAPTER 3. DEVELOPMENT OF COATING CONDITIONS FOR
APPLICATION OF POLYMERIC FILMS ON PELLETS
The application of a uniform coating is necessary in order to achieve sustained drug
released from coated pellets. As the coating conditions in which polymeric films are
applied, could influence both the surface characteristics of the pellets (and
consequently the release rate) and the efficiency of the coating, the optimization of
their coating conditions is therefore necessary. The aims and objectives of the studies
outlined in this chapter are to optimize the process conditions used to apply the coats
and to describe the coating equipment which was used.
3.1 DESCRIPTION OF COATING EQUIPMENTS
An Accela-cota 10 (Manesty, Liverpool, UK) equipped with an air-borne spray unit
(Walther Pilot model WAXVU. Germany) was used for coating. It has an angular
pan that rotates on the horizontal axis. The periphery of the pan is completely
perforated. The drying air enters from above and is exhausted through a stationary
plenum that almost covers the entire bed. The temperature of the inlet air can be
adjusted with a thermostat. The pan is equipped with 8 baffles. The maximum
working capacity of Accela-cota lOis approximately 18 kg. A schematic diagram
of Accela-cota lOis shown in Figure 3.1.
3.1.1 MODIACATION OF THE COATING MACHINE
For this study, the circumference of the pan was meshed with gauze (aperture size
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Figure 3.1. Schematic diagram of Accela-Cota 10.
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3.2 DETERMINATION OF GLASS TRANSITION TEMPERATURE OF THE
POLYMERIC FILMS
It is necessary to characterize the coating of film coated products in order to
optimize the coating formulation or process (Masilungan and Lordi, 1984). One of
the properties of a film-coating material is its glass transition temperature (Tg) which
is the key to film formation (Ghebre-Sellassie et al, 1986). In film formation, during
the drying stage, either the solvent evaporates from the solution or, if water,
evaporates from the dispersion or solution. Initially, the polymers are present as
isolated coils (Osterwald, 1985). If the solvent evaporates slowly the coils approach
until, at a certain polymer concentration, they begin to penetrate each other. A film
is formed provided the sprayed droplets are able to coalesce and penetrate each
other. It is necessary that at least segments of the polymer be mobile, Le. they must
be present above the glass transition temperature in order to penetrate each other
(Osterwald, 1985).
At temperatures above the Tg, the polymer chains have appreciable mobility and are
conducive to film formation. Below the Tg' the polymer chains are immobile, except
for movement around the equilibrium position, making it very difficult for the
polymer particles to coalesce (Ghebre-Sellassie et al, 1986). In other words, below
the T, the polymer is said to exist in the glassy state and is characterized by a
somewhat ordered structure in which there is minimal polymer chain movement.
Another property of the polymer is the thermal softening point (Ts) which indicates
the point at which the polymer softens prior to melting. Usually, the T, lies between
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the Tgand the melting point (Johnson et al, 1991). Since most polymers have a high
Tg and T, which can not be achieved during coating, they need to be plasticized. A
plasticizer is added in order to reduce the T, of a polymer (section 1.12.4.3).
Goodhart et al (1984) stated that when the inlet air temperature during coating
approached the Tg of the polymer, smoother surfaces and faster coalescing of the
film resulted. In film coating, the drying air must be able to provide enough energy
to soften the polymeric chains in order to achieve a uniform film. Therefore
knowledge of the Tg or the T, of a polymer can be used as a guideline for selecting
the inlet air temperature for the coating process (Chang et al, 1987).
Thermomechanical analysis was used in this study to determine the Tg or T, of the
polymeric film. /
3.2.1 MATERIALS
HPMC E5, HPMC E15, Surelease, triacetin and talc, as described in section 2.1,
were used.
3.2.2 METHODS
3.2.2.1 Preparation of free films
The coating fluids of HPMC E5, HPMC E15 and Surelease (prepared as described
in sections 2.2.3.1 and 2.2.3.2) were used to prepare free films. The polymeric films
were prepared by intermittently spraying the coating suspensions, using the Accela-
Cota spray unit, onto the flat surface of a teflon coated pan. This was accommodated
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in the Accela-Cota pan which had been prewarmed by means of the hot air unit. The
films were dried at about 70°C. The dried films were carefully removed from the pan
ter using a spatula and stored over silica gel in a desiccator and used within 24 h of
preparation.
3.2.2.2 Thermomechanical analysis measurements
The thermal transitions of the polymeric films were measured using a TMA Perkin
Elmer Model TMA7, as described in section 2.2.8.1.
3.3 RESULTS AND DISCUSSION
3.3.1 TRANSITION TEMPERATURES OF THE HPMCE5 OR HPMCE15 FILMS
Figure 3.2 is a TMA scan of the free film of HPMC E5. There are two inflections.
According to Johnson et al (1991), who used TMA to measure the T, of HPMC 6
mPa.s films, the first inflection in the scan could be related to the Tg and the second
inflection may be taken as the T; Therefore the glass transition temperature of
HPMC E5 film plasticized with 25% triacetin probably was around 70°C and the
softening point of the polymer was around 161°C. The values of T, and T, reported
by Johnson et al (1991) for HPMC 6 mPa.s films plasticized with 20% w/w triacetin
were about 99°C and 179°C respectively.
The TMA scans of the HPMC E15 films (Figure 3.3) were similar to those of
HPMC E5. There was a sudden shift between 60°C and 86°C. Therefore the T, was
probably around 77°C.
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A TMA scan of the film prepared from Surelease is shown in Figure 3.4. There was
3.3.2 TRANSITION TEMPERATURES OF THE SURELEASE FILM
" a change in the resilience of the film between 40 and 60°C. A similar shift for
softening of the film. Iyer et a1 (1990) found that the softening temperature of
Surelease films was reported by Ghebre-Sellassie et a1 (1988) and attributed to
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Figure 3.2. TMA scan of HPMC E5 film using a penetration probe
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Figure 3.3. TMA scan of HPMC E15 film using a penetration probe
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Figure 3.4. TMA scan of Surelease film using a penetration probe
at a force of 15 mN.
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The following criteria were taken into consideration when choosing the coating
conditions:
1. The surface morphology of the coated pellets. This parameter has a tremendous
effect on the release rate of a coated drug (Mehta and Jones, 1986).
2. The degree of aggregation of the coated pellets.
3. Coating efficiency. This can be used as an indication of the extent of loss of
coating material.
3.4 DEVELOPMENT OF COATING CONDITIONS
The coating conditions were investigated in order to optimize the coating process.
", The pan speed (10 rpm), the position of spray gun (central and 20 cm above the bed
of seeds) and the flow rate of inlet air (approximately 290 cuft/min) were not varied.
The inlet air temperature, spray rate and atomizing air pressure were varied.
3.4.1 MATERIALS
Non-pareil seeds (0.850-1.18 mm), HPMC E5, HPMC E15, Surelease, talc and
triacetin, as described in section 2.1, were used in this study.
3.4.2 METHODS
3.4.2.1 Preparation of coating fluids
The formulations that were employed for coating the pellets with HPMC E5, HPMC
EI5 or Surelease are listed in Tables 2.2, 2.3 and 2.4 respectively.
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3.4.2.2 Coating procedure
The coating fluids for HPMC E5 or HPMC E15 were stirred for 1 h before and
throughout the coating process. The surelease coating suspension was stirred for at
least 30 min before coating and throughout the coating process. Batches of 4500 g
non-pareils (0.850-1.18 mm) were pre-warmed for 10 min prior to coating. The
variations in the parameters of the coating process that were used to coat the non- .
pareils with HPMC E5, HPMC EI5 or Surelease are shown in Tables 3.1, 3.2 and
3.3 respectively. The amount of coating suspension applied in each experiment was
calculated on the basis of a theoretical 4% increase in pellet weight.
3.4.2.3 Evaluation of coating process
Coating efficiency, degree of aggregation of the pellets and surface morphology of
the coated pellets were used in evaluating the coating process. Coating efficiency
was measured as described in section 2.2.4.1, the degree of aggregation of the pellets
was determined as described in section 2.2.4.2 and SEM of the surface of uncoated
and coated non-pareils was carried out as described in section 2.2.43.
3.5 RESULTS AND DISCUSSION
3.5.1 COATING CONDITIONS FOR HPMC E5
A summary of the results obtained from coating pellets with HPMC E5 under the
various conditions are shown in Table 3.1. Although higher temperatures (80-85°C)
reduced the incidence of aggregated pellets to 6% w/w and ensured film formation
because it is above T of the HPMC E5 film (in condition C) the coating efficiencyg
85
Table 3.1. Process conditions used to apply the coating fluid of HPMC E5 onto
non-pareils and the results of degree of aggregation ± SD and coating efficiency
of the coated pellets.
Condition A B C D E
Inlet air temperature (OC) 60-63 72-74 80-85 72-74 72-74
Outlet air temperature eC) 47-49 53-55 60-65 56-59 57-59
Atomizing air pressure (psi) 30 30 30 40 40
Spray rate (g/min) 27 27 27 27 20
Results of degree of aggregation ± SD and coating efficiency
Degree of aggregation 15% ± 3 10% ± 1.5 6% ± 2 5% ± 1.5 1% ± 0.5
Coating efficiency 91% 91% 70% 91% 91%
decreased to 70%. This may indicate that spray drying of the coating liquid droplets
and consequent loss of coating material had occurred. The inlet air temperatures in
conditions A (60-63°C) and B (72-74°C) were also close to the Tg (about 70°C) of
the HPMC E5 coat. Scanning electron micrographs of pellets coated at these
conditions (Figure 3.5) show the formation of film without any cracks. However, due
to the lower degree of aggregation of pellets in condition B the inlet air temperature
for coating process was therefore, selected to be 72-74°C.
The atomizing air pressure was increased (condition D) and consequently the finer.
atomized fluid droplets were produced. This increased the drying efficiency of the
coating droplets and resulted in a lower degree of aggregation (Table 3.1). The spray
rate was lowered to 20 g/min (condition E). This reduced the degree of aggregation.







Figure 3.5. Micrographs of the surface of non-pareils of: (a) uncoated and non-pareil
Coated with HPMC E5 using conditions; (b) A, Cc)B, (d) C, described in table 3.1.
(Magnification x 100).
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3.5.2 COATING CONDITIONS FOR HPMC E15
The Summary of results obtained from pellets coated with HPMC E15 are shown in
Table 3.2.
Table 3.2 Process conditions used to apply the coating fulid of HPMC E15 onto
non-pareils and the results of degree of aggregation ± SD and coating efficiency
of the coated pellets.
Condition F G H
Inlet air temperature (0C) 72-74 80-85 72-74
Outlet air temperature (0C) 52-54 60-62 56-58
Atomizing air pressure (psi) 40 40 40
Spray rate (g/min) 28 28 21
Results of degree of aggregation ± SD and coating efficiency
Degree of aggregation 5% ± 2 1.5% ± 1 1% ± 0.2
Coating efficiency 90% 83% 90%
Although higher temperatures of 80-85°C (Table 3.2 condition G) reduced the
formation of aggregated pellets to 1.5% and ensured the formation of homogenous
films, the coating efficiency decreased to 83%. Again this indicates that spray drying
of the coating liquid droplets and consequent loss of coating material have occurred.
Therefore the inlet air temperature selected for coating HPMC E15 was 72-74°C
(condition F). Scanning electron micrographs of pellets coated under conditions F
"-
and G are shown in Figure 3.6. This indicates the deposition of a film without
cracks. In all cases the inlet air temperature was then able to soften the polymer to




Figure 3.n. Micrographs of the surface of non-pareils coated with HPMC EI5 using
conditions; (a) F, (b) G described in table 3.2. (Magnification x 100).
3.5.3 COATING CONDITIONS FOR SURELEASE
Table 3.3 summarizes the results obtained from pellets coated with Surelease. The
transition observed in Surelease film at 45°C (Figure 3.4) is probably related to the
T).!of Surelease. Therefore, the inlet air temperatures for all conditions Cl to M) were
high enough to promote coalescence of the polymer chains to form a film. The
scanning electron micrographs of pellets coated under conditions I, J and K are
shown in Figure 3.7. The surfaces show the formation of the film without any
cracks. The results in Table 3.3 show that there was no aggregation of the pellets in
condition K but the efficiency of coating decreased in comparison with conditions
I and J. When the atomizing air pressure was increased and spray rate was lowered




Figure 3.7. Micrographs of the surface of non-pareils coated with Surelease using
conditions; (a) I, (b) J, (c) K described in table 3.3. (Magnification x 100).
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Therefore, due to the lower degree of aggregation and higher coating efficiency in
condition M, these conditions were chosen to apply the Surelease coat onto pellets
(chapters 5, 6 and 7).
Table 3.3 Process conditions used to apply the coating fluid of Surelease onto
non-pareils and the results of degree of aggregation ± SD and coating efficiency
of the coated pellets.
Condition I J K L M
Inlet air temperature (OC) 45-50 60-62 70-73 60-62 60-62
Outlet air temperature eC) 38-40 51-53 66-68 50-53 51-53
Atomizing air pressure (psi) 30 30 30 40 40
Spray rate (g/min) 20 20 20 20 16
Results of degree of aggregation ± SD and coating efficiency
Degree of aggregation 7% ± 1.5 5% ± 0.9 0% 1% ± 0.4 0.5% ± 0.3
Coating efficiency 92% 92% 88% 92% 92%
3.6 CONCLUSIONS
The results were used to optimize conditions which were used to apply HPMC E5,
HPMC EI5 or Surelease coating fluids. The conditions are summarized in Table 3.4
and were used as the basis of coating in chapters 4 to 7.
Table 3.4 The optimized conditions which were used to apply HPMC E5, HPMC
EI5 or Surelease coating fluid.
Condition HPMC ES HPMC EIS Surelease
Inlet air temperature (OC) 72-74 72-74 60-62
Outlet air temperature (OC) 57-59 56-58 51-53
Atomizing air pressure (psi) 40 40 40
Spray rate (g/min) 20 21 16
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CHAPTER 4. EFFECT OF HPMC ES OR HPMC EIS ON THE DRUG
RELEASE FROM PELLETS
4.1 INTRODUCTION
Water-soluble polymers, are often used in film coating to protect the dosage form
from environmental influence and to improve its appearance, ingestion, taste, etc
(Osterwald, 1985). HPMC-based aqueous films are the first choice for tablet coatings
that are designed to mask bitter taste, make tablets easy to swallow, impart aesthetic
appearances and identify product (Dansereau et al, 1993). Low viscosity grades of
HPMC are commonly used in film coating. High viscosity grades of HPMC are
unsuitable for film coating because they present some technical problems related
mainly to the need for organic solvents to make sprayable dispersions (Gazzaniga et
al, 1995). Aqueous solutions of high viscosity grades of HPMC can be used but only
at very low concentrations, in order to achieve sprayability. This results in a long
processing time (Maffione et al, 1993). On the other hand, Chang et al (1987)
reported that water soluble polymers which yield solutions of low viscosities are not
suitable for controlled drug release. However these authors have not given empirical
evidence of the unsuitability of low viscosity polymers to control drug release.
i 1.1 AIMS OF THE STUDY
This study was carried out to evaluate the viscosity effect and coating load on the
release of metoclopramide hydrochloride or diclofenac sodium from pellets coated
with low viscosity, water soluble HPMC polymers.
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4.2 MATERIALS AND METHODS
4.2.1 MATERIALS
~, Metoclopramide hydrochloride, diclofenac sodium, HPMC E5, HPMC E15, talc, non-
pareils (0.710-0.850 mm) and triacetin, as described in section 2.1, were used.
4.2.2 METHODS
4.2.2.1 Drug layering of non-pareils
4.2.2.1.1 Preparation of coating suspension of metoclopramide hydrochloride
The composition of the coating suspension used to apply metoclopramide
hydrochloride to the non-pareils is shown in Table 4.1. The HPMC E15 solution was
prepared by dissolving 40 g HPMC E15 in 600 ml water as described in section
2.2.3.1. Metoclopramide hydrochloride was separately dissolved in 400 ml of water
and then mixed with the HPMC E15 solution. The talc, which was dispersed in 100
ml of water, was then added as a suspension.
Table 4.1. Composition of metoclopramide hydrochloride
suspension used for drug layering.
Ingredient Amount
Metoclopramide hydrochloride 200 g




4.2.2.1.2 Preparation of coating suspension of diclofenac sodium
The composition of the coating suspension used to apply diclofenac sodium to the
non-pareils is shown in Table 4.2. Initially a solution of 40 g HPMC E15 in 600 ml
of water was prepared as described in section 2.2.3.1. Diclofenac sodium was
dispersed in 500 ml of water. The dispersion was passed through a 105 urn sieve
with the aid of an additional 100 ml water to remove any large aggregates of drug.
The HPMC solution was then added to the drug suspension.
Table 4.2. Composition of diclofenac sodium suspension
used for drug layering.
Ingredient Amount
Diclofenac sodium 200 g
HPMC E15 40 g
Water 1200 ml
4.2.2.1.3 Coating cif non-pareil seeds with drug
Batches of 4500 g of non-pareil seeds were prewarmed (10 minutes) and coated with
drug suspensions using the conditions shown in Table 4.3. The drug suspensions
were stirred for 1 h before and throughout the coating process. Drug layering
produced pellets with a metoclopramide hydrochloride load of 3.94 ± 0.03% w/w for
HPMC E5 and 3.98 ± 0.05% w/w for HPMC E15 coated pellets. Diclofenac sodium
loaded pellets were coated only with HPMC E15 (section 4.3.2) and the percent of
drug loading was 3.93 ± 0.08% w/w.
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Table 4.3. The conditions used for drug layering.
Condition Metoclopramide Diclofenac
hydrochloride sodium
Inlet air temperature (OC) 60-63 60-63
Spray rate (g/min) 15 18
Atomizing air pressure (psi) 40 40
4.2.2.2 Assay of drug content
The drug content of the drug-loaded non-pareil seeds was determined using the
method described in section 2.2.4.4.
4.2.2.3 Coating of drug loaded non-pareils with HPMC ES or HPMC EIS
Batches of 4500 g drug-loaded pellets were coated with HPMC E5 or HPMC E15
under the conditions shown in Table 3.4 (section 3.6). By taking into consideration
the coating efficiency, samples of 50 g of coated pellets were removed from the
coating pan when the coating loads had reached 4%, 8%, 12%, 16% and 20% w/w.
4.2.2.4 Scanning electron microscopy
Scanning electron microscopy was performed as described in section 2.2.4.3.
4.2.2.5 Dissolution testing
Dissolution studies were carried out as described in section 2.2.6 with modifications.
The pellets were put in small bags (with major dimensions of 2 em x 3 em) made
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from metal gauze (25 urn) to prevent the pellets coming out of the baskets during
dissolution tests. These metal bags were placed inside the dissolution baskets.
II
4.2.2.6 Release kinetics for coated pellets
The kinetics of drug release was studied as described in section 2.2.7.
4.2.2.7 Determination of drug solubility
The solubility of either drug in water at 37°C was determined as described in section
2.2.2.
4.3 RESULTS AND DISCUSSION
4.3.1 EFFECT OF COATING LOAD ON THE RELEASE OF
METOCLOPRAMIDE HYDROCHLORIDE FROM PELLETS COATED WITH
HPMC E5 OR HPMC E15
The release profiles of metoclopramide hydrochloride from pellets coated with
HPMC E5 or HPMC E15 are shown in Figures 4.1 and 4.2 respectively. All
dissolution data were plotted as percent dissolved against time. As the coating load
increased the drug release decreased for pellets coated with either HPMC E5 or
HPMC E15. Although using a different system, similar results were reported by Wan
and Lai (1991). Wan and Lai (1991) demonstrated that the release of
diphenhydramine hydrochloride from lactose granules coated with an HPMC E15
film was dependent, to a large extent, on the total content of the polymer present in
the coat.
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Tables 4.4 and 4.5 summarize the rate constants and the correlation coefficients for
different kinetic models of the release for metoclopramide hydrochloride coated with
t, HPMC E5 or HPMC EI5 respectively. The increase in the coating load for both
HPMC E5 and HPMC EI5 was accompanied by a decrease in the release rate. For
example, the square-root release rate for HPMC EI5 coated pellets was halved as the
coating load increased from 4% to 20% wjw.
Comparison of release rates for HPMC E5 or HPMC EI5 coated pellets indicates
that slower release rates were obtained from HPMC EI5 coated pellets. For example,
at the 20% coating load the square-root release rate of drug was one and half times
faster for HPMC E5 coated pellets than for HPMC EI5 coated pellets.
All the pellets disintegrated during the dissolution test and no gel like structure
remained, indicating complete erosion of the membrane and pellets, even at the 20%
w/w coating load.
1.3.2 EFFECT OF COATING LOAD ON THE RELEASE OF DICLOFENAC
.sODIUM FROM HPMC EI5 COATED PELLETS
Since the use of HPMC E5 or HPMC EI5 as coatings, produced similar release
profiles for metoclopramide hydrochloride from pellets, it was decided to investigate
only the HPMC EI5 coat on the release of diclofenac sodium loaded pellets. Figure
4.3 shows the effect of HPMC EI5 coating load on the release of diclofenac sodium.






























Figure 4.1. Effect of coating load on the release of metoclopramide hydrochloride
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Figure 4.2. Effect of coating load on the release of metoclopramide hydrochloride
from HPMC EI5 coated pellets.
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load increased. The release rates of diclofenac sodium from HPMC E15 coated
pellets (Table 4.6) decreased as the coating load increased. The pellets disintegrated
" during the dissolution test indicating that erosion of the polymeric membrane and
dissolution of the pellets had occurred.
4.3.3 RELEASE KINETICS FOR METOCLOPRAMIDE HYDROCHLORIDE
RELEASE FROM HPMC E5 OR HPMC E15 COATED PELLETS
The correlation coefficients for the best statistical line (Tables 4.4 and 4.5) revealed
that square-root kinetics were probably the most applicable to the release data for
pellets coated with HPMC E5 or HPMC E15.
Release data were also analysed by equations 1.6 and 1.7. Tables 4.7 and 4.8 shows
the values of K, n and I for the release data which corresponded to 15-60% of drug
released from HPMC E5 and HPMC E15 coated pellets, respectively. Considering
the sums of squares (ss) and Schwartz information criterion the equation 1.7 which
included the lag time in calculation of n gave the best fit for release data.
According to Ritger and Peppas (1987) the value of 0.43 < n < 0.85 represents non-
Fickian release mechanism. The mean values of n (equation 1.7) were 0.45 ± 0.03
for HPMC E5 and 0.46 ± 0.04 for HPMC E15 coated pellets indicating non-Fickian
release mechanism.
Generally the values of n were similar for HPMC E5 and HPMC E15 coated pellets
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Figure 4.3. Effect of coating load on the release of diclofenac sodium from HPMC
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indicating that viscosity of HPMC had no apparent effect on the mechanism of drug
release from coated pellets.
Table 4.7 The values of KI, n, based on equation 1.6, K2, I, n, based on equation 1.7
calculated in the range of 15-60% metoclopramide hydrochloride release from
HPMC E5 coated pellets. The values of ss and Schwartz information criterion are
also given.
Coating Equation 1.6 I Equation 1.7 I
load I I I I I IKI" n ss Schwartz Kz" I· n ss Schwartz
4% 13.70 0.78 6.64 7.87 28.00 1.40 0.44 0.00 -137.44
8% 11.10 0.78 26.40 15.86 25.30 1.67 0.42 0.01 -14.61
12% 10.30 0.76 58.60 23.57 23.80 1.80 0.42 1.03 4.96
16% 8.06 0.80 59.50 28.09 18.00 1.81 0.49 1.05 5.64
20% 8.14 0.77 76.80 34.28 17.10 1.87 0.50 3.60 14.81
* Key: The units of KI and K2 are %min-n and the unit of 1 is min.
Table 4.8 The values of KI, n, based on equation 1.6, K2, 1, n, based on equation 1.7
calculated in the range of 15-60% metoclopramide hydrochloride release from
HPMC E15 coated pellets. The values of ss and Schwartz information criterion are
also given.
Coating Equation 1.6 I Equation 1.7
I
load
I I I I IKI" n ss Schwartz Kz" I· n ss Schwartz
4% 11.30 0.81 33.30 16.78 26.30 1.67 0.44 0.90 3.74
8% 8.51 0.84 25.40 19.39 18.00 1.57 0.54 0.17 -3.92
12% 10.40 0.67 79.60 34.53 20.70 1.83 0.42 2.86 13.20
16% 9.59 0.66 108.0 41.64 18.90 1.90 0.42 8.40 23.27
20% 8.39 0.68 107.0 46.44 15.80 1.88 0.47 14.90 30.91
* Key: See table 4.7.
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4.3.4 RELEASE KINETICS FOR DICLOFENAC SODIUM RELEASE FROM
HPMC EIS COATED PELLETS
t! The correlation coefficient for the best statistical fit (Table 4.6) revealed that the
drug release was again probably best described by the square-root kinetic model.
The values of K, n and 1obtained using equation 1.6 and 1.7 are listed in Table 4.9.
Again equation 1.7 gave the lower sums of squares (ss) and Schwartz information
criterion, indicating the better fit for data. The mean value of n (equation 1.7) was
0.50 ± 0.05 indicating non-Fickian diffusion control. The obtained value of n for
release of diclofenac sodium was different from those reported by Liu et al (1993)
for the release of diclofenac sodium from HPMC 50 mPa.s (0.65-0.73) and HPMC
100 mPa.s (0.77-0.87) matrices. Other values of n for the release of diclofenac
sodium from HPMC EIS and HPMC 100 mPa.s matrices were 0.83 (Bain et aI,
1991) and 0.82 (Sheu et aI, 1992), respectively.
Table 4.9 The values of K1, n, based on equation 1.6, K2, 1,n, based on equation 1.7
calculated in the range of 15-60% diclofenac sodium release from HPMC EIS coated
pellets. The values of ss and Schwartz information criterion are also given.
Coating Equation 1.6 I Equation 1.7 I
load I I I I I Scbwartz !K' n ss Scbwartz Kz' I' n ss1
4% 13.00 0.65 19.80 18.14 23.30 1.51 0.42 0.34 -0.55
8% 11.90 0.61 15.90 23.34 18.50 1.35 0.45 0.26 -3.58
12% 8.17 0.66 14.00 31.00 11.17 1.25 0.55 1.86 13.11
16% 7.62 0.68 24.60 36.65 12.00 1.53 0.53 1.37
10.05
20% 6.42 0.69 40.40 49.36 10.30 1.74 0.55 1.04
7.92
* Key: See table 4.7.
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4.4. GENERAL DISCUSSION
As described earlier, the increase in coating load of HPMC resulted in the slower
r' release of both drugs. The reduction in release rate with increasing coating load may
be attributed to the increased diffusional path length with increase in the coating
load. This was confirmed by scanning electron micrographs of the cross section of
the metoclopramide hydrochloride loaded pellets at 4% and 20% w/w coating load
of HPMC E15 (Figure 4.4) where increase in the thickness of the applied coat
lengthened the diffusional path. On the other hand, as proposed by Wan and Lai
(1991), HPMC hydrates and gels when in contact with water. As the coat thickness
increases, the resulting gel could become thicker and therefore its resistance to
penetration by water and to erosion increases. This would lead to a decrease in the
release rate of the drug out of the gelled coat.
Although the coating load of HPMC E5 or HPMC E15 had a great effect on the
..
release rate constants of metoclopramide hydrochloride or diclofenac sodium from
coated pellets (Tables 4.4-4.6) the overall release was fast and the majority of either
drug (> 90%) was released within approximately 1 h, even with a coating load of
20% w/w. This indicates that the pellets coated with HPMC had no sustained release
properties. Rapid release of either drug from the pellets coated with HPMC E5 or
HPMC E15 may be attributed to the pellet disintegration and rapid dissolution of the
polymeric membrane.




Figure 4.4. Micrographs of cross sections of metoclopramide hydrochloride pellets
coated with HPMC E 15 a) 4% w/w coating load b) 20% w/w coating load.
(Magnification x 350).
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the release mechanisms of drugs, diffusion was the predominant mechanism. Drug
solubility did not seem to affect the release mechanism as the values of the exponent
t' n were similar for the release of both metoclopramide hydrochloride and diclofenac
sodium from pellets coated with HPMC E15. Itwas observed that pellets coated with
HPMC EIS released the drug slightly slower than pellets coated with HPMC E5.
This may be due to the fact that increase in the viscosity grade of HPMC in the coat
increased the gel layer viscosity and consequently slowed the erosion of the polymer
and drug diffusion.
Comparison of the release data for metoclopramide hydrochloride and diclofenac
sodium pellets coated revealed that the diclofenac sodium released slightly slower
than metoclopramide hydrochloride at equivalent coating load. As the molecular
weights of both drugs are similar but slightly bigger for metoclopramide
hydrochloride (354.3) than diclofenac sodium (318.13) then the faster release of
metoclopramide hydrochloride may be ascribed to its higher water solubility (> 2.6
g in 1 ml water at 37°C compared to 30 ± 0.3 mg in 1 ml water for diclofenac
sodium at this temperature).
4.5 CONCLUSIONS
Overall, the drug release from HPMC E5 and HPMC E15 coated pellets (upto 20%
w/w) was fast and completed within 1 h. It was found that the release of
metocIopramide hydrochloride decreased as the coating load of HPMC E5 or HPMC
E15 increased. In fact, small differences were observed for performance of HPMC
109
E5 and HPMC E15 in release of metoclopramide hydrochloride at equivalent coating
loads. A similar relationship between coating load and diclofenac sodium release was
'e observed for pellets coated with HPMC E15. However, diclofenac sodium released
slightly slower than metoclopramide hydrochloride at equivalent coating load.
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CHAPTER 5. EFFECT OF SURELEASE ON THE DRUG
RELEASE FROM PELLETS
I 5.1 INTRODUCTION
Many studies have concentrated on developing a method for preparing sustained
release peroral drug products. Film coating is an ideal process for the production of
sustained release dosage forms (Rowe 1985a). For application in controlled-release
delivery systems, film coats with well-characterized permeability properties are
essential. Ethylcellulose is the most widely used water-insoluble polymer in film-
coating (Rowe, 1985a). This polymer is tasteless, odourless and has the ability to
form tough, flexible coatings. Optimization of coating formulations containing
ethylcellulose can easily be achieved due to characteristics of this polymer including
(Porter, 1989a):
a) Availability in a wide range of viscosity (or molecular weight) grades,
b) Solubility in a variety of organic solvents and their mixtures, and
c) Miscibility with various water-soluble materials which cause a change in the
permeability of the resultant film.
While ethylcellulose was initially used in organic solvent-based solutions
(Kannikoski, 1984), the pharmaceutical industry has been shifting towards aqueous
film coating methods (Hogan, 1982) and as a result some water-based dispersions
of ethylcellulose such as Surelease and Aquacoat have been introduced which are
widely used in film coating. The use of ethylcellulose is common in the development
III
of controlled drug delivery systems (Benita and Donbrow, 1982; Miller and Vadas,
1984; Najib and Suleiman, 1985; Porter and D' Andrea, 1985; Bianchini and Vecchio,
,. 1987; Iyer et al, 1993).
5.1.1 AIMS AND OBJECfIVES
The present study was undertaken to determine the effect of coating load on the
release of metoclopramide hydrochloride or diclofenac sodium from pellets coated
with Surelease.
5.2 MATERIALS AND METHODS
5.2.1 MATERIALS
Metoclopramide hydrochloride, diclofenac sodium, Surelease, HPMC E15, Talc, non-
pareils (0.710-0.850 mm), as described in section 2.1, were used.
5.2.2 METHODS
5.2.2.1 Coating of non-pareils with drug
Batches of 4500 g non-pareils were loaded with metoclopramide hydrochloride or
diclofenac sodium as described in section 4.2.2.1. The drug layering process
produced pellets with a metoc1opramide hydrochloride load of 3.96 ± 0.02% w/w and
diclofenac sodium load of 3.93 ± 0.04% w/w.
5.2.2.2 Coating of drug-loaded non-pareils with Surelease
Batches of 4500 g drug-loaded non-pareils were coated with Surelease under the
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conditions shown in Table 3.4 (section 3.6). By taking into consideration the coating
efficiency, samples of 50 g of coated pellets were removed from the coating pan
~... when the coating loads had reached 4%, 8%, 12%, 16% and 20% w/w.
5.2.2.3 Scanning electron microscopy
SEM was performed as described in section 2.2.4.3.
5.2.2.4 Dissolution testing
Dissolution studies on pellets coated with Surelease were performed as explained in
section 2.2.6.
5.2.2.5.Release kinetics for coated pellets
In order to determine the kinetics of drug release, data were fitted to different
equations as explained in section 2.2.7. The data corresponding drug release < 15%
clearly did not concur with controlled drug release. Therefore, the data between 15-
60% were fitted to all equations.
5.3 RESULTS AND DISCUSSION
1,3.1 EFFECT OF SURELEASE COATING LOAD ON THE RELEASE OF
METOCLOPRAMIDE HYDROCHLORIDE
The effect of coating load on the release of metoclopramide hydrochloride from
pellets coated with Surelease is shown in Figure 5.1. Uncoated metoclopramide
hydrochloride pellets disintegrated rapidly in the dissolution medium and released
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their drug content in less than 5 min. The percent of drug released dramatically
decreased as coating loads were increased. For instance at higher coating loads, such
~" as 20% coating, only about 7% of the drug was released in 2 h, whereas those pellets
coated to weight increases of 10% and 4%, released 51% and 97% of drug
respectively in 2 h. In addition, as the level of coating increased, the release profiles
showed biphasic pattern where there was a phase which showed low slope followed
by a phase with a steep slope. The change in release pattern was achieved after a
longer period (which here is named as lag time) as the coating load increased. It is
evident from the results that the coating load had a major effect on the ultimate rate
of drug release and the duration of the lag times. All the pellets remained intact
during dissolution test indicating that the Surelease membrane controls the drug
release.
Table 5.1 shows the release constants (K) and lag times (t) of the fits of release data
to different kinetic models. Due to insufficient data points for release of
metoclopramide hydrochloride from pellets with a 4% coating load of Surelease, it
was not possible to perform regression analysis for these pellets and therefore no
results are reported for 4% coating load. A dramatic decrease in the release rate of
metoclopramide hydrochloride with increasing coating load of Surelease can be
Observed. For instance the first-order release rate was more than five times faster at
the 8% coating load than the 20% load. The calculated lag times increased as the
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Figure 5.1. Effect of coating load on the release of metocloprarnide hydrochloride
from Surelease coated pellets.
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5.3.2 EFFECT OF SURELEASE COATING LOAD ON THE RELEASE OF
DICLOFENAC SODIUM
t The effect of Surelease coating load on the release of diclofenac sodium is depicted
in Figure 5.2. Similar to metoclopramide hydrochloride loaded pellets, uncoated
diclofenac sodium loaded pellets disintegrated rapidly and 100% of drug was
released from pellets in the first 5 min. As the coating load increased the release rate
considerably decreased. For example, increasing the coating load from 12 to 20%
decreased the percent of drug released from 40% to 8% after 2 h. Scanning electron
micrographs of diclofenac sodium pellets coated with 12% Surelease before and after
dissolution are depicted in Figure 5.3. The pellets remained intact after the
dissolution test suggesting that the membrane controlled the release of drug. The lag
time prior to change in release pattern was also observed for diclofenac sodium
pellets coated with Surelease (Figure 5.2). Its duration increased with increasing
coating load. Table 5.2 summarizes the release constants (K) and lag times (t) of the
fits of release data for diclofenac sodium to different kinetic models. The release
rates considerably decreased as the coating load increased. For example the first-
order release rate was four times faster at 8% coating load than 20% coating load.
The calculated lag times were also increased as the coating load increased.
~3.3 RELEASE KINETICS FOR METOCLOPRAMIDE HYDROCHLORIDE
£.ELLETS COATED WITH SURELEASE·
The correlation coefficients (r) for the best statistical fit (Table 5.1) revealed that
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Figure 5.3. Micrographs of diclofenac sodium pellets coated with 12% Surelease a)
before dissolution b) after 12 h dissolution (Magnification x 150).
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Table 5.3 shows the values of K, n and I obtained from equations 1.6 and 1.7.
Considering the sums of squares and Schwartz information criterion, equation 1.7
which included the lag time in calculation of n gave the best fit for release data. The
importance of inclusion of lag time in calculation of n has been discussed by Ford
et al (1991 a). The mean value of n based on equation 1.7 was 0.60 ± 0.03 indicating
that diffusion is the predominant mechanism controlling drug release. It was also
observed that the coating load had no apparent effect on the mechanism of release
of metoclopramide hydrochloride as the values of n were similar for all coating
loads.
Table 5.3. The values of K1, n based on equation 1.6, Kz, 1, n based on equation 1.7
calculated in the range of 15-60% metoc1opramide hydrochloride release from
Surelease coated pellets. The values of ss and Schwartz information criterion are also
given.
Coating Equation 1.6 Equation 1.7
load
Kt" K" rn ss Schwartz 2 n ss Schwartz
8% 0.869 0.971 42.5 34.14 4.740 15.40 0.604 8.46 23.32
12% 0.252 1.030 71.8 42.85 3.720 52.00 0.543 6.29 23.14
16% 0.110 1.090 51.20 43.96 1.950 81.40 0.618 5.27 23.53
20% 0.060 1.110 84.00 60.34 1.480 133.00 0.619 11.80 39.75
* Key: The units of K, and K, are %min-n and the unit of I is min.
2.:.3.4RELEASE KINETICS FOR DICLOFENAC SODIUM PELLETS COATED
.wITH SURELEASE
The correlation coefficient for the best statistical fit (Table 5.2) revealed that the
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first-order kinetics are possibly most applicable to all the release data at all coating
loads except 8% coating which Hixon-Crowell model gave the best fit.
The values of K and n obtained from equations 1.6 and 1.7 are presented in table 5.4
at different coating loads. Again equation 1.7 gave the lowest sums of squares and
Schwartz information criterion indicating better fit of data with this equation. The
mean value of n (equation 1.7) is 0.70 ± 0.20. It seems that diclofenac sodium
release mechanism was dependent on the coating load of Surelease. The higher value
of n for 8 and 12% coating load may be due to contribution of the dissolution of the
drug to the overall release mechanism. While at high coating loads the predominant
mechanism is the diffusion of the drug.
5.4 GENERAL DISCUSSION
It was shown that the release rate of either drug decreased considerably as the
Coating load of Surelease increased. These results are in agreement with the findings
of Ghebre-Sellassie et al (1988) and Porter (1989b) who showed that the release of
drug (diphenhydramine hydrochloride or chlorpheniramine maleate) from pellets
Coated with Surelease was related to the weight of coating material deposited on the
pellets. The dependency of the release of drugs on the thickness of ethylcellulose
membranes has been reported by many authors (Ozturk et al, 1990; Bianchini et al,
1993; Maganti and Celik, 1994; Sarisuta and Punpreuk, 1994).
Scanning electron micrographs of coated pellets with 8% and 20% coating levels
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Table 5.4. The values of K1, n based on equation 1.6, K2, 1,n based on equation 1.7
calculated in the range of 15-60% diclofenac sodium release from Surelease coated
pellets. The values of ss and Schwartz information criterion are also given.
t
Coating Equation 1.6 Equation 1.7
load K· Kz· I·
I n ss Schwartz n ss Schwartz
8% 0.154 1.330 3.07 10.32 0.715 12.40 1.02 0.930 4.94
12% 0.146 1.160 16.10 26.41 1.590 39.40 0.735 1.01 6.28
16% 0.129 1.100 58.00 36.64 4.360 88.50 0.501 0.241 -5.14
20% 0.074 1.120 78.60 52.80 2.620 123.00 0.552 2.56 17.52
* Key: See table 5.3.
before and after dissolution tests are shown in Figures 5.4 and 5.5. The presence and
distribution of the pores are more apparent on the surface of pellets with a low
coating load (8%), than that of the higher coating level (20%). These pores may exist
through the full thickness of the coating and act as points of entry for dissolution
fluid into the pellets and as points of exit for the release of dissolved drug into the
dissolution medium. On the other hand, coating layer was thicker as the load
increased (Figure 5.4b and 5.5b). Therefore, the diffusion path length for the
dissolution medium to enter the core and the dissolved drug to come out through the
Core could be increased. This also would account for the much lower release rates
for pellets with higher coating levels.
Generally in dosage forms which have a water insoluble polymer as the rate
controlling membrane, since the release rate through the membrane controls the
overall release rate of the drug, the membrane properties and geometry, such as
membrane porosity, internal structure (tortuosity) and the membrane thickness may
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be critical factors in determining the release rate of the drug (Tojo and Miyanami,
1983). During film application, the pellets are continuously layered with additional
coating material, the film formed in the coating pan or fluid bed apparatus therefore,
consists of segments which overlap each other (Wouessidjewe et al, 1991). As more
layers of film is applied the holes from overlapping films are gradually blocked.
Hence this reduces the dissolution rate and therefore, the higher the coating level the
longer the lag time and the lower the apparent drug dissolution rate.






where drn/dt is drug diffusion rate, A is surface area of the device, D is the diffusion
of the drug in the barrier membrane, K is the partition coefficient of the drug
between the coating and the medium, Llc is the drug concentration gradient across
the membrane and L is the membrane thickness (Jambhekar et aI, 1987). A delivery
system which follows this model would display zero-order release kinetics as long
as the concentration gradient is kept constant.
However, the kinetic studies for metoclopramide hydrochloride or diclofenac sodium
release showed that the release of either drug from Surelease coated pellets was
probably best described by the first-order kinetic model and not the zero-order
model. First-order release of drugs from ethylcellulose membranes have been




Figure 5.4. Micrographs of metoclopramide hydrochloride pellets coated with 8%
Surelease coating level a) Surface structure of the pellet before dissolution
(Magnification x 150) b) Cross section of the coated pellets (Magnification x 350)




Figure 5.5. Micrographs of metoclopramide hydrochloride pellets coated with 20%
Surelease coating level a) Surface structure of the pellet before dissolution
(Magnification x 150) b) Cross section of the coated pellets (Magnification x 350)
c) Surface structure of the coated pellets after 12 h dissolution (Magnification x
150).
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Robinson, 1988; Sarisuta and Sirithunyalug, 1988; Yang and Ghebre-Sellassie, 1990).
Factors such as dialysis (diffusion through pores) and osmotic effects tend to
influence release through a barrier and as a result deviations from zero-order release
are usually seen (Haluska et al, 1992). In addition, after the initial stages of
dissolution, if the active material within the device is present as an unsaturated
solution, its concentration will fall as the agent is released, and release rate declines
exponentially producing a first-order release profile (Baker, 1987).
One hypothesises suggested to describe the first-order release of drugs from
multiparticulate systems has been given by Griffin and Grattan (1994) who showed
that the release data of dextromethorphan hydrobromide from pellets coated with
mixtures of EC and HPMC fitted the first-order kinetic model. It was shown that
individual beads released their drug at variable zero-order rates (Griffin and Grattan,
1994). This lead to a nett first-order release profile.
The results of the kinetic studies presented in this chapter showed that the coating
load had no effect on the mechanism of drug release. However Zhang et al (1991a)
reported that the release of acetaminophen from beads coated with Aquacoat was
dependent on the levels of the coating. A change in the release mechanism from
diffusion through water filled pores (for 2-10% w/w coating load) to diffusion
through the membrane (for 12-20% w/w coating load) was reported. Similar results
were observed by Dyer et al (1995) who claimed that at low coating levels, the
membrane is relatively more porous and the drug takes the route of least resistance
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for release. As the coating thickness increases, fewer pores are available for drug
transport, thus retarding drug release and it is probable that drug release occurs by
diffusion across the polymeric membrane rather than diffusion through pores or
imperfections within the film coat.
A companson of the release profiles for metoclopramide hydrochloride and
diclofenac sodium coated with Surelease revealed that despite of its lower solubility
diclofenac sodium (30 mg in 1 ml water at 3rC; chapter 4) showed faster release
rates than metoc1opramide hydrochloride (>2.5 g in 1 ml water at 37°C; chapter 4)
at equivalent coating loads (Tables 5.1 and 5.2). It has been claimed that the aqueous
solubility of the drug plays an important role in release rate of the drug from coated
pellets (Ghebre-Sellassie et al, 1988; Iyer et al, 1990). Highly water soluble drugs
generally release faster than poorly water soluble compounds.
Since several factors clearly contributed to the faster release of diclofenac sodium,
the aims of next chapters were to elucidate the cause of this differences.
5.5 CONCLUSIONS
The results presented in this study indicate that Surelease is suitable coating system
for preparing sustained-release dosage forms, especially at high coating levels for
metoclopramide hydrochloride and diclofenac sodium. The coating load had a major
effect on drug release rate. As the coating load increased release rates dramatically
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decreased. The kinetics of the release of either drug were best described by the first
order kinetic model. Diclofenac sodium (with lower aqueous solubility) formulations
showed faster release than metoclopramide hydrochloride (with higher aqueous
solubility) at each coating load.
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CHAPTER 6. EFFECT OF INCLUSION OF HPMC EIS IN SURELEASE
ON THE DRUG RELEASE FROM COATED PELLETS
6.1 INTRODUCTION
Coats consisting of low viscosity hydroxypropylmethylcellulose did not control the
release of metoclopramide hydrochloride or diclofenac sodium from pellets (chapter
4). The majority of either drug was released in less than 1 h, even at the highest
coating load (20% w/w). Drug release from Surelease coated pellets (chapter 5) was
rapid at low coating loads while drug release was sustained over 12 h at high coating
loads. However the release of either drug was incomplete at high coating loads. For
example, only about 70% of either drug was released from pellets coated with 20%
w/w Surelease after 12 h. In addition, the duration of lag times before establishing
controlled release profiles increased at higher coating loads of Surelease. Therefore,
the inclusion of an additional substance into the Surelease film was needed to permit
the drug to be released not too quickly but would allow all of the drug to be released
before the end of the dissolution test.
It has been reported that the drug release from systems coated with insoluble
polymers may be modified by additives that dissolve on exposure to biological fluids
and thus render the coating porous (Lindholm and Juslin, 1982). It is well known
that addition of suitable hydrophillic substances such as methylcellulose (Colletta and
Rubin, 1964; Fites et al, 1970; Yuen et al, 1993), hydroxypropylmethylcellulose
(Ghebre-Sellassie et al, 1988; Li et aI, 1990; Govender et al, 1995),
130
hydroxypropylcellulose (Borodkin and Tucker, 1974; 1975, Donbrow and Samuelov,
1980) polyethylene glycol (Donbrow and Friedman, 1975) to hydrophobic polymer
films is one method of increasing the permeability of that film.
6.1.1 AIMS AND OBJECTIVES
The aims and objectives of the study presented in this chapter were to modify the
permeability of Surelease films by the addition of low viscosity HPMC E15. Release
of metocloprami de hydrochloride or diclofenac sodium was investigated as a function
of coating load and level of the HPMC E15 in the coat.
6.2 MATERIALS AND METHODS
6.2.1 MATERIALS
Metoclopramide hydrochloride, diclofenac sodium, HPMC E15, Surelease, talc, non-
pareils (0.710-0.850 mm), as described in section 2.1, were used.
6.2.2 METHODS
6.2.2.1 Coating of non-pareils with drug
Batches of 4500 g non-pareils were coated with metoc1opramide hydrochloride or
diclofenac sodium as described in section 4.2.2.1. The drug layering process
produced pellets with a metocIopramide hydrochloride load of 3.95 ± 0.08% w/w and
diclofenac sodium load of 3.93 ± 0.01% w/w.
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6.2.2.2 Preparation of the coating suspension containing mixtures of Surelease
and HPMC EI5
The amounts of HPMC EI5 needed for 1200 g Surelease (solid weight) to make
films containing 5%, 7.5% or 10% w/w HPMC EI5, were 60, 90 or 120 g
respectively. Solutions of HPMC (5% w/w) were prepared as described in section
2.2.3.1 and kept overnight. The Surelease was diluted with water to 15% w/w. Then
5% HPMC solution was added to the diluted Surelease to produce the required
HPMC contents and stirred.
6.2.2.3 Coating of drug loaded non-pareils with mixtures of Surelease and
HPMC EI5
Batches of 4500 g drug-loaded pellets were coated with Surelease/HPMC under the
conditions used to apply Surelease (Table 3.4). By taking into consideration the
coating efficiency, samples of 50 g of coated pellets were removed from the coating
pan when the coating loads had reached 4%,8%, 12%, 16% and 20% w/w.
6.2.2.4 Dissolution testing
Dissolution studies on coated pellets were performed as explained in section 2.2.6.
6.2.2.5 Release kinetics for coated pellets
The release data between 15-60% were fitted to the different kinetic models
described in section 2.2.7.
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6.2.2.6 Scanning electron microscopy
The micrographs of the pellets before and after dissolution were taken as described
in section 2.2.4.3.
6.2.2.7 Determination of HPMC release from free films of Surelease containing
7.5% HPMC
To examine the effect of HPMC E15 on the Surelease films, Surelease/HPMC films
containing 7.5% HPMC were prepared as described in section 3.2.2.1. Films of 64
± 10 urn thickness (measured by micrometer Mitutoyo, Japan) were cut into strips
of 5 cm x 5 cm using scissors and weighed precisely using an Oertling analytical
balance (West Midlands, UK). The films were placed in stoppered glasses containing
50 ml of distilled water at 37°C and shaken in a shaker bath (Companstat 882942,
UK) for 30 min. After this period the content of each stoppered glass was passed
through Whatman No.1 filter papers (Whatman International Ltd. Maidston, UK) to
remove undissolved particles and films and the filter papers were washed with 20 ml
additional water. The aqueous extracts of the films were collected in previously tared
100 ml beakers and heated to reduce their water content. The beakers were kept in
oven at 60°C until the contents were dry and then weighed. The increase in the
weight of beakers was taken as the amount of HPMC EI5 released. The same
procedure was performed, as a reference, for Surelease films without HPMC. The
procedure was repeated three times for each type of film .
. I
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6.3 RESULTS AND DISCUSSION
6.3.1 EFFECT OF INCLUSION OF HPMC E15 ON THE RELEASE OF
METOCLOPRAMIDE HYDROCHLORIDE
Figures 6.1-6.3 show the plots of release of metoclopramide hydrochloride from
pellets coated with Surelease containing 5, 7.5 and 10% HPMC E15, respectively.
As the coating loads increased, the percent of metoclopramide hydrochloride released
at each time interval decreased at each coating composition. The amount of drug
released increased with increase in the HPMC content of the coats.
The release rates (K) and lag times (t) of the fits of release data to the different
kinetic models are shown in Tables 6.1-6.3. No results are reported for the 4%
coating load due to insufficient data points for regression analysis. The release rates
decreased as the coating loads increased, irrespective of the kinetic model used. On
the other hand increasing the HPMC content in the coats increased the release rates
at equivalent coating loads. For example, the first-order release rate was more than
three times faster when the HPMC content was 10% than when the HPMC content
was 5% at the coating load of 20%. Therefore the ratio of HPMC/Surelease had a
major effect on the release rate of the drug. Similar to Surelease coated pellets
(chapter 5) a lag time was observed before establishing the controlled release
profiles. The durations of this lag time increased with increasing coating load but
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6.3.2 EFFECT OF INCLUSION OF HPMC E15 ON THE RELEASE OF·
DICLOFENAC SODIUM FROM PELLETS
Figures 6.4-6.6 show the release of diclofenac sodium from pellets coated with
Surelease containing 5%, 7.5% and 10% HPMC E15, respectively. At each coat
composition, as the coating load increased, the release of diclofenac sodium
decreased.
The release rates (K) and lag times (t) of the fits of diclofenac sodium release data
to different kinetic models are shown in Tables 6.4-6.6. Due to insufficient data
points for regression analysis no results were obtained for 4% coating load for all
pellets and also for the 8% coating containing 7.5% or 10% w/w HPMC E15.
\
Release rates decreased as the coating loads increased. Similarly to metoclopramide
hydrochloride pellets, inclusion of HPMC in the coat increased the release rates of
diclofenac sodium compared to those coated with only Surelease. Release rates were
similar for pellets coated with Surelease/5% HPMC E15 and Surelease/? .5% HPMC
E15. Increasing the HPMC content in the film to 10% increased release rates.
Addition of 5% HPMC into Surelease film increased the first-order release rate by
a factor of four compared to those coated with Surelease solely at the 20% coating
load (Table 5.2). When the HPMC content in the film reached 10% the first-order
release rate (Table 6.6) was one and half times faster than from pellets containing
5% HPMC (Table 6.4) at the 20% coating load. Here again the inclusion of HPMC
decreased the lag times before the release profiles were established. Contrary to
metoclopramide hydrochloride loaded pellets, the inclusion of 5% HPMC
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Figure 6.4. Effect of coating load on the release of diclofenac sodium from pellets






















o 100 200 300 400 500 600 700 BOO
Time (min)
coated with Surelease containing 7.5% HPMC E15.



















-= 40 Coating load (~ w/w)0
'+-I
0 4"..... 30 •Q.,... -0- 8~




o 100 200 300 400 SOO 600 700 800
Time (min)
Figure 6.6. Effect of coating load on the release of diclofenac sodium from pellets
coated with Surelease containing 10% HPMC EIS.
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time decreased from about 80 min to about 30 min after the inclusion of 5% HPMC
into the Surelease coat for pellets with a 20% coating load.
6.3.3 RELEASE KINETICS FOR METOCLOPRAMIDE HYDROCHLORIDE
Correlation coefficients (r) of the fits of metoclopramide hydrochloride release data
to different kinetic models are shown in Tables 6.1-6.3. The correlation coefficients
for the best statistical fits revealed that, similar to pellets coated with Surelease
solely, the first-order kinetic model is probably the most applicable model to all the
release data. The coating load and also the HPMC content in the film did not appear
to change the kinetic model which provided the best fit for the data.
Tables 6.7-6.9 summarize the values of K, n and I obtained from equation 1.6 and
1.7. The lower sums of squares and Schwartz information criterion indicate a better
fit of the data to equation 1.7. Coating load had no apparent effect on the value of
n for each HPMC content in the film. Generally the values of n for pellets coated
with mixtures of Surelease and 5% HPMC were slightly higher than those observed
for pellets coated with mixtures of Surelease and 7.5% or 10% HPMC. To gain an
insight into the release mechanism the values of n (equation 1.7) were averaged. The
mean value of n was 0.57 ± 0.09 which resembled those obtained for pellets coated
solely with Surelease (0.60 ± 0.03; Table 5.3). The value of release exponent (n)
indicates that similar to pellets coated with Surelease solely, diffusion is the
predominant mechanism controlling the release of metoclopramide hydrochloride
from pellets coated with Surelease/HPMC E15.
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Table 6.7. The values of KI, n. based on equation 1.6, K2, I, n, based on equation 1.7
calculated in the range of 15-60% metoclopramide hydrochloride release from
Surelease/5% HPMC EI5 coated pellets. The values of ss and Schwartz information.
criterion are also given.
Coating Equation 1.6 I Equation 1.7 I
load I I I I I IKI• n ss Schwartz K1• I· n ss Schwartz
8% 0.80 1.040 99.20 40.93 5.00 13.40 0.628 18.40 29.54
12% 0.17 1.140 123.0 52.70 2.18 36.90 0.677 18.90 36.23
16% 0.11 1.100 132.0 58.47 1.84 72.50 0.639 21.50 40.93
20% 0.03 1.280 125.0 67.85 0.80 104.0 0.751 27.80 50.92
Table 6.8. The values of KI•n, based on equation 1.6, Kz, 1, n, based on equation 1.7
calculated in the range of 15-60% metoclopramide hydrochloride release from
Sureleasen.5% HPMC E15 coated pellets. The values of ss and Schwartz
information criterion are also given.
Coating Equation 1.6 I Equation 1.7 I
load
I I I I I IKI• n ss Schwartz K· I· n ss Schwartz2
8% 1.37 1.040 136.0 33.06 9.36 9.46 0.552 16.60 22.21
12% 0.23 1.270 97.0 35.91 5.04 23.20 0.609 5.64 17.94
16% 0.21 1.150 82.2 34.75 6.03 46.00 0.500 2.60 12.51
20% 0.13 1.160 113.0 41.94 4.59 64.80 0.522 4.12 17.55
Table 6.9. The values of KI• n, based on equation 1.6, K2• I, n, based on equation 1.7
calculated in the range of 15-60% metoclopramide hydrochloride release from
Surelease/10% HPMC E15 coated pellets. The values of ss and Schwartz information
criterion are also given.
Coating Equation 1.6 I Equation 1.7 I
load
I I I I I IK· n ss Schwartz K· I· n ss SchwartzI 1
8% 3.36 0.869 67.9 24.31 20.50 9.18 0.364 0.69 -3.00
12% 0.48 1.250 149.0 33.59 7.26 14.40 0.593 17.60 22.59
16% 0.32 1.160 160.0 39.40 5.91 28.60 0.553 15.00 24.80
20% 0.29 1.130 164.0 39.59 7.39 38.50 0.483 7.10 19.55
* Key: The units of K, and K2 are %min'n and the unit of 1 is min.
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6.3.4 RELEASE KINETICS FOR DICLOFENAC SODIUM
Correlation coefficients (r) of the fits of diclofenac sodium release data to different
kinetic models are shown in Tables 6.4-6.6. The correlation coefficients for the best
statistical fits revealed that the zero-order kinetic model is probably the most
applicable to all the release data. Coating load and HPMC content of the coat did not
change the best kinetic model.
Tables 6.10-6.12 summarize the values of K, n and I obtained from equations 1.6 and
1.7. The lower sums of squares and Schwartz information criterion indicate a better
fit of release data to equation 1.7 except for those coated with the mixture of
Surelease and 7.5% HPMC which showed no improvement in the fit when using
equation 1.7. The coating load and HPMC content in the film had no apparent effect
on the mechanism of drug release. The mean value of n (equation 1.7) is 1.28 ±
0.25. A comparison of release exponent n with those obtained for pellets coated with
Surelease solely (Table 5.4) showed that different mechanisms control drug release
from pellets coated with Surelease/HPMC blends and those coated with solely
Surelease. The values of n indicate erosion controlled release mechanism. Therefore
it may be concluded that in systems with numerous pores present in the coat
diffusion of drug is a rapid process and is not the rate limiting step. In this case it
is probable that the rate of pore formation control drug release.
6.3.5 LEACHING OF HPMC E15 FROM SURELEASE FILM
In order to understand the mechanisms of the enhancement of release rate of the
drugs through Surelease coat following the addition of HPMC EI5, studies were
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Table 6.10. The values of KI, n, based on equation 1.6, K2, 1, n, based on equation
1.7 calculated in the range of 15-60% diclofenac sodium release from Surelease/5%
HPMC E15 coated pellets. The values of ss and Schwartz information criterion are
also given.
Coating Equation 1.6 I Equation 1.7 I
load I I I I I IK· n ss Schwartz K/ r n ss SchwartzI
8% 1.770 1.280 4.88 6.95 6.270 2.81 0.875 0.000 -146.4
12% 0.036 1.910 19.80 18.14 0.974 13.50 1.150 6.630 14.28
16% 0.008 2.050 10.80 17.86 0.138 16.20 1.460 4.920 14.93
20% 0.004 2.030 3.88 11.72 0.045 20.20 1.550 1.840 9.02
Table 6.11. The values of KI, n, based on equation 1.6, K2, 1, n, based on equation
1.7 calculated in the range of 15-60% diclofenac sodium release from Sureleasen.5%
HPMC E15 coated pellets. The values of ss and Schwartz information criterion are
also given.
Coating Equation 1.6 I Equation 1.7 I
load I I I I I IKI• n ss Schwartz K2• I· n ss Schwartz
8% Not enough data points
12% 0.12 1.720 24.30 19.16 1.69 10.10 1.080 7.53 14.92
16% 0.02 1.890 14.00 22.39 0.05 6.59 1.660 12.60 23.59
20% 0.01 1.860 8.63 18.98 0.04 11.60 1.590 7.21 19.66
Table 6.12. The values of KI, n, based on equation 1.6, K2, 1, n, based on equation
1.7 calculated in the range of 15-60% diclofenac sodium release from Sureleasell 0%
HPMC E15 coated pellets. The values of ss and Schwartz information criterion are
also given.
Coating Equation 1.6 I Equation 1.7 I
load I I I I I IKI• n ss Schwartz K2• I· n ss Schwartz
8% Not enough data points
12% 0.68 1.450 7.10 10.61 2.65 3.21 1.060 0.07 -6.54
16% 0.18 1.510 18.90 21.20 1.150 8.666 1.090 8.30 18.07
20% 0.04 1.690 21.70 28.78 0.22 9.90 1.350 14.00 27.37
* Key: The units of Kt and K2 are %min-n and the unit of 1 is min.
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performed on free films containing 7.5% HPMC E15 representative of
Surelease/HPMC films. The amount of HPMC leached out is presented in Table
6.13. Aqueous extracts of the membranes yielded 45.5% of the total HPMC in the
film after just 30 min, while for Surelease films without any HPMC, no soluble
material was recovered.
This suggests that as pellets undergo dissolution, HPMC in the coat would dissolve
and leach out, leaving pores through which the drug may be released. These results
are in accord with those published by Donbrow and Sarnuelov (1980) and Lindholm
et al (1986) for the effects of polyethylene glycol or polysorbate 20 in ethylcellulose
films, respectively. However these results contradict those published by Donbrow and
Sarnuelov (1980) for the effect of hydroxypropylceUulose (HPC) as an additive in
ethylcellulose films. These authors stated that the increase in permeation through the
ethyIcellulose/HPC film was due to retention of the HPC in the film and the
formation of swollen hydrated channels. The difference between the results of this
study and those performed by Donbrow and Sarnuelov may be due to the differences
in the type of cellulose ether used. The reduced interaction of HPMC with
ethylcellulose due to its increased substitution (Sakellariou et al. 1986) may be
responsible for the leaching out of HPMC from these films.
Table 6.13. The results of leaching studies for Surelease and Surelease/? .5% HPMC
films.
Type of film Percent of HPMC leached out of the film
Surelease/? .5% HPMC E15 45.5 ± 2.1
Surelease 0
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6.3.6 SURFACE MORPHOLOGY OF THE PELLETS
The surfaces of the coated pellets were also examined by scanning electron
microscopy before and after dissolution. The surface characteristics of either the
metoclopramide hydrochloride or diclofenac sodium pellets coated with
Surelease/HPMC (in. all HPMC content) films at high coating load, such as 20%,
were similar before and after dissolution. Due to the porous nature of the coat it was
not possible to distinguish between pores resulting from dissolution of HPMC and
pores which already existed in the coat.
However at the lower coating load (8%) there were few cracks on the surface of the
some of the pellets after dissolution which has been shown as an example for pellets
coated with Surelease containing 7.5% HPMC in Figure 6.7. Such these cracks were
not observed for pellets coated with Surelease solely.
The development of these cracks at low coating loads may be explained as follows:
As the retention of the HPMC in the ethylcellulose/HPMC blend depends on the
coating thickness (Shah and Sheth, 1972), it is more likely that at a low coating load
(8%) the dissolution and leaching out of HPMC occurs through the full thickness of
the coat. However at the higher coating load (20%), with increased coating thickness,
the possibility of retention of HPMC in the inner layers is more than at the lower
coating load. Leaching out of HPMC provides some weak points in the membrane
which cause it to be ruptured under the internal stresses as water penetrate the core.
However at a high coating load, the support provided by the inner layers of the coat




Figure 0.7. Micrographs of diclofenac sodium pellets coated with Surelease
containing 7.5% HPMC E 15 at the X% coating load. a) before dissolution b) after




The results of this study indicate that the addition of the hydrophilic HPMC
increased the release rate of both drugs from pellets coated with Surelease.
Hydrophilic additives can increase the permeability of hydrophobic films by several
mechanisms. Some additives make the film more porous such as polyethylene glycol
(Donbrow and Friedman, 1975) or form a hydrated network inside the film such as
hydroxypropylcellulose (Donbrow and Samuelov, 1980). Others may act as carriers
for drugs such as Span 20 for salicylic acid through ethylcellulose films (Lindholm
and Juslin, 1982) or form complexes, which increase the solubility of the drug in the
membrane or increase the diffusion coefficient, such as the complex of
tetrabutylammonium bromide with salicylic acid (Lindholm et al, 1982).
The ability of HPMC to modify the release of drugs from systems coated with water
insoluble polymers has been demonstrated previously for ethylcellulose films
(Kannikoski et al, 1984; Ghebre-Sellassie et al, 1988; Gilligan and Po, 1991) and
Eudragit films (Govender et al, 1995). Studies on free films revealed that the HPMC
dissolved and consequently the formation of pores in the film was probable. These
pores, which might facilitate the ingress of water into the pellets and release of the
drug from the pellets were responsible for the faster release rates of drugs. According
to Sakellariou et al (1986) the formation of pores is expected in films prepared from
mixtures of HPMC and ethylcellulose as these blends show phase separation. They
suggested that in pharmaceutical formulations coated with these blends, the soluble
component would leach out leaving pores available for drug release.
155
It was observed that diclofenac sodium was released more quickly than
metoclopramide hydrochloride from pellets coated with solely Surelease (chapter 5).
One explanation which may describe this faster release is that the mechanism
involved in the release of these drugs from Surelease coated pellets is diffusion
through the intact polymeric film, In this case, drugs of low water solubility may be
released more rapidly than expected (Porter and Ghebre-Sellassie, 1994). However
when the drug is released via diffusion through water filled pores or channels within
the coat, the solubility of the drug in water will be a significant factor in determining
the release rate (Porter and Ghebre-Sellassie, 1994).
The change in the release mechanism from diffusion through intact coat to diffusion
through pores upon addition of HPMC to an ethylcellulose coat has been discussed
by Gilligan and Po (1991). The faster release ,of diclofenac sodium compared to
metoclopramide hydrochloride was also observed for pellets coated with Surelease
containing HPMC. It may be concluded that differences in the release rates of the
two drugs are not due to differences in their rates of diffusion through the polymer
as this behaviour was also observed for those pellets coated with Surelease/HPMC
E15 blends. Therefore other possible causes must be explored to explain the
differences between release behaviour of these drugs from Surelease coated pellets.
Addition of HPMC increased the release of diclofenac sodium to a larger extent than
metoc1opramide hydrochloride (Tables 6.1-6.3 and 6.4-6.6). The values of n were
higher for diclofenac sodium than metoc1opramide hydrochloride indicating different
mechanisms for the release of these drugs. Release of metoc1opramide hydrochloride
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was controlled mainly vai diffusion. However the contribution of diffusion as a rate
limiting step in the release of diclofenac sodium was reduced. The different release
behaviour of these two drugs may stem from their interaction with either polymer
in the coat. It has been reported that diclofenac sodium dehydrates the HPMC and
reduces its cloud point (Rajabi-Siahboomi et al, 1994a) while hydrochloride salts of
organic compounds salt in HPMC and increase its solubility (Mitchell et ai, 1993c).
If this interaction occurred in pellets coated with Surelease/HPMC blends, for
metoclopramide hydrochloride pellets, faster hydration of HPMC and consequently
faster dissolution of this polymer would result in the rapid formation of pores and
dissolution of the drug. Therefore diffusion of metoclopramide hydrochloride should
be a rapid process and faster than diclofenac sodium. However slower release of
metoclopamide hydrochloride than diclofenacs sodium from pellets coated with
Surelease/HPMC ruled out the occurrence of these interactions and therefore other
possible interactions must be investigated.
6.5 CONCLUSIONS
The release rates of both drugs increased with increasing the amount of hydrophillic
polymer in the film. The ratio of Surelease to the HPMC had a major effect on drug
release rate. High proportions of HPMC component in Surelease membrane caused
a rapid release of drugs even at high coating loads. This effect was probably related
to the leaching out of the HPMC from the Surelease film, which led to the formation
of pores. These pores may act as points for entry of dissolution medium through the
film into the core and consequent dissolution and release of drug from the pellets.
Diclofenac sodium released faster than metoclopramide hydrochloride. The
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mechanism of release of these two drugs were also different.
The possible explanations for different release behaviour of these drugs are discussed
in more details in chapter 8.
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CHAPTER 7. EFFECT OF APPLICATION OF HPMC SEAL-COAT OR
UNDERCOAT ON THE DRUG RELEASE FROM COATED PELLETS
7.1 INTRODUCTION
Metoclopramide hydrochloride was released more slowly than diclofenac sodium
from Surelease-coated pellets despite the higher water solubility of the former
(chapter 5). The differences between the release behaviour of these two drugs were
also observed for pellets coated with mixtures of Surelease/HPMC EI5 (chapter 6).
Any interaction between a drug and the coating formulation during the application
of the film might influence the release. These interactions may be prevented by
application of a seal-coat (Porter, I989a). In an attempt to elucidate if migration of
the drugs to the coat had occurred and to evaluate the existence of any interaction
between the drugs and the Surelease during application, drug-loaded pellets were
initially seal-coated with 2% w/w HPMC E5 prior to the application of the Surelease
coat.
On the other hand the release of both drugs was very rapid from pellets coated with
as much as 20% HPMC EI5 (chapter 4). As the performances ofHPMC E5 and EI5
were similar (section 4.3.1), in order to evaluate the effect of seal-coat load on drug
release from Surelease-coated pellets and also to investigate the effect of a Surelease
coat in preventing the rapid erosion and disintegration of HPMC EI5 coated pellets,
pellets coated with 20% HPMC EI5 were overcoated with Surelease.
159
7.1.1 AIMS AND OBJECTIVES
The objectives were to evaluate if and how a 2% w/w seal-coat of the water soluble
polymer (HPMC E5) affected the release of metoclopramide hydrochloride or
diclofenac sodium from Surelease coated pellets.
The study was also performed to examine how the application of Surelease overcoat
on the pellets which have been coated with 20% w/w HPMC EI5 affected drug
release from these pellets. Therefore as these pellets already contained a 20% w/w
HPMC E15 coat, Surelease was applied only up to 12% w/w. The results were
compared to those obtained for pellets containing 2% seal-coat in order to ascertain
the effect of seal-coat load on drug release.
7.2 MATERIALS AND METHODS
7.2.1 MATERIALS
Metoclopramide hydrochloride, diclofenac sodium, HPMC E5, HPMC EI5,
Surelease, talc. triacetin, non-pareils (0.710-0.850 mm). as described in section 2.1,
and drug-loaded pellets which had already been coated with 20% w/w HPMC EI5,
prepared as described in section 4.2.2.3, were used in this study.
7.2.2 METHODS
7.2.2.1 Coating of non-pareils with drug
Batches of 4500 g non-pareils were coated with metoclopramide hydrochloride or
diclofenac sodium as described in section 4.2.2.1. The drug layering process
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produced pellets with a metoclopramide hydrochloride load of 3.95 ± 0.1% w/w and
a diclofenac sodium load of 3.98 ± 0.05% w/w.
7.2.2.2 Seal-coating of drug loaded pellets with HPMC E5
Batches of 4500 g drug-layered pellets from section 7.2.2.1 were seal-coated with
a 2% w/w HPMC E5 to 2% weight increase using the formulation shown in Table
2.2 and under the conditions outlined in Table 3.4 (section 3.6).
7.2.2.3 Coating of seal-coated or undercoated drug layered pellets with Surelease
Batches of 4500 g seal-coated. drug-layered pellets from section 7.2.2.2 were coated
with Surelease under the conditions outlined in Table 3.4. By taking into
consideration the coating efficiency. samples of 50 g of coated pellets were removed
from the coating pan when the coating loads had reached 4%. 8%, 12%, 16% and
20% w/w.
Batches of 4500 g metoclopramide hydrochloride or diclofenac sodium loaded pellets
which had been already coated with 20% w/w HPMC EIS (section 4.2.2.3) were
overcoated with Surelease under the same conditions as above. By taking into
consideration the coating efficiency, samples of 50 g coated pellets were removed
from the coating pan when the coating load had reached 4%, 8% and 12% w/w.
7.2.2.4 Dissolution testing
Dissolution studies on coated pellets were performed as explained in section 2.2.6.
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7.2.2.S Release kinetics for coated pellets
The release data between 15-60% were fitted to the different kinetic models
described in section 2.2.7.
7.2.2.6 Scanning electron microscopy
Scanning electron microscopy on pellets before and after dissolution was performed
as described in section 2.2.4.3.
7.3 RESULTS AND DISCUSSION
7.3.1 EFFECf OF SURELEASE COATING LOAD ON THE RELEASE OF
METOCLOPRAMIDE HYDROCHLORIDE FROM SEAL-COATED OR
UNDERCOA TED PELLETS
7.3.1.1 Pellets seal-coated with 2% HPMC ES
The coating load of Surelease had a major effect on metoclopramide hydrochloride
release from seal-coated pellets (Figure 7.1). Table 7.1 lists the release rates and lag
times calculated based on equations 1.1-1.4. As the coating load increased the release
rates progressively decreased. Similar to pellets coated with only Surelease, a lag
time was developed and became longer as the coating load increased. A comparison
of release rates of seal-coated pellets coated with Surelease with those obtained for
pellets coated with Surelease without a seal-coat (Table 5.1) indicated that
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Figure 7.1. Effect of Surelease coating load on the release of metoclopramide
hydrochloride from pellets which had been seal-coated with 2% w/w HPMC E5.
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7.3.1.2 Pellets undercoated with 20% w/w HPMC EIS
Figure 7.2 indicates that increasing the coating load of Surelease decreased the
metoclopramide hydrochloride release from pellets already coated with 20% HPMC
EI5. However pellets coated with a 4% Surelease overcoat, disintegrated after 5
minutes and therefore rapidly released all their contents.
The calculated release rates and lag times based on equations 1.1-104, are shown in
Table 7.2. No release data were obtained for the 4% w/w coating load as these
pellets rapidly disintegrated. Increasing the Surelease coating load from 8% to 12%
w/w decreased the zero-order release rate by about 56%. Pellets with a Surelease
overcoat on 20% HPMC EI5 undercoat released their drug at a faster rate than
pellets with 2% HPMC E5 seal-coat (Table 7.1). The scanning electron micrographs
of these pellets before and after dissolution tests revealed that there were big pores
and cracks in the pellets undercoated with 20% HPMC EI5 and overcoated with
12% Surelease following dissolution (Figure 7.3). Similar pores and cracks were not
observed inthe pellets with an overcoat of 12% Surelease onto 2% HPMC E5 after
dissolution. These cracks may be a consequence of the hydration and swelling of the
HPMC undercoat which lead to the rupture of the Surelease overcoat. These cracks
and pores accounted for the faster release rate from pellets with the 20% HPMC EIS
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Figure 7.2. Effect of Surelease coating load on the release of metoc1opramide
hydrochloride from pellets already coated with 20% w/w HPMC E15.
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Table 7.2. Values of release constants (K), correlation coefficients (r) and lag times
(t) obtained from data corresponding to 15-60% release of metoclopramide
hydrochloride from pellets already coated with 20% HPMC EI5 and overcoated with








K, 0.83 ± <0.01 0.46 ± <0.01
Zero-order 0.983 0.992r
(Equation 1.1) P< 0.001 0.001
tI 0.9 ± 0.8 30.5 ± 2.3
K., 11.3 ± 0.1 9.8 + 0.1
Square-root
r· 0.995 0.998
(Equation 1.2) P< 0.001 0.001
t2 10.9 ± 0.5 43.2 ± 1.4
K, 0.0140 ±<0.0001 0.0078 + <0.0001
First-order 0.997 1r
(Equation 1.3) P< 0.001 0.001
t3 9.9 + 0.2 45.5 + 1.2
KJ. 0.0181 ± 0.0002 0.0101 + <0.0001
Hixon-Crowell
0.994 0.999r
(Equation 1.4) P< 0.001 0.001
t4 6.8 ± 0.7 42.1 ± 1.5
* Key: See table 7.1.
7.3.2 EFFECT OF SURELEASE COATING LOAD ON THE RELEASE OF
DICLOFENAC SODIUM FROM SEAL-COATED OR UNDERCOATED PELLETS
7.3.2.1 Pellets seal-coated with 2% HPMC E5
Similar to metoclopramide hydrochloride seal-coated pellets, release of diclofenac
sodium markedly decreased as the coating load of Surelease increased (Figure 7.4).




Figure 7.3. Micrographs of metoc1opramide hydrochloride pellets already coated with
20% HPMC E15 and overcoated with 12% Surelease a) Surface structure of the
pellet before the dissolution b) Surface structure of the pellets after 12 h dissolution
testing (Magnification x 50).
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coat (Figure 5.2) showed that the application of a seal-coat had a profound effect on
the release of diclofenac sodium from 4% Surelease coated pellets. While more than
70% of the drug was released in 5 min from 4% Surelease-coated pellets without
seal-coat, those pellets with seal-coat released 20% of the drug in 5 min.
Table 7.3 lists the release rates and lag times calculated using equations 1.1-1.4. A
lag time before establishing the controlled release profile was also observed for
diclofenac sodium seal-coated pellets which became larger with increasing coating
load. A comparison of release rates of seal-coated pellets coated with Surelease with
those obtained for pellets coated with Surelease without a seal-coat (Table 5.2)
indicated that application of a seal-coat decreased the release rates of diclofenac
sodium at equivalent coating loads.
7.3.2.2 Pellets undercoated with 20% HPMC EIS
Figure 7.5 shows that again the coating load of Surelease had a great influence on
the release of diclofenac sodium from pellets already coated with 20% HPMC EI5.
Release rates decreased as the Surelease coating load increased (Table 7.4). There
were not enough data points to allow regression analysis for pellets coated with 4%
Surelease. Increasing the Surelease coating load from 8% to 12% decreased the
release rate by about 52%. Pellets with a Surelease overcoat on 20% HPMC EI5
undercoat released their drug at a faster rate than pellets with 2% HPMC E5 seal-
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Figure 7.4. Effect of Surelease coating load on the release of diclofenac sodium from
pellets which had been seal-coated with 2% w/w HPMC E5.
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Figure 7.5. Effect of Surelease coating load on the release of diclofenac sodium from
pellets already coated with 20% w/w HPMC EIS.
172
Table 7.4. Values of release constants (K), correlation coefficients (r) and lag times
(t) obtained from data corresponding to 15-60% release of diclofenac sodium from









K. 0.56 + <0.01 0.29 + <0.01
Zero-order 0.999 0.997r
(Equation 1.1) p< 0.001 0.001
tl 3.3 ± 0.9 44.1 ± 5.0
K,_ 8.8 ± 0.1 7.3 ± 0.1
Square-root
r 0.997 0.987
(Equation 1.2) p< 0.001 (1.001
t2 15.6 ± 1.8 61.5 ± 3.0
K'\ 0.0092 + 0.0001 0.0051 + <OJ)OOl
First-order 0.995 0.979r
(Equation 1.3) p< 0.001 0.001
t3 15.7 + 1.5 70.3 + 4.1
K4 0.0121 + 0.0002 0.0064 + <0.0001
Hixon-Crowell 0.998 0.987r
(Equation 1.4) P< 0.001 0.001
t4 11.9 + 2.9 62.8 + 3.5
* Key: See table 7.1.
the scanning electron micrographs of the pellets overcoated with 12% Surelease
before and after the dissolution test showed development of big pores and cracks
following dissolution (Figure 7.6). These pores and cracks were not observed in
pellets with overcoat of Surelease on 2% HPMC E5 coated pellets.
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7.3.3 RELEASE KINETICS FOR METOCLOPRAMIDE HYDROCI-ll..ORIDE
RELEASE FROM SEAL-COATED OR UNDERCOATED PELLETS
OVERCOATED WITH SURELEASE
7.3.3.1 Pellets seal-coated with 2% HPMC.ES
Correlation coefficients (r) of the fits of release data to the different kinetic models
(Table 7.1) showed that the first-order kinetic model was probably the most
applicable to all coating loads. Neither the coating load of Surelease nor the presence
of a 2% seal-coat changed the kinetic model which produced the best fit compared
to those without a seal-coat (Table 5.1). Table 7.5 shows the values of K, n and I
obtained from equations 1.6 and 1.7. Again the application of equation 1.7 gave the
lower sums of squares and Schwartz information criterion indicating the better fit of
data to this model.
To understand the mechanism of drug release the values of n (equation 1.7) were
averaged. The mean value of n is 0.60 ± 0.06 and is similar to those pellets coated
with Surelease without any seal-coat (Table 5.3). Therefore the application of a 2%
seal-coat did not change the mechanism of drug release and diffusion mainly
controlled drug release.
7.3.3.2 Pellets undercoated with 20% HPMC EIS
Correlation coefficients (r) of the fits of release data to different kinetic model (Table
7.2) showed that, similar to pellets with a 2% seal-coat of HPMC E5 the first-order




Figure 7.6. Micrographs of diclofenac sodium pellets already coated with 20%
HPMC EIS and overcoated with 12% Surelease a) Surface structure of the pellet
before the dissolution b) Surface structure of the pellets after 12 h dissolution testing
(Magnification x 150).
175
Table 7.5 The values of K1, n, based on equation 1.6, Kz, 1, n, based on equation 1.7
calculated in the range of 15-60% metoclopramide hydrochloride release from
Surelease coated pellets which had been seal-coated with 2% HPMC E5. The values
of ss and Schwartz information criterion are also given.
Coating Equation 1.6 I Equation 1.7 I
load
I I I I I IK" n ss Schwartz K2" r n ss Schwartz1
8% 0.87 0.88 148.00 49.38 5.74 27.60 0.51 24.70 35.43
12% 0.18 1.00 50.90 43.91 2.07 64.00 0.61 5.12 23.23
16% 0.06 1.10 68.30 64.40 0.89 121.00 0.69 12.00 42.74
20% 0.02 1.20 97.30 64.63 1.33 212.00 0.61 8.53 35.56
* Key: The units of K, and Kz are %min-n and the unit of 1 is min.
Table 7.6 shows the values of K, n and I obtained from equations 1.6 and 1.7.
Comparison of the values of n (equation 1.7) for these pellets with the corresponding
values in Table 7.5 shows that the values of n is slightly higher than those obtained
for pellets with a 2% seal-coat of HPMC E5 at equivalent coating loads of Surelease.
This suggests that the contribution of diffusion as a rate limiting step was reduced
in these pellets. This may be attributed to the ease of diffusion due to the presence
of the cracks in the coat. However comparison of the values of n with that obtained
for 20% HPMC E15 coated pellets (Table 4.8) shows that release mechanism has
changed to erosion. This may be attributed to the presence of Surelease overcoat on
top of the HPMC E15 which reduced the rate of erosion of the HPMC undercoat and
made the erosion as a rate limiting process.
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Table 7.6 The values of K1, n, based on equation 1.6, K2, 1,n, based on equation 1.7
calculated in the range of 15-60% metoclopramide hydrochloride release from pellets
already coated with 20% HPMC E15 and overcoated with Surelease. The values of
ss and Schwartz information criterion are also given.
Coating Equation 1.6 I Equation 1.7 I
load I I I I I IKI' n ss Schwartz K' I' n ss Schwartz2
8% 0.71 1.03 119.0 47.42 4.24 13.90 0.64 21.00 34.00
12% 0.10 1.29 173.0 50.77 2.01 37.30 0.73 45.40 40.93
* Key: See table 7.5.
7.3.4 RELEASE KINETICS FOR DICLOFENAC SODIUM RELEASE FROM
SEAL-COATED OR UNDERCOATED PELLETS OVERCOATED WITH
SURELEASE
7.3.4.1 Pellets seal-coated with 2% HPMC E5
Table 7.3 showed that, similar to metoclopramide hydrochloride pellets, the first-
order kinetic model was probably the most applicable model to all the release data.
Again neither Surelease coating load nor presence of a 2% seal-coat changed the
kinetic model which produced the best fit compared to pellets coated with Surelease
without seal-coat (Table 5.2).
Table 7.7 shows the values of K, n and 1obtained from equations 1.6 and 1.7.Again
equation 1.7 gave better fit than equation 1.6 (except for the 8% coating load). The
value of n was higher for the 8% coating load, probably because at this coating load
more pores exist in the coat (Figure 5.4) which facilitated diffusion of the drug and
hence the contribution of diffusion as a rate limiting step was reduced. While lower
value of n for coating loads of ~12 indicates that release mechanism is
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predominantly diffusion controlled. The mean value of n (equation 1.7) is 0.69 ±
0.15 which is similar to that obtained for pellets coated with Surelease without a
seal-coat (Table 5.4).
Table 7.7 The values of K], n, based on equation 1.6, K2, I, n, based on equation 1.7
calculated in the range of 15-60% diclofenac sodium release from Surelease coated
pellets which had been seal-coated with 2% HPMC E5. The values of ss and
Schwartz information criterion are also given.
Coating Equation 1.6 I Equation 1.7 I
load
I I I I I IK' n ss Schwartz K' I' n ss Schwartz1 1
8% 0.44 0.99 1.02 4.55 0.54 2.92 0.95 0.86 5.28
12% 0.08 1.20 33.90 32.34 1.76 63.20 0.68 1.19 7.63
16% 0.12 1.03 37.00 43.71 2.29 109.00 0.57 1.11 8.31
20% 0.08 1.03 76.00 61.42 1.92 152.00 0.56 5.39 29.59
• Key: See table 7.5.
7.3.4.2 Pellets undercoated with 20% HPMC EIS
Table 7.4 shows that zero-order kinetic model is probably the most applicable model
to the release data for diclofenac sodium. While for pellets with 2% HPMC E5 seal-
coat, the first-order kinetic model gave the best fit.
Table 7.8 shows that application of equation 1.7 gave the lower sums of squares and
Schwartz information criterion. Comparison of the values of n (equation 1.7) with
the corresponding values in Table 7.7 shows that the value of n is higher than those
obtained for pellets with a 2% HPMC E5 seal-coat at equivalent coating loads of
Surelease. The higher value of n for these pellets may be due to development of
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pores or cracks which facilitate diffusion of the drug through the coat and eliminate
the diffusion as a rate limiting step. However comparison of the values of n with that
obtained for 20% HPMC E15 coated pellets (Table 4.9) shows that release
mechanism has changed to erosion. This maybe ascribed to the slower erosion of
HPMC undercoat in the presence of Surelease.
Table 7.8 The values of KI, n, based on equation 1.6, K2, 1,n, based on equation 1.7
calculated in the range of 15-60% diclofenac sodium release from pellets already
coated with 20% HPMC E15 and overcoated with Surelease. The values of ss and
Schwartz information criterion are also given.
Coating Equation 1.6 I Equation 1.7 I
load
I I I I I IK· n ss Schwartz K· r n ss SchwartzI z
8% 0.41 1.06 12.80 30.06 1.18 11.10 0.85 0.39 -2.39
12% 0.04 1.34 5.47 23.49 0.11 15.90 1.18 2.75 18.32
* Key: See table 7.5.
7.4 GENERAL DISCUSSION
The application of a 2% seal-coat of HPMC to drug-layered pellets, decreased the
release rate of both drugs from Surelease coated pellets compared to pellets without
the seal-coat at an equivalent coating load of Surelease. The retardation of drug
release after application of a seal-coat has been reported and ascribed to the reduced
drug migration during the application of the sustaining coat (Ghebre-Sellassie et al,
1987; Porter, 1989b; Yang and Ghebre-Sellassie, 1990).
The presence of a 2% HPMC E5 seal-coat did not change the drug release
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mechanism for either drug and diffusion appeared. to be the most important
mechanism controlling drug release from the Surelease coated pellets.
Although diclofenac sodium was released more slowly than metoclopramide
hydrochloride from a 2% seal-coated pellets at Surelease coating loads of 4% and
8% (Tables 7.1 and 7.3), at coating loads of 2=12%again diclofenac sodium showed
faster release rate than metoclopramide hydrochloride. This indicates that interactions
between drugs and coating formulation (such as migration) during film application
is not the only factor responsible for the observed differences between these two
drugs as again at coating loads of 2=12%Surelease diclofenac sodium was released
slightly faster than metocloprarnide hydrochloride. These interactions will be
discussed in details in chapter 8.
When Surelease was applied on pellets which have already been coated with 20%
w/w HPMC E15 both drugs were released faster than those when Surelease applied
on pellets with a 2% seal-coat of HPMC E5. The values of n were also higher than
those for pellets containing a 2% HPMC E5 seal-coat indicating a change in the
release mechanism. The faster release of both drugs was attributed to the
development of cracks in the barrier coat due to the swelling of HPMC undercoat.
This was resulted in a loss of protective properties of the membrane. The application
of a water insoluble polymer on top of a coat of a swelling agent has been used by
Ueda et al (1994) to develop a novel controlled drug release system, called the time-
controlled explosion system (TES). In this system, expansion of the swelling agent
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following water penetration through the insoluble outer membrane caused destruction
of the membrane by stress due to swelling. Therefore rapid drug release occurred
after a lag time. In these systems lag times can be controlled by the thickness of the
outer membrane.
The comparison between metoclopramide hydrochloride and diclofenac sodium
release rates from pellets already coated with 20% HPMC and overcoated with
Surelease (Table 7.2 and 7.4) showed that metoc1opramide hydrochloride released
faster than diclofenac sodium. Opposite results were obtained for the pellets with a
2% seal-coat overcoated with 12% Surelease (Tables 7.1 and 7.3). Several factors
may contribute to the faster release of metoclopramide hydrochloride from these
pellets. The solubility of metoc1opramide hydrochloride in water is much higher than
diclofenac sodium. As the cracks and pores penetrate the whole thickness of the
Surelease coat (Figures 7.3 and 7.6) therefore water solubility could play an
important role in drug release.
The faster release of metoc1opramide hydrochloride may also be ascribed to the
build-up of a higher osmotic pressure in the core due to the higher solubility of this
drug. According to Van't Hoff and More equation the osmotic pressure of a solution
(7t) can be calculated by equation 7.1:
7r = cRT EqUllllon 7.1
where c is the concentration of the solute in moles per litter, R is the gas constant
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and T is the absolute temperature. Therefore in the saturated solutions of these drugs
(as it may be obtained in microenvironment of the pellets), the concentration of the
metoclopramide hydrochloride solutions would be higher than diclofenac sodium
solutions due to the higher solubility of the former. This results in production of a
higher osmotic pressure inside metoclopramide hydrochloride loaded pellets. The
higher osmotic pressure generated by highly water soluble metoclopramide
hydrochloride might amplify the stresses due to the swelling of HPMC and cause the
development of more cracks and pores in a shorter period of time.
The other reason may be due to the effect of drugs on swelling properties of HPMC.
Diclofenac sodium reduces the cloud point of HPMC and dehydrate this polymer
(Rajabi-Siahboomi et al, 1994a) while hydrochloride salts of organic compound
increase the cloud point of HPMC and facilitate hydration of this polymer (Mitchell
et al, 1993c). Therefore it may be expected that HPMC can swell to a greater extent
in the presence of metocloprarnide hydrochloride than in the presence of diclofenac
sodium. The higher extent of swelling may create more cracks and therefore increase
the release rate of metocloprarnide hydrochloride to a higher degree than diclofenac
sodium.
7.5 CONCLUSIONS
The application of a 2% w/w seal-coat of water-soluble HPMC E5 decreased release
rates of either drug from Surelease coated pellets compared to those pellets coated
with Surelease without any seal-coat. However the application of a seal-coat did not
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have any effect on the mechanism of drug release. Release of diclofenac sodium was
faster than metoclopramide hydrochloride at coating loads of ~12 of Surelease over
a 2% HPMC E5 seal-coated pellets.
When Surelease was applied on pellets with 20% w/w coat of HPMC E15. the
release of both drugs was faster compared to those pellets containing a 2% seal-coat
of HPMC E5. The faster release of drugs was due to the rupture of the barrier coat.
Surelease even at 12% coating load was unable to withstand the stresses caused by
the swelling of the HPMC undercoat. Metoclopramide hydrochloride was released
faster than diclofenac sodium which may be because of the higher water solubility
of thisg drug.
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CHAPTER 8. FACTORS AFFECTING THE RELEASE OF DICLOFENAC
SODIUM OR METOCLOPRAMIDE HYDROCHLORIDE FROM
PELLETS COATED WITH SURELEASE
8.1 INTRODUCTION
The physicochemical property of a drug is one of the factors which has a profound
impact on its release from coated pellets. The water solubility is of outmost
importance to the formulation of coated pellets when the mechanism of release is
mainly by transport of the dissolved drug through water-filled pores or channels
within the coating. Water solubility is also a major factor affecting the osmotic
pressure inside the coated pellets when the pellets are in contact with dissolution
medium. As the difference between the osmotic pressure inside the pellets and the
dissolution medium plays an important role in the release of drug from coated pellets
(Ghebre-Sellassie et al, 1987; Rekhi et aI, 1995), it may be expected that a highly
water soluble drug which could generate more osmotic pressure will be released
faster than a drug with a lower solubility (Nesbitt et aI, 1985).
The results in chapters 5 and 6 revealed that water solubility may not be an
,~mportant factor in the release of metoclopramide hydrochloride and diclofenac
sodium from pellets coated with Surelease. Diclofenac sodium was released faster
than metoclopramide hydrochloride from pellets coated with Surelease or
Surelease/HPMC despite its lower solubility.
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The differences between the rates of diffusion of these two drugs through the
membrane could not also account for the observed differences in the release rates of
two drugs from pellets coated with Surelease as the difference in the release rates
was also observed for pellets coated with Surelease/HPMC (chapter 6). As the
molecular weights of drugs are similar (353.3 and 318.13 for metoclopramide
hydrochloride and diclofenac sodium, respectively), the molecular size was also not
responsible for the slower release of metoclopramide hydrochloride from pellets
coated with Surelease.
8.1.1 AIMS AND OBJECTIVES
The intent of the studies in this chapter was to examine the possible factors which
may explain the unexpected slower release of metoclopramide hydrochloride
compared to diclofenac sodium from pellets coated with Surelease. These factors
include:
1- The physico-mechanical properties of the drug-loaded non-pareils such as its size
and morphology which could influence the release rate of a drug considerably.
2- The interaction between core ingredients and Surelease.
8.2 MATERIALS AND METHODS
8.2.1 MATERIALS
Non-pareils coated with metoclopramide hydrochloride or diclofenac sodium
obtained in section 7.2.2.1, drug-loaded 2% HPMC E5 seal-coated pellets overcoated
with 12% Surelease obtained in (section 7.2.2.3), metoclopramide hydrochloride
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(section 2.1), diclofenac sodium (section 2.1), ammonia solution (General Purpose
Reagent with specific gravity 0.88 g/ml and about 35% NH3) and oleic acid obtained
from British Drug Houses (Poole, Dorset, UK) were used in this study.
8.2.2 METHODS
8.2.2.1 Sieve analysis
The average particle sizes and size distributions of the pellets before and after drug
layering were evaluated by mechanical sieving using a series of sieves (Endcotts
Ltd., London, U.K.) with aperture size 1 mm, 0.850 mm, 0.710 mm and 0.600 mm
as indicated in section 2.2.4.2. The load of the sample was 100 g. The weight of the
portion of the sample retained on each sieve after sieving was determined. The
method of Parrot (1986) was used to determine the average particle size of the
pellets. The size of pellets retained on each sieve was taken as the arithmetic mean
of the two sieves (the larger sieve which pellets passed through and the smaller sieve
which pellets were retained on). The percentage weight of sample retained on each
sieve was multiplied by the arithmetic mean of two sieves and added to the values
obtained for the other sieves. Then the value of sums was divided by 100 and used
as the average pellet size. Duplicate samples were run for each batch of pellets.
8.2.2.2 Scanning electron microscopy and energy dispersive X-ray microanalysis
The surfaces of drug-layered pellets were examined by scanning electron microscopy
(section 2.2.4.3).
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The distribution of metoclopramide hydrochloride across a section of coated pellets
was examined using a scanning electron microscope (JSM 840, Tokyo, Japan)
coupled with an X-ray spectrometer (model Link 860 II, London, U.K.). X-ray
microanalysis is a non-destructive technique that allows the detection of elements in
situ. In this technique, bombarding the sample with an electron beam results in
emission of X-rays which are specific to each element. The emitted X-rays were
detected by the X-ray spectrometer. The coated pellets were sliced using razor blade,
mounted on stubs and coated with gold prior to scanning as described in section
2.2.4.3. Since metoclopramide hydrochloride has chlorine atoms in its structure, the
X-ray characteristics of chlorine were used to trace the distribution of the drug.
8.2.2.3 Preparation of metoclopramide hydrochloride base
Ammoniated water containing 0.5% w/w ammonia (which corresponds to the
concentration of ammonia in the diluted Surelease) was prepared by appropriate
dilution of 35% w/w ammonia solution. Metoclopramide hydrochloride (2 g) was
added to 100 ml water containing 0.5% w/w ammonia and stirred. The precipitate
formed following addition of metoclopramide hydrochloride was collected on filter
paper (Whatman No.1) and washed with 20 ml water. The precipitate was dried at
50°C for 24 h.
8.2.2.4 Differential scanning calorimetry
DSC was performed as described on section 2.2.8.2.
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8.2.2.5 Curing of the pellets
Quantities of 2% seal-coated pellets overcoated with 12% Surelease equivalent to 15
mg of either drug were spread on paper trays and stored at 60°C for 1, 3 or 6 days.
Drug release from the cured pellets was studied.
8.2.2.6 Dissolution testing
Dissolution studies were performed as described in section 2.2.6.
8.2.2.7 Release kinetics for coated pellets
The release data between 15-60% were fitted to the different kinetic models
(equations 1.1-1.4) as described in section 2.2.7.
8.2.2.8 Dialysis studies
In order to investigate the interaction between the drugs and the surfactant present
in Surelease, it was necessary to prepare ammonium oleate. This was accomplished
by adding 690 mg of 35% w/w ammonia solution to 4 g of oleic acid precisely
weighed using an Oertling analytical balance (West Midland, UK). The blend was
mixed thoroughly and left at room temperature for 24 h to nearly dry.
Lengths of 20 cm visking dialysis tubes (size 5, diameter 14/32", cut off 12000-
14000 Dalton; Medicell International Ltd., London, U.K.) were boiled in distilled
water for 20 minutes. A double knot was tied at one end of each tube.
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500 mg of the prepared ammonium oleate was dissolved in 50 ml water. Samples
(1 ml) equivalent to 10 mg ammonium oleate, were transferred to 5 ml beakers. Then
15 mg of either metoclopramide hydrochloride or diclofenac sodium accurately
weighed was added to the beakers and mixed. Each solution was poured into a
dialysis tubes. The respective beakers were washed with the aid of an additional 4
ml of water in two steps (2 x 2 ml) and added to the tubes. A double knot was tied
at the top of each dialysis tubes so that the length between the two ties was 6 cm. '
A reference dialysis tube was prepared containing 15 mg of either metoclopramide
hydrochloride or diclofenac sodium in 1 ml of water instead of 1 ml ammonium
oleate solution and prepared exactly as above (5 ml total volume). The tubes were
immersed into the dissolution vessels of the Pharmatest dissolution tester (section
2.2.6) containing 900 ml distilled water at 37°C and stirred with a paddle (USP
apparatus II) at 50 rpm. The media were automatically sampled at 30 min intervals
using an Ismatic peristaltic pump (section 2.2.6). Drug passage from the tubes was
determined spectrophotometrically using a Hewlett Packard spectrophotometer
(section 2.2.6) at 309 nm and 275 nm for metoclopramide hydrochloride and
diclofenac sodium respectively. The mean of three determinations is reported for
each system.
In another series of experiments, the above procedure was repeated using Surelease
instead of the ammonium oleate solution. Quantities of Surelease (about 460 mg)
equivalent to 10 mg ammonium oleate were added to the beakers and the procedure
was carried out as above.
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8.3.1 PHYSICO-MECHANICAL PROPERTIES OF DRUG-LOADED NON-
8.3 RESULTS AND DISCUSSION
PAREIL SEEDS
8.3.1.1 Size and size distribution of the drug-loaded non-pareil seeds
The surface areas of the pellets, which are a function of the pellet size, SIze
distribution and shape (Bertelsen et al, 1994) considerably influence the release rate
of a drug. The average sizes of the pellets before and after drug layering are shown
in Table 8.1. Although the results indicated that the drug layering process may have
increased the average pellet particle size, the Student's t test showed no significant
differences (P< 0.05) between the size of the pellets before and after drug layering
(for both drugs). Student's t test also showed that there was no significant differences
between the size of pellets coated with metoclopramide hydrochloride or those
coated with diclofenac sodium (P< 0.05). Therefore, the differences between release
rates of two drugs can not attributed to differences in the sizes of the pellets.
Table 8.1. The average particle size of non-pariels before layering and after layering
with metoclopramide hydrochloride or diclofenac sodium.
Sample Average particle size (um)
Non-pareil seeds 783 ± 4
Metoclopramide hydrochloride-layered pellets 806 ± 15
Diclofenac sodium-layered pellets 800 ± 10
The effects of particle size on drug release have been previously demonstrated.
Porter (1989a) showed that chlorpheniramine maleate release from pellets coated
with 10% Surelease was faster from beads of smaller size (30-35 mesh) than from
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those of larger size (14-18 mesh). This effect was attributed to the higher surface
area of the smaller pellets. Similar results were reported by Li et al (1989a) for the
release of indomethacin from non-pareil seeds.
The size distribution of pellets should also be as narrow as possible in order to limit
variation in the coating thickness due to variation in the surface area of pellets which
must be covered during coating (Mehta, 1989). The size distributions of the drug-
layered pellets are shown in Figure 8.1. This indicates that although the percent of
larger particles was higher for metoclopramide hydrochloride-layered pellets, overall
the pellets remained approximately in the same size range as before layering.
8.3.1.2 Morphology of surfaces of the drug-loaded non-pareil seeds
Scanning electron micrographs of pellets layered with metoclopramide hydrochloride
or diclofenac sodium are shown in Figure 8.2. There were only small differences in
terms of roughness between the surface characteristics of pellets.
As the surface characteristics of pellets affect the surface area that must be covered
by coating fluids, the surface morphology of pellets can therefore dramatically
influence the release of a drug (Zhang et al, 1991bj.When an equivalent amount of
coating was applied to drug-layered non-pareils, smoother pellets produced lower
release rates than those pellets with rough surfaces (Mehta, 1989; Porter, 1989a).
This effect was due to the fact that pellets with rougher surfaces had a greater
surface area for covering by the coating formulation.
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The small differences observed between the surface characteristics of the drug-
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Figure 8.1. The size distribution of the pellets before layering and after layering with




Figure 8.2. Micrographs of pellets layered with (a) Metoclopramide hydrochloride
and (b) Diclofenac sodium (Magnification x 150).
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8.3.2 INTERACfION BETWEEN CORE INGREDIENTS AND SURELEASE
8.3.2.1 Interaction between core ingredients and Surelease during film
application
The existence of an interaction between either drug and the Surelease during film
application was assessed by applying a 2% w/w seal-coat of HPMC E5 onto drug-
layered pellets before the application of Surelease (chapter 7). The application of a
2% seal-coat of HPMC E5 before Surelease decreased the release of both drugs from
Surelease-coated pellets (Tables 7.1 and 7.3) compared to those coated with
Surelease without a seal-coat (Tables 5.1 and 5.2). This decrease was more
pronounced for diclofenac sodium than metoclopramide hydrochloride at low coating
loads. For example application of a 2% HPMC E5 seal-coat prior to Surelease coat
reduced the amount of diclofenac sodium released after 5 min from 75% (for those
pellets coated with 4% Surelease without seal-coat) to 20% at 4% Surelease coat.
The corresponding values for metoclopramide hydrochloride were 33% and 21%.
As mentioned in section 7.1, any interaction between a core and a coating
formulation during the application of the film might substantially affect the release
rates. It is well known that aqueous polymeric dispersions coagulate upon addition
of ionic solutions (Lippold et al, 1990; Porter and Ghebre-Sellassie, 1994). Bodmeier
and Paeratakul (1989) reported that the addition of salts of basic drugs to
ethylcellulose pseudolatexes resulted in latex flocculation or coagulation due to
interaction of the cationic drug with anionic surfactants contained in the pseudolatex.
The type and concentration of the ions determine the extent of coagulation. Nesbitt
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et al (1994) reported the interaction between cores containing different drugs during
application of Aquacoat. This accounted for the formation of a discontinuous
membrane around the core.
Interactions between the active substrate and the aqueous polymeric dispersion
during the application of the coat may cause deposition of a non-uniform film in the
early stages of the film coating process and therefore more layers of coating should
be applied to obtain the desired release profiles (Porter and Ghebre-Sellassie, 1994).
Sodium salts of active substance are reported to be more likely to interact with
aqueous polymeric dispersions than chloride ions (Porter and Ghebre-Sellassie,
1994).
The problem of interaction may be prevented by the application of a seal-coat prior
to application of the retarding membrane. On the other hand, the active substance
may be soluble in the coating fluid and migrate into the coat layers during
application of the film. The degree of migration of the active substance during the
application of the sustaining coat has a significant role in the performance of the
coating materials (Ghebre-Sellassie et al, 1987). A porous structure may, as a
consequence, be formed during dissolution. The use of a seal-coat is also effective
in preventing the migration of drugs during the application of the sustaining coat for
those drugs which are soluble in the coating fluid (Ghebre-Sellassie et al, 1987;
Porter, 1989a).
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Since metoclopramide hydrochloride is a highly water soluble drug, its migration
through the film during the coating process might be anticipated. However when a
small amount of metoclopramide hydrochloride was added to ammoniated water
containing about 0.5% w/w ammonia a white precipitate was formed. Figure 8.3
shows a typical DSC scan of this precipitate. Two peaks were observed at 127°C and
148°C. These peaks correspond to those observed for metoclopramide base (Mitchell,
1985). The first peak corresponds to a solid-solid transition while the second peak
corresponds to the melting point of metoclopramide base (Mitchell, 1985). Therefore,
it may be concluded that migration of metoclopramide hydrochloride into the
Surelease coat during mm application is negligible due to the low solubility of this
drug at high pH. Therefore the decrease in release rate of the drug after seal-coat
application may be attributed mostly to the covering the irregularities and smoothing
the surface of the drug-layered pellets after application of a seal-coat.
Diclofenac sodium is the sodium salt of an acidic substance with a pKa of 4
(Adeyeye and Li, 1990). According to the Henderson-Hasselbalch relationship for
a weak acid (equation 8.1) at pH 9.5-11.5, which corresponds to the pH of the
Surelease dispersion (Moore, 1989), 99.99% of the drug would be in its ionized
form. Therefore this drug may potentially interact with the Surelease during
deposition of the film.
'II Ionized = 1_00 _
1 + tultilog (pK. - pH)
Equation 8.1
As diclofenac sodium is freely soluble at pH > 6 (Navarro and Ballesteros, 1994),
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Figure 8.3. DSC scan of precipitate formed upon addition of metoclopramide
hydrochloride to 0.5% w/w ammonia solution.
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it is also more likely to migrate to the applied coat than metoclopramide
hydrochloride. These facts suggests that the extent of interaction between diclofenac
sodium and Surelease or migration of this drug into the Surelease during application
of film may be more than metoclopramide hydrochloride. Here a seal-coat not only
imparts smoothness to the surface of the drug-layered pellets but also prevents
migration of diclofenac sodium into the Surelease film. This should decrease the
drug release to a greater extent than metoclopramide hydrochloride.
Although diclofenac sodium release was slower from pellets coated with 4% or 8%
Surelease on 2% HPMC E5 seal-coated pellets, at a coating load of ~12% again
diclofenac sodium showed faster release than metoclopramide hydrochloride. These
findings indicate that migration of diclofenac sodium into Surelease during the
application of the coat has been an effective factor causing faster release of
diclofenac sodium specially at low coating loads. However the difference between
the release rates of these two drugs was also observed for 2% seal-coated pellets at
coating loads of ~12.
8.3.2.1.1 The effect of curing on the release of drug
The effect of curing on the release of metoclopramide hydrochloride from 2% seal-
coated pellets overcoated with 12% Surelease (as an intermediate coating load) is
shown in Figure 8.4. Table 8.2 lists the release rates for these pellets using different
kinetic models. The release rates increased as the curing time increased. Release
rates were also faster for the cured pellets than for the uncured pellets (Table 7.1).
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Similar to uncured pellets, the best statistical fit was obtained when using the first-
order kinetic model.
The release of diclofenac sodium from 2% HPMC E5 seal-coated pellets overcoated
with 12% Surelease were almost the same before and after curing (Figure 8.5)
suggesting that complete film coalescence had taken place during film application
(Porter, 1989a; Dyer et al, 1995). Table 8.3 lists the release rates for these pellets
using different kinetic models. No special trend was observed between release rates
and curing times. The release rates of diclofenac sodium from cured pellets
resembled those observed for uncured pellets (Table 7.3). The best statistical fit was
with the Hixon-Crowell model.
It has been reported that pseudolatexes undergo a process of further gradual
coalescence after initial film formation, to form a homogeneous continuous film
(Miller and Vadas, 1984; Onion, 1986b). Further gradual coalescence is both
temperature and time dependent (Murthy and Ghebre-Sellassie, 1993).
Coated dosage forms are generally subjected to elevated temperatures for a specified
period of time to accelerate the curing process. As stated above, the release of
metoclopramide hydrochloride increased after curing while that of diclofenac sodium
was nearly unchanged. These results contradict those published by Ghebre-Sellassie
et al (1988). They showed that storage of pellets at 60°C led to a significant
reduction in release rates of drugs (diphenhydramine hydrochloride and
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pseudoephedrine hydrochloride) from pellets coated with mixtures of Surelease and
HPMC. Similar reduction in the release rates after curing had been reported by
Goodhart et al (1984) for release of phenylpropanolamine hydrochloride from
Aquacoat coated pellets. Their results suggested that a curing step after coating is
necessary to prevent changes in the release characteristics of the final products on
storage.
However Porter (1989a) showed that this step may not always be necessary.
Complete coalescence of a latex or pseudolatex coating is dependent on heat and
capillary forces created as a result of water evaporation during film deposition. These
are affected by the process conditions. Therefore use of optimized process conditions
eliminates the post-coating curing step (Porter, 1989a). Similar results were reported
by Chang and Hsiao (1989) for the release of theophylline from pellets coated with
Eudragit RS and by Dyer et al (1995) for the release of ibuprofen from Surelease-
coated pellets indicating that gradual coalescence was completed within the coating
time.
On the other hand the increase in the release of metoclopramide hydrochloride after
curing was in agreement with results of Porter and Ghebre-Sellassie (1994). An
increase in release of chlorpheniramine maleate from pellets coated with Aquacoat
was reported by these authors and attributed to the migration of the water soluble
drug through the coat during drying.
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Table 8.2. Values of release constants (K), correlation coefficients (r) and lag times
(t) obtained from data corresponding to 15-60% release of metoclopramide
hydrochloride from 2% seal-coated pellets overcoated with 12% Surelease and cured
at 60°C for 1, 3 and 6 days, using equations 1.1-1.4.
I Model I • I 1 day I 3 days I 6 days I
Kl 0.38 ± 0.01 0.48 ± 0.01 0.66 ± 0.01
Zero-order
r 0.965 0.956 0.943
(Equation 1.1) p< 0.001 0.001 0.001
t1 -3.3 ± 2.5 -3.3 ± 1.7 -14.5 ± 6.4
K2 7.9 ± 0.2 8.8 ± 0.2 9.5 ± 0.3
Square-root
0.982 0.981 0.973r
(Equation 1.2) p< 0.001 0.001 0.001
t2 23.6 ± 1.2 16.5 ± 0.8 6.5 ± 2.1
K3 0.0067 ± 0.0002 0.0083 ± 0.0002 0.0113 ± 0.0002
First-order
r 0.990 0.986 0.975
(Equation 1.3) p< 0.001 0.001 0.001
t3 19.8 ± 1.8 11.9 ± 1.0 0.1 ± 3.3
K4 0.0086 ± 0.0003 0.0107 ± 0.0003 0.0146 ± 0.0001
Hixon-Crowell
r 0.983 0.978 0.966
(Equation 1.4) p< 0.001 0.001 0.001
t4 12.9 ± 1.9 7.1 ± 1.4 -2.5 ± 5.6
lie Key: The units of release constants are: K) (%min'\ K2 (%min,)!2),K3 (rnin'), K4
(%I!3min'l) and the units of the lag times corresponding to different equations (1.1-
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Figure 8.4. The effect of curing time on the release of metoc!opramide hydrochloride
from pellets coated with 12% Surelease over a seal-coat of 2% HPMC E5.
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Table 8.3. Values of release constants (K), correlation coefficients (r) and lag times
(t) obtained from data corresponding to 15-60% release of diclofenac sodium from
2% seal-coated pellets overcoated with 12% Surelease and cured at 60°C for 1, 3 and
6 days, using equations 1.1-1.4.
I Model I • I 1 day I 3 days I 6 days I
Kt 0.25 ± 0.01 0.26 ± <0.01 0.23 ± <0.01
Zero-order
r 0.997 0.998 0.997
(Equation 1.1) p< 0.001 0.001 0.001
tl 8.7 ± 4.0 10.4 ± 2.5 lOA ± 3.9
x, 5.9 ± 0.1 6.1 ± <0.1 5.6±0.1
Square-root 0.997 0.995 0.995r
(Equation 1.2) p< 0.001 0.001 0.001
t2 43.2 ± 2.1 34.9 ± 1.4 36.6 ± 1.9
K3 0.0041 ± 0.0002 0.0044 ± 0.000 1 0.0039 ± 0.000 1
First-order 0.996r 0.997 0.996
(Equation 1.3) p< 0.001 0.001 0.001
t3 33.1 ± 3.3 35.3 ± 2.4 34.8 ± 3.2
K4 0.0054 ± 0.0002 0.0056 ± <0.000 1 0.0049 ± 0.000 1
Hixon-Crowell
r 0.999 0.998 0.998
(Equation 1.4) p< 0.001 0.001 0.001
t4 2604 ± 2.7 27.8 ± 2.2 27.9 ± 2.4
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Figure 8.5. The effect of curing time on the release of diclofenac sodium from pellets
coated with 12% Surelease over a seal-coat of 2% HPMC ES.
204
The migration of metoclopramide hydrochloride during storage at elevated
temperature was investigated using X-ray microanalysis for 2% seal-coated pellets
overcoated with 12% Surelease. The white line which is the scan of chlorine (Figure
8.6) across the sample shows a maximum just beneath the coat. No chlorine was
traced in the thickness of the coat (Figure 8.6). Indeed the distinct boundary between
the coat and drug layer confmned that no migration had occurred during storage at
elevated temperature. Therefore the increase in release rate of metoclopramide
hydrochloride from Surelease coated pellets after curing was not related to the
migration of the drug into the coat.
8.3.2.2 Interaction between core ingredients and surelease during dissolution
8.3.2.2.1 Dialysis studies
Another possible interaction which may describe the slower release of
metoclopramide hydrochloride is related to the interaction between the cationic
metoclopramide hydrochloride and the anionic ammonium oleate, present in the
Surelease. The potential for interaction between either drug and anionic surfactant
(ammonium oleate) was investigated by dialysis studies (section 8.2.2.8). When
metoclopramide hydrochloride was added to the ammonium oleate solution, a
precipitate was formed while the solution containing diclofenac sodium was clear.
Figure 8.7 shows that, the passage of metoclopramide hydrochloride from a solution
containing ammonium oleate through the dialysis bag was much slower than that of
metoclopramide hydrochloride from water. This retardation was due to the formation




Figure 8.6. Metoclopramide hydrochloride distribution across Surelease coated pellets
a) before and b) after curing ( Magnification x 500).
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containing ammonium oleate was very little different to that from water.
When metoclopramide hydrochloride was added to the beakers containing Surelease,
a precipitate could not be seen because Surelease is a milky liquid. Figure 8.8 shows
the dramatic reduction which was observed for the passage of metoclopramide
hydrochloride from tubes containing Surelease compared to tubes containing water.
This retardation may be ascribed, not only to the interaction between metoclopramide
hydrochloride and ammonium oleate, but also to the precipitation of metoclopramide
hydrochloride as a base at high pH of Surelease (section 8.3.2.1). Again passage of
diclofenac sodium from tubes containing Surelease was similar to those containing
water.
In general, surfactants are added to the aqueous dispersions of polymers in order to
decrease the interfacial tension between the organic polymer solution and the
aqueous phase during preparation of the pseudolatex. They prevent agglomeration
and coalescence of the dispersed polymer particles during storage (Bodmeier and
Paeratakul, 1991). Surelease contains oleic acid as stabiliser in ammoniated water.
Therefore the formation of ammonium oleate acting as an anionic surfactant is
predicted. Surfactants will also remain in the coating after formation of the film.
The retardation effect of ionic surfactants (such as sodium dodecyl sulphate) on the
release of drugs (chlorpheniramine maleate and propranolol hydrochloride) from
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It has been claimed that ammonia is evaporated during the coating process
(Bodmeier and Paeratakul, 1991) leaving ammonium oleate as oleic acid. However
it is possible that some of anionic surfactant remains in the coat after
formation of the film and interacts with the drug.
Therefore, the slower release of metoclopramide hydrochloride from Surelease coated
pellets may be due to the in situ formation of a poorly soluble complex of the drug
and surfactant. This complex, because of its lower solubility than metoc1opramide
hydrochloride or its large molecular size, may diffuse more slowly through the film
and hence cause a reduction in the release rate of metoclopramide hydrochloride
from Surelease coated pellets.
8.4 GENERAL DISCUSSION
In order to understand the mechanism of slower release of metoclopramide
hydrochloride than diclofenac sodium from pellets coated with Surelease (chapter 5)
several factors were investigated. Application of either drug on the non-pareil seeds
produced drug-layered pellets with similar size and surface morphology which could
not account for the observed differences in the release of these drugs from Surelease-
coated pellets.
It was thought that due to the higher solubility and also complete ionization of
diclofenac sodium at high pH of Surelease, the extent of interaction between
diclofenac sodium and Surelease and/or migration of this drug into the coat was
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greater than those might happen with metoclopramide hydrochloride. Interaction
between either drug with Surelease during its application was studied by applying
a 2% seal-coat of HPMC E5 before Surelease. As coat of water soluble polymer
prevents direct contact of the drug with Surelease therefore it reduces the extent of
migration of drug and/or flocculation of the Surelease if these interactions are
responsible for different release behaviour of these drugs. However after 2% seal-
coat application the release of diclofenac sodium was slower than metoclopramide
hydrochloride only at 4% and 8% Surelease coating load but at higher coating loads
metoclopramide hydrochloride was released more slowly than diclofenac sodium.
Changes in the release rates after curing was more pronounced for metoclopramide
hydrochloride than diclofenac sodium. In addition the release of diclofenac sodium
was slower than metoclopramide hydrochloride after curing. These results suggested
that other interactions might exist between drugs and Surelease. In vitro experiments
showed that metoc1opramide hydrochloride precipitated in the presence of surfactant
(ammonium oleate).
Therefore interaction between the cationic metoclopramide hydrochloride and anionic
ammonium oleate is the most probable reason for the observed differences in the
release of metoclopramide hydrochloride and diclofenac sodium. The amount of
surfactant at low coating loads of Surelease (4% and 8%) over a 2% seal-coat of
HPMC E5 might not be enough to slow down the release of metoclopramide
hydrochloride. However at higher coating loads which corresponded to the higher
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concentration of surfactant in the coat the extent of interaction between
metocIopramide hydrochloride and ammonium oleate might increase. This interaction
could also describe the release characteristics of the drugs after the curing process.
During curing, ammonia was evaporated from the pellets. The release of ammonia
may be due to dissociation of the ammonium oleate to oleic acid and ammonia when
heated. This could explain the marked increase in the release rate of metoclopramide
following curing. The interaction between cationic drug and anionic surfactant was
minimized by reduced concentration of anionic surfactant after curing and hence
increase in release rate would be expected.
As indicated by Ford et al (1991b) presence of HPMC facilitated the precipitation
of the complex formed between drug and surfactant. A similar explanation may also
be used to explain the differences observed between release of diclofenac sodium
and metocIopramide hydrochloride from pellets coated with mixtures of Surelease
and HPMC (chapter 6). Addition of 5% HPMC in Surelease (section 6.3.1 and 6.3.2)
markedly increased release rate of diclofenac sodium while this amount of HPMC
had lower effect on the release of metoclopramide hydrochloride from Surelease
coated pellets.
8.5 CONCLUSIONS
From the results of particle size analysis it can be concluded that the mean particle
size and distribution could be eliminated as factors contributing to the observed
differences in the release behaviour of metoclopramide hydrochloride and diclofenac
212
sodium from Surelease coated pellets. The drug polymer interaction during film
application was found to have a little effect in this regard. However the interaction
between cationic drug and surfactant (ammonium oleate) in the coat in situ is the
most possible cause of difference in release rate of the drug.
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CHAPTER 9. DRUG RELEASE FROM
HYDROXYPROPYLMETHYLCELLULOSE MATRICES
9.1 INTRODUCTION
Hydroxypropylmethylcellulose is the water soluble polymer most commonly used in
the formulation of sustained release hydrophilic matrices. Rapid formation of the gel
layer around the matrix is the basis for the performance of these matrices (Alderman,
1984). The drug is released by a combination of diffusion through and erosion of the
gel layer. The release kinetics are dependent upon the relative magnitude of the rate
of polymer swelling at the moving rubbery/glassy front and the rate of polymer
erosion at the swollen polymer/dissolution medium front (Kim, 1995).
Synchronization of these phenomena is necessary in order to obtain zero-order
release kinetics (Colombo et al, 1996). With HPMC matrices, synchronization of
front movement is difficult to achieve, therefore the kinetics of drug release depend
on the relative movement of the erosion and swelling fronts. Drug release patterns
from HPMC matrices generally fit a square-root of time kinetic model (Ford et aI,
1985a; 1985b; 1987).
Factors influencing the in vitro drug release from HPMC matrices have been the
focus of a many studies. The effect of polymer:drug ratio (Ford et al, 1985a; 1985
b), presence of lubricant (Ford et al, 1985a), presence of surfactants (Daly et aI,
1984; Ford et al, 1991b), effect of drug particle size (Ford et al, 1985c; Bodea et aI,
1995), effect of drug molecular weight (Baveja et al, 1988), effect of tablet shape
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(Ford et aI, 1987), compaction force (Ford et al, 1987; Bodea et al, 1995), polymer
particle size (Alderman, 1984; Mitchell et al, 1993d), particle shape (Bonferoni et
al, 1995),-polymer moisture content (Mosquera et al, 1996) and polymer viscosity
grade (Salomon et al, 1979; Daly et al. 1984; Ford et al, 1985a) have been studied
extensively. However there are conflicting reports about the effect of polymer
viscosity on the release rate of the drug.
9.1.1 AIMS AND OBJECTIVES
The performance of HPMC of low viscosity grade as a rate retarding membrane on
pellets was evaluated in earlier chapters. It was observed that the application of
HPMC of low viscosity to coated pellets was not successful in retarding the release
rates of metoclopramide hydrochloride or diclofenac sodium. On the other hand it
is impossible to easily use a high viscosity grade of HPMC for coating due to the
long processing time required (Gazzaniga et al, 1995).
The main objectives of this chapter were to examine how the HPMC of low and high
viscosity grade affected the dissolution rates and release mechanisms of
metoclopramide hydrochloride and diclofenac sodium from matrices. In addition, the
effect of substitution type of HPMC on the release of these two drugs was also
investigated.
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9.2 MATERIALS AND METHODS
9.2.1 MATERIALS
Metoclopramide hydrochloride, diclofenac sodium, HPMC K4M, HPMC Kl00,
HPMC E4M, HPMC EIS and magnesium stearate, as described in section 2.1, were
used.
9.2.2 METHODS
9.2.2.1 Preparation of tablets
Tablets containing 15 mg metoc1opramide hydrochloride or diclofenac sodium, and
45,60,75 or 150 mg of HPMC K4M, HPMC Kl00, HPMC E4M or HPMC EIS
were prepared as described in section 2.2.5. The tablet weights were 60, 75, 90 or
165 mg based on the polymer content.
9.2.2.2 Dissolution testing
Dissolution studies were performed as described in section 2.2.6.
9.2.2.3 Release kinetics for matrices
Release data between 15-60% of drug release were fitted to different kinetic models
as described in section 2.2.7.
9.3 RESULTS AND DISCUSSION
9.3.1 Release of metoclopramide hydrochloride from HPMC matrices
The release profiles of metoc1opramide hydrochloride from tablets containing
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different amounts of HPMC E15, HPMC E4M, HPMC Kl00 and HPMC K4M are
shown in Figures 9.1-9.4 respectively. All the dissolution data were plotted as a
percentage of drug released against square-root of time. An increase in HPMC
content resulted in a decrease in the percent of drug release at each time interval for
all grades of HPMC used. These results are in agreement with those published by
Ford et al (1985b) and Mitchell et al (1993b) who stated that the major factor
controlling the release of drug from matrices is the drug/polymer ratio. A higher
amount of HPMC in the matrix absorbed more water and caused a greater of
swelling (Wan et al. 1993). This in turn increased the diffusional path length and
decreased the rate at which drug was released. Skoug et al (1993) considered that an
increase in polymer concentration caused an increase in the viscosity of the gel layer.
This caused a decrease in the effective diffusion coefficient of drug. However
Mitchell et al (1993b) claimed that decrease in the apparent diffusion coefficient of
drug through the gel was due to the formation of a more concentrated gel and
increased gel tortuosity at higher amounts of HPMC.
Tables 9.1-9.4 represent the release rates which were calculated from regression
analysis of release data using different kinetic models. As the polymer content in the
matrix increased the release rates decreased for each type of matrix. The lag times
predicted by the models generally showed negative values, except for those predicted
from square-root kinetics. The release rates were faster for matrices containing
HPMC EI5 than HPMC E4M at equivalent polymer content. Similar results were
obtained by Daly et al (1984) for the release of the water soluble, chlorpheniramine
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maleate from HPMC EIS and HPMC E4M matrices. Metoclopramide hydrochloride
was also released faster from matrices containing HPMC K100 than from matrices
containing HPMC K4M. These results are in agreement with those published by Ford
et al (1985a) who showed that promethazine hydrochloride was released faster from
HPMC KI00 matrices than from HPMC K4M matrices. The release rates were
similar for HPMC K4M and HPMC E4M at equivalent polymer contents suggesting
that the substitution type of HPMC may have little effect on the release of drug from
HPMC matrices. However, matrices containing HPMC EIS showed faster release
rates than HPMC Kl00 matrices which may ascribed to its lower viscosity.
9.3.2 RELEASE OF DICLOFENAC SODIUM FROM HPMC MATRICES
Similar to metoclopramide hydrochloride, the drug:polymer ratio had a great
influence on the release of diclofenac sodium from HPMC EIS, HPMC E4M, HPMC
Kl00 and HPMC K4M matrices (Figures 9.5-9.8).
The release rates decreased as the polymer content increased (Tables 9.5-9.8). The
release rates of diclofenac sodium from HPMC EIS matrices were faster than those
observed for HPMC E4M at equivalent polymer content. Comparison of release rates
for HPMC Kl00 and HPMC K4M matrices at the same polymer content indicated
a faster release of diclofenac sodium from HPMC K100 matrices. These results
indicate that increasing the polymer viscosity decreases the release rate of the drug.
Such dependency of release rate of diclofenac sodium on the viscosity of HPMC
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Figure 9.1. The effect of HPMC content on the release of metoclopramide
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Figure 9.3. The effect of HPMC content on the release of metoclopramide
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Figure 9.4. The effect of HPMC content on the release of metoclopramide
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K4M and by Liu et al (1995) when using HPMC 60-SH, 50 mPa.s and HPMC 60-
SH, 4OCX)mPa.s.
The release rates of diclofenac sodium from HPMC K4M matrices were similar to
those observed for HPMC E4M matrices at equivalent polymer content. However the
release of drug was faster when HPMC E15 was used than when HPMC Kl00 was
used which may be attributed to the lower viscosity of the HPMC E15 matrices.
9.3.3 RELEASE KINETICS FOR METOCLOPRAMIDE HYDROCHLORIDE
Correlation coefficients for the best statistical fit for the release of metoclopramide
hydrochloride from HPMC matrices are shown in Tables 9.1-9.4. The close values
of correlation coefficients for the square-root, first-order and Hixon-Crowell models
made it difficult to judge about the best applicable model to the release data. This
might indicate that mixtures of these models can be used to describe the release
profiles.
The mechanism of drug release was investigated by fitting the data to equations 1.6
and 1.7. Statistical analyses showed that at each polymer content, the best fit with
the lowest sums of squares of errors and the lowest information criteria were found
when equation 1.7 was used (Tables 9.9-9.12). As there was no special trend
between the polymer content and the value of n for the different grades of HPMC,
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Figure 9.5. The effect of HPMC content on the release of diclofenac sodium from
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Figure 9.6. The effect of HPMC content on the release of diclofenac sodium from
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matrices containing 45, 60, 75 and 150 mg HPMC KIOO.
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Figure 9.8. The effect of HPMC content on the release of diclofenac sodium from
matrices containing 45, 60, 75 and 150 mg HPMC K4M.
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The mean values of n are 0.63 ± 0.01, 0.54 ± 0.01, 0.60 ± 0.03 and 0.56 ± 0.04 for
HPMC E15, HPMC E4M, HPMC Kl00 and HPMC K4M matrices. These values
indicate that the mechanism of drug release from all grades of HPMC is anomalous
transport or non-Fickian diffusion (Ritger and Peppas, 1987). In other words a
combination of diffusion through the gel and erosion of the polymer controlled drug
release.
Generally the values of n for matrices containing lower viscosity HPMCs (HPMC
E15 and HPMC Kl(0) were higher than those for HPMC of higher viscosity grades
(HPMC E4M and HPMC K4M). This higher value of n indicate that the role of
erosion in controlling drug release was greater for lower viscosity grade HPMCs than
for higher viscosity grades.
9.3.4 RELEASE KINETICS FOR DICLOFENAC SODIUM
Tables 9.5-9.8 show the correlation coefficients for the release of diclofenac sodium
from HPMC matrices. Again due to the close values of (r) for square-root, first order
and Hixon-Crowell model it is not possible to consider one model as a best fit.
Therefore it may be concluded that mixtures of these models may apply to the
release data.
The values of the release exponents are listed in Tables 9.13-9.16. Statistical analyses
showed that at each polymer content, the best fit was found when equation 1.7 was
used. The mean value of n (equation 1.7) is 0.74 ± 0.04, 0.63 ± 0.01, 0.68 ± <0.01
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and 0.61 ± 0.01 for HPMC E15, HPMC E4M, HPMC KIOO and HPMC K4M
matrices. The mean values of n indicate that although both diffusion and erosion
control the mechanism of diclofenac sodium release, the role of erosion is greater
than that was a case for metoclopramide hydrochloride. These values of n are in the
range reported by Liu et al (1993) for the release of diclofenac sodium from HPMC
of different viscosity (0.64-0.87). However Liu et al (1995) obtained values of 0.56
and 0.61 for the release of diclofenac sodium from matrices containing HPMC 4000
mPa.s and HPMC 50 mPa.s respectively. Values of n reported by other workers
include 0.78 (Sheu et al, 1992) for release of diclofenac sodium from HPMC K4M
matrices, 0.77 (Liu et al, 1993) and 0.82 (Sheu et ai, 1992) for release of diclofenac
sodium from HPMC K100 matrices and 0.83 (Bain et al, 1991) for the release of this
drug from HPMC E15 matrices.
Again the values of n for matrices containing the lower viscosity HPMCs (HPMC
E15 and HPMC Kl00) were higher than those of HPMC of higher viscosity grades
(HPMC E4M and HPMC K4M) indicating that erosion has a higher contribution to
the release of diclofenac sodium from matrices containing the low viscosity grade
HPMC.
9.4 GENERAL DISCUSSION
The release rates of metocl opram ide hydrochloride or diclofenac sodium from HPMC
EI5 matrices were higher than for HPMC E4M matrices. Similar results were
obtained for the release rates of these two drugs from matrices containing HPMC
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Kl00 and matrices containing HPMC K4M. Therefore, the release of either drug was
affected by the viscosity of the HPMC. However there are conflicting reports about
the effect of viscosity of the HPMC on the release of drugs, some of them stating
that viscosity does not have any effect and some have introduced viscosity as an
important factor in the control of drug release from matrices.
Salomon et al (1979) showed that only the lag time for the release of potassium
chloride was affected by the viscosity of HPMC in matrices while the release rates
were the same for each viscosity grade of HPMC examined. Alderman (1984) stated
that the release of a drug would be slower if a higher viscosity grade of HPMC was
used in the matrix and this was attributed to an increase in gel layer viscosity.
Similar results were found by Daly et al (1984) for the release of chlorpheniramine
maleate from HPMC E5, HPMC E15, HPMC E50 or HPMC E4M matrices.
Ford et al (1985a; 1985b) reported that matrices composed of HPMC K4M, HPMC
K15M or HPMC KIOOM showed similar release profiles for promethazine
hydrochloride, propranolol hydrochloride and aminophylline while the lowest
viscosity grade (HPMC K100) behaved differently and gave faster release rates. Ford
et al (l985b) showed that both the lag times and release rates were generally
unaffected by the viscosity grade of HPMC for propranolol hydrochloride and
aminophylline. Ford et al (1985c) claimed that for a poorly water soluble drug, such
as indomethacin, the viscosity grade plays a major role in controlling the rate of drug
release. In the present study the viscosity grade of the HPMC affected the release of
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both drugs.
Baveja et al (1988) reported the that release rates of a series of bronchodilators did
not vary significantly for matrices containing HPMC K4M, HPMC K15M and
HPMC Kl00M which was in agreement with earlier studies (Salomon et al, 1979:
Ford et al 1985a; 1985b).
Cheong et al (1992) showed that the viscosity grade had no major effect on the
release of propranolol hydrochloride from matrices containing 50-75% w/w polymer
(HPMC K4M, HPMC K15M, HPMC K30M and HPMC KIOOM) in the formulation
while it had a tremendous effect on the release rate of drug when the amount of
polymer was in the range of 5-25% w/w of formulation. However, in this study using
lower viscosity grades of HPMC, the effect of viscosity was observed in matrices
containing 75-90% polymer in the formulation.
What we may conclude from the results of this study and other reports is that there
is a treshhold for viscosity of the HPMC above which there is no effect on drug
release rate but below it, the drug release is greatly affected by the viscosity. These
results are confirmed by Gao et al (1996) who showed that gel layer thickness and
consquently dissolution of drug have been affected by the viscosity of HPMC below
a critical molecular weight. For matrices containing high viscosity HPMCs (>4000
mPa.s) the gel composition and thickness is identical. However for low viscositiy
HPMCs «100 mPa.s) the swelling is not homogeneous maybe due to rapid
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dissolution of polymer (Gao et al, 1996).
The mathematical modelling of release data proved that drug release mechanism was
controlled by both diffusion through and erosion of the polymer for both drugs.
However depending on the type of drug used one mechanism may have more
significant role than the other. The values of n were between, 0.53-0.64 for
metoclopramide hydrochloride release from HPMC matrices with different viscosity
grades. Previously Ford et al (1987) reported values of n between 0.65-0.71 for the
release of soluble drugs from HPMC K15M matrices. Other values of n were 0.63
(Ranga Rao et al, 1990) or 0.60 (Dabbagh, 1995) for propranolol hydrochloride
release from HPMC K4M matrices. The value of n obtained for metoclopramide
hydrochloride is approximately in the range obtained by other workers.
The values of n for diclofenac sodium release from HPMC matrices with different
viscosity were in the range of 0.59-0.80. However the values of n reported by Ford
et al (1987) for insoluble drugs were 0.82-0.90. Hence the value of n for diclofenac
sodium was lower than those obtained for insoluble drugs. This may be attributed
to the higher water solubility of diclofenac sodium compared to those drugs
(indomethacin and diazepam) used by Ford et al (1987).
A comparison of the release exponents for metoclopramide hydrochloride and
diclofenac sodium (Table 9.17) shows that the value of n is higher for the latter drug.
This indicates different mechanisms control the release of these drugs. The release
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of the more water soluble drug is predominantly controlled by diffusion through
HPMC matrices while the higher value of n for diclofenac sodium shows that there
is a larger contribution by erosion to the release of this drug. This is in agreement
with findings of Skoug et al (1993), Pham and Lee (1994) and Tahara et al (1996).
Skoug et al (1993) showed that the release of flurbiprofen from HPMC matrices was
mainly an erosion-controlled mechanism while adinazolam mesylate exhibited an
entirely diffusion-controlled mechanism. Alprazolam release was controlled by both
diffusion and erosion. Pham and Lee (1994) also reported that the release of a water
soluble compound occurred mostly by swelling-controlled diffusion process while for
relatively water insoluble drugs and/or lower viscosity grades of HPMC, polymer
dissolution plays a more significant part in control of drug release rate.
Table 9.17. The value of n for the release of metoclopramide hydrochloride or
diclofenac sodium from matrices containing different grade and viscosity of HPMC.
I Drug II HPMC EIS I HPMC E4M I HPMC KIOO I HPMC K4M !
Metoclopramide 0.63 ± 0.01 0.54 ± 0.01 0.60 ± 0.03 0.56 ± 0.04
hydrochloride
Diclofenac sodium 0.74 ± 0.04 0.63 ± 0.01 0.68 ± 0.01 0.61 ± 0.01
It has been claimed that, due to faster hydration, HPMC K type produced slower
release rates than HPMC E type (Alderman, 1984). Recent studies have shown that
the extent and rate of gel formation is similar for different types of HPMC (Mitchell
et al, 1993a; Rajabi-Siahboomi, 1994b). Rajabi-Siahboomi (1996) suggested that
HPMC K4M gel offered a greater diffusional resistance to water within the inner gel
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region. However the results of this study indicated that the performance of HPMC
K4M and HPMC E4M were similar for the release of metoclopramide hydrochloride
or diclofenac sodium. These results are in agreement with those published by
Mitchell et al (1993a) who reported that substitution type had a little effect on the
dissolution of propranolol hydrochloride. Indeed, no differences observed for the
release rate of propranolol hydrochloride from matrices containing HPMC K4M,
HPMC E4M or HPMC F4M (Mitchell et al, 1993a).
9.5 CONCLUSIONS
The results of this study indicated that the polymer/drug ratio has a great effect on
the release of drug from HPMC matrices. The release rates of both drugs decreased
as the polymer content increased. The rate of metoclopramide hydrochloride or
diclofenac sodium release was greatly affected by the viscosity of the HPMC
polymer. The lower viscosity grade polymers produced faster release rates for both
drugs.
The results also showed that drug solubility affected not only the release rate but
also the release mechanism. The drug with the lower solubility was released more
slowly than the more water soluble drug. Erosion had a greater contribution in the
release mechanism of diclofenac sodium than metoclopramide hydrochlordie from
HPMC matrices.
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CHAPTER 10. DRUG RELEASE FROM MATRICES PREPARED BY
WET GRANULATION PROCEDURE USING SURELEASE
10.1 INTRODUCTION
The release of metoclopramide hydrochloride and diclofenac sodium from HPMC
matrices was characterised in chapter 9. Changes in polymer content, viscosity or
type produced zero-order release for neither drug. It has been reported that sustained
release dosage forms based on mixtures of HPMC and ionic cellulose ethers such as
sodium carboxymethylcellulose may produce zero-order release (Baveja et aI, 1987;
1988; Ranga Rao et al, 1988; Dabbagh, 1995). However few studies investigated
mixtures of HPMC with the non-ionic ethylcellulose. Feely and Davis (1988b) found
that the addition of ethylcellulose as a powder to HPMC matrices did not have any
,
profound effect on the release of chlorpheniramine maleate. Indeed, a slight increase
in the release rate was observed after the addition of ethylcellulose. Similarly
Dabbagh et al (1996) stated that as the proportion of ethylcellulose (as powder) in
HPMC matrices increased, the release rates of propranolol hydrochloride increased.
Aqueous dispersions of ethylcellulose have been used as a granulating agent to
produce tablets, containing drug and excipients such as dicalcium phosphate, with
sustained release properties (Klinger et al, 1990). However there are no reports on
the application of these dispersions in the granulation of HPMC. In order to obtain
the desired release profiles from hydrophilic matrices, it is essential to use either
high molecular weight polymers or a high concentration of the polymer. The use of
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a high molecular weight polymer, or a high concentration of it, caused unacceptable
flow characteristics which could be troublesome, especially when high-speed
tableting machines are used (Sheskey et al, 1994). Therefore, to ensure good content
uniformity and to avoid flow-related problems, granulation may be the preferred
procedure to manufacture commercial hydrophilic sustained release matrix tablets
(Timmins et al, 1991).
10.1.1 AIMS AND OBJECflVES OF THE STUDY
The aims of the work presented in this chapter were to examine the potential for
sustained release of HPMC matrices granulated with Surelease.
10.2 MATERIALS AND METHODS
10.2.1 MATERIALS
HPMC K4M.. metoclopramide hydrochloride «90 urn particle size), diclofenac
sodium «90 urn particle size), Surelease and magnesium stearate, as described in
section 2.1, were used.
10.2.2 METHODS
10.2.2.1 Preparation of granules
The granules were prepared on a small scale. Mixtures (12 g) of 1:5 drug:HPMC
K4M blends were prepared using a tumbler mixer as described in section 2.2.5. The
mixed powders were transferred to a blender (Moulinex Blender 531, Spain). As
Surelease contains 25% w/w solid, the amount of dispersion that can be used at each
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step of the granulation was low because otherwise the granulation become too damp
to process with larger volumes of dispersion. Quantities (4 g) of undiluted Surelease
were weighed using an Oertling analytical balance (West Midland, UK) and were
added to the mixture of the drug and polymer in stages and mixed thoroughly for 1
min. The wet mass was passed manually through a 600 urn sieve and dried at 50°C
for 45 min, before further granulating agent was added as required. This procedure
was repeated until the desired amount of Surelease was added, to produce granules
containing 14.28%.25% or 33.33% w/w (based on the dried weight) Surelease. This
resulted in granules which contained 1:5:1. 1:5:2 or 1:5:3 drug:HPMC
K4M:Surelease ratios. The final granules were dried overnight at 50°C. Control
granules were prepared by the addition of 4 g water to the drug and polymer
mixtures instead of Surelease and processed as described above.
10.2.2.2 Preparation of tablets
The granules prepared in section 10.2.2.1 were mixed with 0.5% w/w magnesium
stearate for 5 min using a tumbler mixer. Flat-faced tablets, 7.14 mm in diameter.
containing amounts of granules equivalent to 15mg of drug, were compressed on a
Manesty F3 single punch tableting machine at 20 kN compaction force as described
in section 2.2.5. The tablet weights were 105, 120 or 135 mg based on the Surelease
content in the granules.
10.2.2.3 Evaluation of matrices
The crushing strengths of the tablets were measured using a motorised tablet
249
hardness tester (Scleuniger, model 2E, Switzerland) 24 h after compaction. An Air
Comparison Pycnometer (Model 930, Beckman Instruments Ltd. UK) was used to
determine the true densities of the physical mixtures of drug and HPMC K4M and
their granules. The mean of three determinations was used for each sample. The
thicknesses and diameters of the tablets were measured using a screw-gauge
micrometer (Mitutoyo, Japan) in order to 'calculate the volume of the tablets. The
porosities of the tablets were determined consequently using equation 10.1.
E = (1 - p. lp, ) x 100 EqUlltion 10.1
In equation 10.1, E is the porosity of the tablet, Pa is the apparent density of the
tablet (g.crn") and p, is the true density of the powder or granule (g.cm"). The means
of four determinations were used to calculate the porosity of the tablets prepared
from physical mixtures and those prepared from granules. The mean values of 4
tablets for each formulation are reported.
Dissolution was carried out as described in section 2.2.6. The release data between
15-60% were fitted to different kinetic models as described in section 2.2.7.
10.3 RESULTS AND DISCUSSION
10.3.1 CRUSHING STRENGTHS AND POROSITIES
Table 10.1 shows the crushing strengths of tablets made from physical mixtures and
of those prepared by wet granulation using either water or Surelease. The crushing
strengths of the tablets decreased after granulation suggesting the formation of hard
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granules which resist deformation during compaction. The crushing strengths of the
tablets were generally independent of the amount of Surelease applied (Table 10.1).
These results are in agreement with those published by Liu et al (1993) who showed
that increasing the amount of water used in the preparation of HPMC granules
lowered the hardness of the resultant tablets. Similar findings have been reported for
other cellulose derivatives. Microcrystalline cellulose (MCC) pellets, granulated with
water, resisted rupture on compaction due to the high bond strength (Millili and
Schwartz, 1990). This resulted in low surface to surface contacts for bonding, thus
producing weaker tablets. Similarly Schwartz et al (1994) claimed that MCC beads
prepared by extrusion/spheronisation using water were hard and did not easily
deform.
Table 10.1. Crushing strengths of tablets (kP) prepared from physical mixtures and
granules containing different amount of Surelease.
Tablets prepared from: Metoclopramide Diclofenac
hydrochloride sodium
Physical mixture 7.60 ± 0.17 6.43 ± 0.26
Water granulated 2.13 ± 0.09 3.03 ± 0.05
Granules containing 14.28% Surelease 2.50 ± 0.21 3.10 ± 0.04
Granules containing 25% Surelease 3.36 ± 0.12 3.50 ± 0.22
Granules containing 33.33% Surelease 2.73 ± 0.12 3.67 ± 0.19
Table 10.2 illustrates the porosities of the tablet. The porosities of the tablets
increased, for both drugs, after granulation. Therefore the low crushing strenghts of
tablets prepared from granules may be ascribed to the higher pororsities of these
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tablets. The porosities were generally independent of the amount of Surelease used.
Table 10.2. Porosities of tablets (%) prepared from physical mixtures and granules
containing different amounts of Surelease.
Tablets prepared from: Porosity (%)
Metoclopramide Diclofenac
hydrochloride sodium
Physical mixture 8.40 ± 0.08 9.89 ± 0.16
Water granulated mixture 15.27±0.17 13.03 ± 0.15
Granules containing 14.28% Surelease 16.03 ± 0.38 13.45 ± 0.34
Granules containing 25% Surelease 15.03 ± 0.05 13.62 ± 0.45
Granules containing 33.33% Surelease 15.90 ± 0.16 16.01 ± 0.12
10.3.2 RELEASE OF METOCLOPRAMIDE HYDROCHLORIDE FROM
MATRICES PREPARED BY WET GRANULATION
The addition of Surelease caused a dramatic decrease m the amount of
metoclopramide hydrochloride released from matrices compared to those granulated
with water (Figure 10.1). The release rates were slightly higher for the mixture
granulated with water compared to the physical mixture (Table 9.4). The release
rates considerably decreased as the amount of Surelease increased in the granules
(Table 10.3). Square-root kinetics was probably the most applicable model for
matrices containing 14.28% and 25% Surelease. However for matrices containing
33.33% Surelease, the square-root, first-order and Hixon Crowell models gave the
close values of correlation coefficients (Table 10.3). When the data were fitted to
equations 1.6 and 1.7. equation 1.7 gave the best fit (Table 10.5). The values of
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Figure 10.1. The effect of Surelease content on the release of metoclopramide
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diffusion contributed to the control of drug release. The release exponent increasedas
the Surelease content of the granules increased suggesting a shift of release
mechanism towards erosion.
10.3.3 RELEASE OF DICLOFENAC SODIUM FROM MATRICES PREPARED
BY WET GRANULATION
Incorporation of Surelease had little retarding effect on the release rate of diclofenac
sodium from matrices compared to those prepared using water as a granulating agent
(Figure 10.2 and Table 10.4). The release rates of tablets prepared from mixtures
granulated with water were similar to those of physical mixtures (Table 9.8). Again
due to close values of (r) it for the square-root, first-order and Hixon-Crowell model
it was not possible to consider one model as the best fit.
The values of exponent n (equation 1.7) were in the range of 0.51 < n < 0.60
indicating both erosion and diffusion controlled drug release mechanism (Table 10.6).
The release exponents were similar for tablets containing different amounts of
Surelease. These values also resembled those obtained for physical mixtures of the
drug and HPMC K4M (1:5 drug:HPMC K4M; Table 9.16).
10.4 GENERAL DISCUSSION
Comparison of the release rates for tablets prepared from water-granulated mixtures
with those of directly compressed mixtures (chapter 9) shows that former mixtures
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rt'\o-
metoclopramide hydrochloride. These findings are not in agreement with those
reponed by Mandal (1995) who stated that the amount of drug dissolved from wet
granulated HPMC tablets were considerably higher than from directly compressed
matrix formulations. The slight increase in the release rate of metoclopramide
hydrochloride after granulation seen in this study, could be due to the higher porosity
of the tablets prepared from granules (Table 10.2).
The release rates of metoc1opramide hydrochloride were slower than diclofenac
sodium from Surelease granulated matrices at equivalent Surelease content. On the
other hand incorporation of Surelease into the HPMC matrix had little effect on the
release of diclofenac sodium from granulated matrices while the release of
metoclopramide hydrochloride was considerably affected by the amount of Surelease
added. Kawashima et al (1989) reported that different release patterns could be
observed from matrices containing different drug types and prepared using aqueous
dispersions of Eudragit. Kawashima et al (1989) showed that although Eudragit NE
30D was an effective polymer in retarding the release of theophylline from matrices
prepared by wet granulation, it was less effective in matrix tablets containing
propranolol hydrochloride. Klinger et al (1990) showed that the incorporation of
5.2% Surelease into a matrix formulation containing theophylline and hydrous lactose
prolonged the drug release. In another part of their study, increasing the amount of
Surelease from 4.2% to 16.6% in a formulation containing chlorpheniramine maleate
and dicalcium phosphate dramatically decreased the release rate of the drug.
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As mentioned before, Surelease contains 0.8-1% w/w ammonia. It was shown in
section 8.3.2.1 that metoclopramide hydrochloride precipitated in the 0.5% ammonia
solution as a metoclopramide base. Additionally the passage of metoclopramide
hydrochloride through a dialysis tube reduced to a great extent in the presence of
Surelease (8.3.2.2.1) while no significant difference was evident for the passage of
diclofenac sodium in the presence of Surelease. Therefore it may be concluded that
the slow release of metoclopramide from Surelease granulated tablets compared to
the water granulated tablet was due to the formation of metoclopramide base.
Comparison of the exponent n for metoclopramide hydrochloride or diclofenac
sodium release from granulated matrices showed that drug release mechanism for
both drugs from Surelease granulated mixtures was non-Fickian diffusion. In other
words coupling of diffusion and erosion contributed to the release. The release
exponent n for metoclopramide hydrochloride shifted to a higher value when the
Surelease content reached 33.33% (Table 10.5). This may be explained by the fact
that the highly water soluble metoclopramide hydrochloride was converted to its base
form upon addition of Surelease which has a much lower solubility (Pitre and Stradi,
1987). Decrease in drug solubility meant that the role of erosion in the release
mechanism increased. However Dabbagh et al (1996) showed that the value of n .
remained unchanged as the proportion of ethycellulose powder in the admixtures of
HPMC and ethylcellulose increased. For diclofenac sodium matrices, the increase in
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The incorporation of Surelease into HPMC matrices affected the release of
metoclopramide hydrochloride and diclofenac sodium to different extents. However,
zero-order release was not obtained for either drug. The release of metoclopramide
hydrochloride decreased as the Surelease content in the granules increased. The
release of diclofenac sodium was less affected by incorporation of Surelease into the
HPMC K4M matrices.
The release mechanism for both drugs was a combination of diffusion and erosion.
Incorporation of Surelease into the matrices shifted the mechanism of release of
metoclopramide hydrochloride to a more erosion-controlled system compared to
water granulated matrices. However, the mechanism of release of diclofenac sodium
was hardly affected by use of Surelease.
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CHAPTER t 1. GENERAL DISCUSSION
11.1 INTRODUCTION
One of the greatest opportunities in the field of pharmaceutical industry lies in
conversion of standard solid oral dosage forms to safer, more convenient or more
effective controlled-release formulations. Today several types of oral controlled-
release products have been designed to release the drug at various rates. They are
mainly classified either as multiparticulate systems such as pellets or single-unit
system s such as tablets. Basically in all these systems the release of drug is
controlled by diffusion either through a membrane (reservoir devices) or within a
carrier (matrix systems) and/or dissolution of the membrane or carrier.
Polymeric materials are considered to be essential for achieving controlled delivery
of drug s. Cellulose ethers are the most commonly used polymers in the preparation
of oral controlled-release formulations. Among the cellulose ethers,
hydroxypropylmethylcellulose and ethylcellulose are used extensively as diffusion
harriers in the fabrication of all types of controlled release formulations.
This study investigated the application of the hydrophilic polymer.
hydroxypropylmethylcellulo se of different viscosities, and the hydrophobic polymer,
ethylcellulose (a s an aqueous dispersion) and their mixtures in the preparation of
controlled-release pellets and matrices using two structurally different model drugs
meroclopramide hydrochloride and diclofenac sodium. The effects of polymer content
2()2
on the release rates and mechanisms of release were investigated for each system.
In addition the rates and mechanisms of release of both drugs were compared.
11.2 DRUG RELEASE FROM PELLETS
11.2.1 APPLICATION OF HPMC IN COATED PELLETS
Metoclopramide hydrochloride-layered pellets were coated with HPMC E5 or HPMC
EIS up to a coating load of 20% w/w. As these polymers produced similar release
profiles for the release of metoclopramide hydrochloride, pellets layered with
diclofenac sodium were therefore only coated with HPMC EIS up to the 20% w/w
coating load. The release of either drug was dependent, to a large extent, on the total
content of the polymer present in the coat. Wan et al (Il)Y5b), similarly,
demonstrated that the release of chlorpheniramine maleate from pellets decreased as
the coating load of HPMC (Metolose f)O-SH, 400 mPa.s) increased. All the HPMC
coated-pellets disintegrated during the dissolution test and no gel like structure
remained at the end of dissolution studies indicating that complete erosion of the
membrane and the pellets had taken place, even at the 20% w/w coating load.
The reduction in the release rates with increased coating load was attributed to the
increased diffusional path length. On the other hand, with increasing coating
thickness. the resulting gel would become thicker and therefore its resistance to
penetration by water and to erosion would increase (Wan and Lai, Il)YI). This would
lead to a decrease in the release rate of the drug out of the gelled coat. Although the
increusinu cnatinu load of HPMC E5 or HPMC EIS decreased the release rates of
... ...
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both drugs. the majority of both drugs (> 90%) was released within approximately
I h. even at the 20% w/w coating load of HPMC E5 or HPMC EIS, indicating that
the release was not controlled by applying a HPMC membrane.
Comparison of the release data for metoclopramide hydrochloride and diclofenac
sodium pellets coated revealed that diclofenac sodium was released slightly more
slowly than metoclopramide hydrochloride at equivalent coating loads. This was
attributed to the hiuher water solubility of the metoclopramiJe hydrochloride than...
diclofenac sodium.
In order to understand the mechanism of drug release, data were fitted to two
mathematical models (equations 1.6 and 1.7). In all cases equation 1.7, proposed by
Ford et al (199 Ia). gave the better tit than equation 1.6, proposed by Korsmeyer et
al (19X3a). The value of exponent n was in the range of 0.42 < n < 0.50 and 0.42
< n < 0.54 for the release of metocIopramide hydrochloride from HPMC E5 and
HPMC EIS coated pellets. respectively, indicating that diffusion was the
predominant mechanism controlling drug release. The corresponding values for
diclofenac sodium were 0.42 < n < 0.55 which again indicates that the release
mechanism was predominantly diffusion controlled. The similar values of n for each
drug indicated that drug solubility may have little effect on the mechanism of drug
release from HPMC coated pellets.
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11.2.2 APPLICATION OF SURELEASE IN COATED PELLETS
Metoclopramide hydrochloride or diclofenac sodium-layered pellets were coated with
Surelease to different thicknesses up to 20% coating load. The coating load had a
major effect on the ultimate rate of drug release and the duration of the lag times
prior to controlled release. In other words the release rates of both drugs
dramatically decreased as the coating load of Surelease increased. Similar results
have been reported by other workers (Ghebre-Sellassie et al, 1YXX;Porter, IYXYa:
Ozturk et al. IYY(); Maganti and Celik, 1l)l)4). All the pellets remained intact during
the dissolution test indicating that the Surelease membrane controlled drug release.
Generally. in coated dosage forms the membrane properties and geometry, such as
membrane porosity. internal structure (tortuosity) and the membrane thickness
critically affect the release rate of a drug (Tojo and Miyanami, IYX3). It was shown
that the distribution of pores was greater at low coating loads of Surelease.
Therefore. the permeability of both drugs through the coating was rather high when
there was a small amount of coating because of cnating imperfections. On the other
hand. the coating layer was thicker as the load increased. Therefore, the path length
for diffusion of the dissolution medium to enter the core ami for the dissolved drug
to come out through the coat would also be increased.
It has been claimed that the aqueous solubility of a drug plays an important role in
the release of a drug from coated pellets. Highly water 'soluble drugs are generally
released faster than poorly water soluble compounds (Ghebre-Sellassie et al. IYXX;
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Iyer et al. ll)l)(). This has been reported to be mainly due to the different rates of
migration of the drugs during the coating process. DUling film deposition, highly
water soluble drugs dissolve in the sprayed droplets and remained embedded in the
film after the evaporation of water. As more and more layers of film are applied. the
migration of drug diminishes. Since the presence of the drug in the inner layers of
the coating leads to a porous structure during dissolution, a thicker coat is required
to generate a specific release profile than would be the case with poorly water
soluble drugs (Ghebre-Sellassie et ai, lYX7).
It was thought that metoclopramide hydrochloride, due to its higher solubility, might
migrate to a greater extent than diclofenac sodium into the Surelease coat during its
application and therefore should be released faster than diclofenac sodium. However
it was observed that when metoc1npramide hydrochloride was added to ammoniated
water containing similar amounts of ammonia to diluted Surelease, a precipitate was
formed. The melting point of the precipitate corresponded to the melting point of
metoclopramide base (Mitchell. Il)X5). However, diclofenac sodium is freely soluble
at pH > 6. Therefore it might be more prone to migrate into the Surelease than
metocloprumide hydrochloride.
A compunson of the release profiles for metoc1opramide hydrochloride and
diclofenac sodium coated with Surelease revealed that despite its solubility.
diclotenac sodium showed faster release rates than metoc1opramide hydrochloride at
equivalent coating loads. For example the first-order release rate of diclofenuc
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sodium was 33% faster than the release rate of metoclopramioe hydrochloride at the
20rk w/w coating load. Therefore the results of this study indicated that water
solubility may not be an important factor in controlling the release of drug hom
Surelease-coated pellets.
The drug release mechanism was evaluated by determining the release exponent n
for both drugs. It was observed that the coating load of Surelease had no effect on
the mechanism of the release of metoclopramide hydrochloride as the values of n
were similar for all coating loads. The value of n was in the range of 0.54 < n <
OJ)2 indicating that mechanism of release was mostly diffusion controlled. However
the release mechanism of diclofenac sodium was dependent on the coating load of
Sureleuse, The higher value of n for the X% and 12% coating loads (1.02 and O.7S.
respectively) indicates that the contribution of diffusion as a rate limiting step was
reduced. This maybe attributed to the presenec of more pores at low coating loads
of Surelease which facilitated the diffusion process. However at high coating loads
diffusion mainly controlled the release of drug. The values of n for 16% and 20%
coating loads were 0.50 and O.SS. respectively.
11.2.3 APPLICATION OF SURELEASEIHPMC EIS MIXTURES DIRECTLY ON
DRUG-LA YERED PELLETS
The addition of water soluble polymers, such as HPMC, to ethylcellulose aqueous
dixperxions is used to increase the permeability of the resulting film (Ghebre-
Sellassie et al. ILJXX:Gilligan and Po, ILJLJI), although it has been shown that this
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could result in flocculation of the ethylcellulose dispersion (Wong and Bodmeier,
Il)l)(). In this study. Sure lease films containing 5%, 7.5% or 10% w/w HPMC EIS
were applied onto drug-layered pellets up to the 20% w/w coating load. Again,
coating load had a major effect on the rate of drug released. On the other hand
increasing the HPMC content in the coats increased the release rates of both drugs
at equivalent coating loads. For example, the first-order release rate of
metnclopramide hydrochloride was more than three times faster when the HPMC
content was 10% than when the HPMC content was S% at a coating load of 20%
w/w. High proportions of HPMC in the Surelease membrane caused a rapid release
of both drugs even at high coating loads. Therefore the ratio of HPMC/Surelease had
a major effect on the release rate. These results are in agreement with those reported
by Kannikoski et al (ll)X4) and Gilligan and Po (ll)l) 1).
The durations of lag times increased with increasing coating load but they were
reduced as the amount of HPMC in the coats increased. Neither variation in HPMC
content of the tilm nor variation 'in coating thickness provided zero-order release of
drugs.
Studies on free tilms suggested that the increase in the release rates upon inclusion
of HPMC was probably due to the dissolution of HPMC which left pores in the coat
for drug release. These results are different to those published by Donbrow and
Samuelov (Il)XO) who showed that hydroxypropylcellulose (HPC) remained in an
ethylcellulose film and formed swollen hydrated channels in the coat. The difference
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between the results of this study and those performed by Donbrow and Samuelov
may be due to the differences in the types of cellulose ethers used. The reduced
interaction of HPMC with ethylcellulose due to its increased substitution (Sakellariou
et al. Il)X6) may be responsible for the leaching out of HPMC from these blends.
The flocculation phenomena mentioned above. which could interfere with the film
formation from a colloidal polymer dispersion (Wong and Bodmeier, 1l)l)6), may also
account for the increased rate of drug release.
The inclusion of 5% HPMC considerably increased the release rate of diclofenac
sodium while that of metoclopramide hydrochloride just showed a marginal increase.
Additionally the lag time decreased to a greater extent than with metoclopramide
hydrochloride. In general. diclofenac sodium release rates were faster than
metocloprurnide hydrochloride at similar HPMC contents in the film and coating
loads suggesting that drug solubility again is not an important factor in the release
from pellets coated with SureleaselHPMC mixtures.
These results ruled out the possibility that differences in the release rates of two
drugs might be due to differences in their rates of diffusion through the Surelease
coat. It might have been expected that diclofenac sodium with lower solubility.
would have more affinity than metoclopramide hydrochloride for the hydrophobic
ethylcellulose. Therefore. diclofenac sodium might diffuse more easily than
metocloprumide hydrochloride through the Surelease film. If this were the case it
would have been expected that where drug release occurred through the pores.
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metocJopramide hydrochloride would be released faster than diclofenac sodium
because of its higher water solubility. However, in pellets coated with
Surelease/HPMC diclofenac sodium was again released faster than metoclopramide
hydrochloride suggesting that differences in release rates of the two drugs were not
related to the differences in their rates of diffusion through the coat.
Dialysis studies proved that the interaction of metoclopramide hydrochloride with the
anionic surfactant, ammonium oleate. present in the Surelease resulted in the
formation of a precipitate. This interaction is the most probable mechanism for the
slower release of metoclopramide hydrochloride from Surelease coated pellets. The
retarding effect of anionic surfactants on the release of cationic drugs from
hydrophilic matrices (Ford et aI, ll)l) Ib) and inert matrices (Wells and Parrott, 1l)l)2)
has heen reported. Complexation of drug with the surfactant decreased the solubility
of the metoclopramide hydrochloride. In addition this complexation and subsequent
precipitation provided a more tortuous pathway for drug release. The presence of
HPMC would facilitate the formation of a precipitate between a cationic drug and
an anionic surfactant (Ford et al. ll)l)lb). This explanation may apply here to account
for the marginal increase in the release rate of metoclopramide hydrochloride upon
inclusion of 5clc HPMC into the Surelease film compared to the marked increase in
the release rate of diclofenac sodium.
For both drugs, coating load had no upparent effect on the value of n for each
HPMC content in the tilm. Although the value of n for the release of
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metoclopramide hydrochloride was in the range of O.3n < n < 0.75 the majority of
the values of n were around O.n. This indicates that, similar to pellets coated with
Surelease, diffusion was the predominant mechanism controlling the release of
metoclopramiue hydrochloride from pellets coated with SureleaselHPMC E15.
However for diclofenac sodium. the values of n were in the range of O.X7 < n <
I'()(). A comparison of the value of the release exponent n with those obtained for
pellets coated with Surelease solely showed that different mechanisms controlled
release of diclofenac sodium from pellets coated with SureleaselHPMC blends and
those coated with solely Surelease. The high value of n indicates the reduced
contribution of diffusion as a rate limiting step in the release of drug. Therefore it
is probable that the rate of pore formation controls drug release rate.
11.2.4 APPLICATION OF SURELEASE ON 2% HPMC E5 SEAL-COATED
PELLETS
The application of a 2% seal-coat of HPMC to drug-layered pellets decreased the
release rate of both drugs from Surelease coated pellets compared to pellets without
a seal-coat at an equivalent coating load of Surelease. The retardation of drug release
after application of a seal-coat has been reported and ascribed to the reduced drug
migration during the application of the sustaining coat (Ghebre-Sellassie et al. 19X7;
Porter. Il)X9b; Yang and Ghebre-Sellassie. 1l)l)O). Application of a seal-coat had a
profound effect on the release of diclofenac sodium from 4% Surelease coated
pellets. While more than 70% of the drug was released in 5 min from 4% Surelease-
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coated pellets without seal-coat, those pellets with a seal-coat, released only 20% of
the drug in 5 min.
As the coating load of Sure lease increased, the release rates progressively decreased.
Similar to pellets coated with only Surelease, a lag time developed and became
loncer as the coatinz load increased. Althouah diclofenac sodium was released~ ~ ~
slightly more slowly than metoclopramide hydrochloride from seal-coated pellets at
Surelease coatings of 4% and K% w/w, at coating loads of ;;:::12%w/w. diclofenac
sodium again showed higher release rates than metoc1opramide hydrochloride. This
indicates that the faster release of diclofenac sodium from Surelease-coated pellets
at low coating loads was mostly due to the migration and/or interaction (coagulation
of Surelease in the presence of Na") of the diclofenac sodium with Surelease during
application. These findings are not surprising if we consider the high solubility of
diclofenac sodium and also complete ionization of this drug at the high pH of the
Surelease dispersion. However migration and/or interaction were not the only factors
contributing to the faster release of diclnfenac sodium from pellets coated with
Surelease.
Additionally when the pellets with a 12% coating load of Surelease over a 2% seal-
coat of HPMC E5 were cured at nODe, the release rates of metnclopramide
hydrochloride markedly increased while those of diclofenac sodium remained nearly
unchanged. Opposite results were found by Bodrneier and Paeratakul (I L)L)4). These
authors stated that marked increase in the release of the hydrophobic ibuprofen was
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observed from Aquacoat coated pellets, while the release of hydrophilic
chlorpheniramine maleate, depending on the plasticizer content in the film, decreased
or remained unchanged, after curing. This was attributed to dissolution and diffusion
of ibuprofen across the Aquacoat tilm following curing because of the high solubility
of this drug in the tilm. In addition the low melting point of ibuprofen promoted the
migration of drug into the coat during curing, while chlorpheniramine maleate did
not diffuse into the coat due to its low affinity for the Aquacoat (Bodrneier and
Paeratakul. 1l)l)4). The migration of metoclopramide hydrochloride into the Surelease
coat. although unlikely to occur due to the hydrophilicity of this drug, was examined.
No drug migration was observed for metoclopramide hydrochloride following curing.
The release of metocloprarnide hydrochloride was faster than diclofenac sodium for
12(k surelease coated pellets over a 2% seal-coat after curing.
After curing. the surfactant due to its unstable nature in heat is converted to its
constituents. This may account for the increase in the release rate of metoclopramide
hydrochloride after curing. The interaction of metoclopramide hydrochloride with
ammonium oleate reduced as the concentration of surfactant decreased following
curing. This led to faster release of metoclopramide hydrochloride after curing.
The values of the release exponent for metoclopramide hydrochloride were in the
range of O.SI < n < O.(1l) which resembled those of pellets coated with Surelease
without any seal-coat. The corresponding values for diclofenac sodium were 0.56 <
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n < O.YS which agam were similar to those obtained for pellets coated with
Surelease without a seal-coat. It should be mentioned that high values of n (-().LJ5)
were only obtained for pellets with a low coating load of Surelease (X%). while for
other coating loads the values of n were about O.SO-().oO indicating that diffusion is
the major mechanism controlling drug release. Therefore the presence of a 2%
HPMC E5 seal-coat did not change the drug release mechanism for either drug
compared to those coated with Surelease without a seal-coat.
11.2.5 APPLICATION OF SURELEASE ON DRUG-LAYERED PELLETS
ALREADY COATED WITH 20% HPMC El5
The drug-layered pellets already coated with 20% w/w HPMC E 15 were overcoated
with Surelease up to a 12% w/w coating load. Drug release characteristics were
completely different from pellets with a 2% seal-coat of HPMC ES. Pellets with a
Surelease overcoat on 20% HPMC E 15 undercoat released their drug at a faster rate
than pellets with a 2% HPMC E5 seal-coat. The scanning electron micrographs of
former pellets before and after dissolution tests revealed that there were big pores
and cracks in the pellets undercoated with 20% HPMC E 15 and overcoated with
12(k Surelease. The presence of these cracks was attributed to the hydration and
swelling of the HPMC undercoat which lead to the rupture of the Surelease overcoat.
These cracks and pores accounted for the faster release rate from pellets with the
20Ck HPMC EIS undercoat than the 2% HPMC ES seal-coat. The cracks penetrated
the whole thickness of the Surelease coat for former pellets, therefore water
solubility could play an important role in drug release. The comparison of
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metoc loprarnide hydrochloride or diclofenac sodium release rates from pellets already
coated with 2Wk HPMC and overcoated with Surelease showed that metnclopramide
hydrochloride was released faster than diclofenac sodium.
The faster release of metoc1opramide hydrochloride in this case could be due to its
higher solubility in water than diclofenac sodium in water. The faster release of
metoclopramide hydrochloride may also be ascribed to the build-up of a higher
osmotic pressure in the core due to the higher solubility of this drug. In addition
these drugs affect the swelling properties of HPMC in different manners. Diclofenac
sodium reduces the cloud point of HPMC and dehydrates this polymer (Rajabi-
Siahboomi et at. 1l)l)4a) while hydrochloride salts of organic compound increase the
cloud point of HPMC and facilitate hydration of this polymer (Mitchell et al, IlJlJ3c).
Therefore HPMC may swell to a greater extent in the presence of metoclopramide
hydrochloride than in the presence of diclofenac sodium. The greater extent of
swelling may create more cracks and therefore increase the release rate of
metoclopramide hydrochloride to higher degree than diclofenac sodium.
The values of n were O.M and 0.73 for the release of metoclopramide hydrochloride
from pellets with X% and 12% w/w coating loads of Surelease, respectively. The
corresponding values for diclofenac sodium were O.X5 and 1.1X. These values of n
are slightly higher than those obtained for pellets with a 2% seal-coat of HPMC E5
at equivalent Surelease coating loads. This suggested that the contribution of
diffusion as a rate limiting step was reduced in these pellets. This may be explained
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by the ease of diffusion due to the presence of the cracks in the Surelease coat and
also the increased role of erosion of HPMC undercoat on drug release mechanism.
I1.J DRUG RELEASE FROM MATRICES
Hydroxypropylmethylcellulose E 15. when used in a matrix, produced better control
of drug release than when used as a coat on drug-layered pellets. For example the
zero-order release rate of rnetocloprarnide hydrochloride from 1:5 drug:HPMC E 15
matrices was O.4X %min-' compared to 2.1 %min-' for the 20% coating load of
HPMC E 15 (where the drug:HPMC E 15 ratio is approximately 1:5). This was
attributed to the faster dissolution of HPMC El5 applied on a large surface area of
the pellets.
Generally, the release rates from HPMC matrices decreased as the polymer content
in the matrices increased irrespective of the grade of polymer used. These findings
are similar to findings of Ford et al (ll)X5b), Ranga Rao et al (ll)l)O) and Mitchell
et al (1l)l)3b).
Drug release from HPMC matrices was dependent on the viscosity of the HPMC
used in the formulation. The rank order in HPMC release rate was HPMC E 15>
HPMC K I()(l> HPMC K4M eo HPMC E4M. These results are in accord with those
reported by Daly et al (Il)X4). Liu et at (ll)l)2) and Gao et al (ll)l)(i). However
Salomon et al (ll)70). Ford et al (Il)X5a, b) and Baveja et at (ll)XX) stated that the
viscosity of HPMC did not affect the release rate of a drug. Gao et at (I <)<)(i)
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considered that the viscosity of HPMC affects the matrix dissolution rate and
development of the gel layer thickness only below a critical value of viscosity. They
showed for matrices composed of HPMC above a limiting viscosity grade (HPMC
K4M). gel composition and thickness were identical while for matrices composed of
low viscosity grades of HPMC (HPMC KUX) LV), swelling was inhomogeneous due
to rapid erosion.
Release rates were faster for the more soluble metoc1opramide hydrochloride than
the less soluble diclofenac sodium at similar drug:HPMC ratio and equivalent HPMC
grade. However. Zhang et al (1990) reported that there were no differences between
the release rates of theophylline and chlorpheniramine maleate from HPMC E5
matrices. They claimed that in erodible devices containing polymers such as HPMC
E5. drug release is independent of drug solubility.
Mathematical modelling showed that both diffusion and erosion contributed to the
release of both drugs. The values of n were between, 0.53-0.64 for metoclopramide
hydrochloride release from HPMC matrices with different viscosity grades. These
values are similar to those obtained by Ford et al (l9X7) for the release of soluble
drugs from HPMC K15M matrices (0.65-0.71).
The values of n for diclofenac sodium release from HPMC matrices with different
viscosities were in the range of O.5lJ-O.XO.Ford et al (ll)X7) found the value of 0.61
< n < 0.67 for release of theophylline from HPMC KI5M matrices. Dic10fenac
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sodium although more soluble than theophylline showed similar values of n for
release from HPMC K I 00, HPMC K4M or HPMC E4M matrices.
Release exponents for metocloprarnide hydrochloride were generally lower than that
of diclofenac sodium. This indicates that for the release of the less water soluble
diclofenac sodium. the contribution of erosion to the overall mechanism of release
was more than that of metoclopramide hydrochloride. This is in agreement with
findings of Ford et al (l9X7) Skoug et al (1<)93).Pham and Lee (1994) and Tahara
et al ( 1l)90) who stated that the release of water soluble drugs was controlled mainly
by diffusion while for water insoluble drugs, release was predominantly erosion
controlled.
It has been reported that HPMC K4M gel may have a greater diffusional resistance
to water within the inner gel region than other grades (Rajabi-Siahboomi et al, 1990).
However the results of this study indicated that the performance of HPMC K4M and
HPMC E4M were similar for the release of metoclopramide hydrochloride or
diclofenac sodium. These results are in agreement with those published by Mitchell
et al (19l)3a) who reported that substitution type had little effect on the dissolution
of propranolol hydrochloride.
11.4 APPLICATION OF SURELEASE IN HPMC K4M MATRICES
Surelease has been demonstrated to be an effective wet granulation binder for the
production of matrix controlled release tablets (Colorcon technical data). The
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Surelease was included in the matrices containing 1:5 drug:HPMC K4M using wet
granulation. The prepared granules contained I :5: I, I :5:2 or 1:5:3 drug:HPMC
K4M:Sllrelease.
The porosities of the tablets prepared from granules were higher than those prepared
from physical mixtures. Correspondingly the crushing strengths of the tablet
decreased following granulation of HPMC matrices with water or Surelease.
Similarly Liu et al (1l)l)3) showed that increasing the amount of water used in the
granulation of HPMC decreased the hardness of the resultant tablets.
The release rates of metoclopramide hydrochloride were greatly reduced by
incorporating Surelease into the HPMC K4M matrices. However the release rate of
diclofenuc sodium was less affected by incorporation of Surelease. Previously
Klinger et al (1l)l)O) reported that increasing the amount of Surelease from 4.2% to
16.6Cff in a formulation containing chlorpheniramine maleate and dicalcium
phosphate dramatically decreased the release rate of the drug.
The slow release of metoclopramide from Surelease granulated matrices was
attributed to the conversion of highly water soluble metocloprarnide hydrochloride
to metoclopramide base with much lower solubility at high pH of Surelease.
Therefore care must be taken when using Surelease as granulating agent as its high
pH may affect the solubility of the drugs which are sensitive to high pH.
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The values of exponent n for metoclopramide hydrochloride were in the range of
0.46 < n < 0.62 indicating both erosion and diffusion controlled release. The release
exponent increased as the Surelease content of the granules increased. This suggests
that erosion controlled mechanism become more important for granules containing
higher amounts of Surelease compared to those containing lesser amounts of
Surelease or water granulated matrices. Decrease in drug solubility may account for
the increased role of erosion in the release mechanism.
The values of the exponent n for diclofenac sodium were in the range of O.SI < 11
< 0.60. For diclofenac sodium matrices the increase in Surelease content in the
granules had no apparent effect on the drug release mechanism.
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CHAPTER 12. CONCLUSIONS AND RECOMMENDATIONS FOR
FUTURE STUDIES
12.1 CONCLUSIONS
Hydroxypropylmethylcellulose, hydrophilic polymer, and commercially available
ethylcellulose aqueous dispersion (Surelease) as hydrophobic polymer were used in
the preparation of coated pellets as well as matrix tablets to provide controlled
release of metoclopramide hydrochloride as a cationic very water soluble drug and
diclofenac sodium as an anionic drug with lower water solubility.
Drug release from pellets coated with low viscosity grades of HPMC was decreased
with increasing coating load of polymer but, overall, drug release was fast and the
majority of both drugs was released in less than I h even at high coating load (20%
w/w). Diclofenac sodium was released more slowly than metoclopramide
hydrochloride from pellets coated with HPMC.
The coating load of Surelease had a great retarding effect on the release of both
drugs either when directly applied on drug-layered pellets or applied onto a 2% seal-
coat of HPMC E5. The release of either drug was sustained over 12 h at high
coating loads of Surelease. No improvement in the release pattern towards zero-order
release was observed with increasing coating load of Surelease. Incorporation of
HPMC into the Surelease film increased the release of both drugs. The
Surelease:HPMC ratio had a major effect on the release rate of both drugs. Drug
solubility was not an important factor in the release of drug from Surelease or
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SureleaselHPMC coated pellets. Diclofenac sodium was released faster than
metoclopramide hydrochloride despite its lower solubility. Thermal treatment of
Surelease-coated pellets increased the release of metoclopramide hydrochloride but
did not have any profound effect on the release of diclofenac sodium. The different
release behaviour of these two drugs was attributed mostly to the interaction between
cationic metoclopramide hydrochloride with anionic surfactant in situ.
When Surelease was applied on the pellets already coated with 20% HPMC E15
release rates of either drug were higher than when Surelease was applied onto 2(Jc
HPMC E..4:) coated pellets. The development of cracks due to the swelling of HPMC
accounted for the higher release rates.
Drug release from HPMC matrices was dependent on the solubility of the drug.
polymer content and viscosity. When Surelease incorporated into HPMC K4M
matrices. it retarded the release of metoclopramide hydrochloride to greater extent
than diclofenac sodium. This was attributed to the precipitation of rnetoclopramide
hydrochloride as its base form.
12.2 RECOMMENDATION FOR FUTURE STUDIES
I. The interaction between metoclopramide hydrochloride and ammonium oleate was
proposed as a possible mechanism for the slower release of this drug than diclofenac
sodium from Surelease-coated pellets. Thorough investigation of this interaction and
the resulted precipitate is recommended.
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2. As the ammonium oleate is an unstable surfactant it would be interesting to study
the effect of aging and storage of the pellets in different conditions of temperature
and humidity on the release of drugs from both cured and uncured pellets.
3. It would be interesting to compare sodium or hydrochloride salts of other drugs
for their potential interaction with Surelease.
4. In this study an Accela-Cota (a perforated coating pan) was used to apply coating
formulation. Since the drying efficiency of the coating pans is low it is recommended
to use other coating techniques such as tluidized bed devices and investigate the drug
release characteristics.
5. It would also be useful to compare other commercially available ethylcellulose
aqueous dispersions (eg. Aquacoat) which contain sodium lauryl sulphate as an
anionic surfactant to see whether or not the differences between the release of these
two drugs are maintained.
(). In this study the application of Surelease on pellets already coated with 20%
HPMC E 15 was studied. It would be interesting to investigate the potential of
Surelease coat to provide zero-order release of these two drugs from their matrices





































































pKa Negative logarithm of the
Dissociation constant.
pSI Pounds per square inch
r Correlation Coefficient
SD Standard Deviation
SEM Scanning Electron Microscopy
ss Sums of squares of errors




IISP United State Pharmacopoeia
UV Ultraviolet
w/w Weight in Weight
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